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ABSTRACT 
Neutrophils have capacity to cause tissue damage in chronic inflammatory 
disease. In rheumatoid arthritis (RA) they infiltrate joints, secrete proteases 
and reactive oxygen species (ROS), and express cytokines. RA neutrophils 
express NAMPT which is a highly conserved, pleiotropic protein, that 
catalyses the rate-limiting step of the NAD salvage pathway, but also has 
cytokine-like activity. NAMPT is elevated in inflammation and exerts pro-
inflammatory effects on neutrophils. The aim of this research was to 
determine the role of NAMPT, as a signalling molecule and as an enzyme, 
in regulating neutrophil activities of pathological importance. 
Neutrophils were isolated from the blood of healthy donors and either 
stimulated with NAMPT or else NAMPT was inhibited (with FK866), in 
the presence and absence of pro-inflammatory cytokines in vitro. Assays 
for specific neutrophil functions such as production of ROS, bacterial 
killing and apoptosis were performed, and expression of cytokines was also 
examined. Transcriptome sequencing of neutrophils treated with FK866 
and TNFα in combination, was carried out to investigate the wider impact 
of NAMPT inhibition on neutrophil gene expression. NAMPT expression 
was also examined in control, cytokine treated and RA patient neutrophils. 
NAMPT had little capacity to prime neutrophils, although it did delay 
neutrophil apoptosis and stabilise the anti-apoptotic protein Mcl-1. 
NAMPT inhibition in neutrophils, depleted NAD(P)/H and had effects on 
neutrophil functions and gene expression. Notably, FK866 decreased ROS 
production but did not affect the ability of neutrophils to kill bacteria. 
NAMPT-inhibited neutrophils exhibited decreased activation of signalling 
pathways and a diminished response to cytokines; transcriptome analysis 
showed that FK866 decreased TNFα-induced expression of many genes. 
NAMPT expression was not dynamically regulated in control neutrophils, 
but in RA patient neutrophils, NAMPT mRNA correlated with TNFα 
expression in a cohort of patients, and NAMPT protein was elevated in 
synovial fluid neutrophils compared to those from paired blood. 
Thus, NAMPT is elevated in activated inflammatory neutrophils and 
correlates with other markers of inflammation in RA, suggesting that it 
may be a marker of inflammation in these cells. Also, as a NAD 
biosynthetic enzyme, NAMPT regulates neutrophil functions and gene 
products central to RA disease pathology, without affecting bacterial 
killing capacity. This suggests that inhibition of NAMPT may potentially 
have the capacity to decrease neutrophil mediated tissue-damage observed 
in chronic inflammation, without adversely compromising host defence, 
and thus may be a future treatment option for diseases such as RA. 
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CHAPTER 1: Introduction 
1.1 Project Overview 
Neutrophils are an essential component of the innate immune system; they 
contain an arsenal of anti-microbial proteins and oxidants which are 
employed to kill invading pathogens 
1
. Neutrophils however act as a 
double-edged sword, as this anti-microbial arsenal is also capable of 
causing host tissue damage if neutrophil function and apoptosis are not 
appropriately controlled 
2
. Regulation is achieved by the two-step 
activation of neutrophils; initial priming by immune mediators followed by 
subsequent full activation, and also by the short half-life and constitutive 
apoptosis of these cells 
3–5
. Neutrophil apoptosis is transiently delayed to 
allow response to an immune challenge. However, dysregulation of 
neutrophil activation and apoptosis is a key feature of a number of 
inflammatory diseases, including the inflammatory joint disease 
rheumatoid arthritis (RA) 
2,6
. Neutrophils are primed by exposure to 
increased levels of circulating cytokines in this disease, and migrate 
towards the high local concentration of chemoattractants in the inflamed 
rheumatoid joint. Neutrophils infiltrate the normally acellular rheumatoid 
joint in large numbers, and are by far the most abundant immune cell 
present 
7,8
. Once in the joint space, primed neutrophils are stimulated to 
release cytotoxic proteins and reactive oxygen species (ROS), mainly by 
immune complexes of autoantibodies and antigen 
9
. These complexes can 
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also be found embedded in the pannus of proliferative tissue that is the site 
of bone and cartilage degradation in this disease 
10
. These neutrophil 
products cause a significant amount of tissue damage at these sites, as 
neutrophil apoptosis is delayed for up to several days following migration 
into the joint 
2,11–13
. 
Rheumatoid arthritis is a heterogenous disease and its etiology is 
incompletely understood. As such, the patient response to the various 
treatments available is also varied 
14
. As RA is progressively degenerative, 
it is important to establish patients on a successful treatment regimen as 
soon as possible, and although many patients do respond well to 
conventional therapies, a number remain refractory to treatment. As such it 
is of interest in the field to identify novel biomarkers of disease that may 
serve as diagnostic predictors of response to treatment or lead to 
development of new drug targets 
14–16
. Neutrophils are an attractive target 
in RA because they are the main cell type responsible for causing tissue 
damage in the disease 
11
. 
It is now appreciated that neutrophils also contribute to the progression of 
inflammation via expression of cytokines and chemokines; the expression 
profile of an activated neutrophil is very different from that of a resting cell 
17
. A high-level screen of the neutrophil transcriptome in a number of 
inflammatory diseases (RA, Beçet’s disease and scleroderma) was carried 
out in-house to identify disease-specific neutrophil biomarkers of 
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activation. Notably, high expression of the transcript for NAMPT was 
observed across all diseases. NAMPT has been previously identified as 
correlating with inflammation and inflammatory disease markers 
18
, and is 
proposed to exert a number of pro-inflammatory effects in a number of cell 
types 
19–24
. It is a ubiquitously expressed molecule with a number of 
described functions 
23,25
. It has been established that NAMPT is a 
nicotinamide phosphoribosyltransferase enzyme that catalyses the rate-
limiting step in the nicotinamide adenine dinucleotide (NAD) salvage 
pathway. NAD is an essential metabolic co-factor and is required for a 
number of oxidation reactions 
26–30
. NAMPT has also been described as a 
cytokine-like molecule, distinct from its enzyme activity, and more 
controversially has been described as an insulin mimetic adipokine 
20,22,23,31,32
. Inhibition of the enzyme function of NAMPT has shown 
promise for the alleviation of inflammation and the symptoms of 
inflammatory disease in mouse models of inflammatory arthritis, and it has 
also been reported to exert a number of anti-inflammatory effects on 
immune cells in vitro 
33–35
. 
The high level of NAMPT expressed by neutrophils from patients with 
inflammatory diseases, and its correlation with disease activity, suggest 
that it is an important molecule in the regulation of the inflammatory 
process. The work in this thesis investigated the role of NAMPT in a 
variety of neutrophil functions important in inflammation, and on 
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neutrophil gene expression. The NAMPT inhibitor, FK866 was used to 
investigate the role of NAMPT and NAD production on these neutrophil 
properties. RA was used as a model of inflammatory disease. The aim of 
this research was to achieve a better understanding of the role of NAMPT 
in neutrophil function in inflammation, and to determine how therapeutic 
NAMPT inhibition would affect the ability of these cells to carry out their 
role in host defence. 
1.2 The Neutrophil 
1.2.1 Overview of neutrophil function 
Neutrophils are key components of the innate immune system and 
represent the first line of defence against bacterial and fungal infection 
36
. 
Neutrophils are produced in the bone marrow at a rate of 5 x 10
10
 – 10 x 
10
10
 cells/day and circulate in the blood in an inactive state; they are the 
most common white blood cell, found at a concentration of 3-5 x 10
6
 cells 
per mL of blood 
11,37
. Marginated pools of neutrophils are also found 
within specific tissues such as the spleen and liver and at the site of 
production in the bone marrow 
37
. Neutrophil homeostasis in the 
circulation is achieved by control of production and release but also by 
apoptosis; neutrophils constitutively undergo apoptosis and have a 
relatively short half-life 
38
. Estimates for this half-life in the circulation 
vary from 6-18 h, but recent evidence suggests that this may be an 
underestimate 
4,5,39
. Upon initial exposure to immune agonists or cytokines, 
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inactive circulating neutrophils undergo a series of rapid changes, known 
collectively as priming, and their apoptosis is transiently-delayed. Priming 
enables a more effective response to an invading pathogen as it rapidly 
increases the number and/or affinity of plasma membrane receptors for 
immune agonists and overall enhances the capacity for bacterial killing 
1,3,40
. Primed neutrophils also produce cytokines which activate and recruit 
further neutrophils and other immune cells 
41,42
. The dynamic regulation of 
neutrophil membrane receptors facilitates transmigration along a 
chemotactic gradient towards the site of infection, binding to the blood 
vessel endothelium and migration into the tissue. Upon encountering a 
pathogen, membrane receptors facilitate recognition and binding, and the 
pathogen is engulfed by phagocytosis (Fig. 1.1). Neutrophils then employ a 
number of potent bactericidal mechanisms to destroy the engulfed 
pathogen. Firstly, neutrophils contain membrane bound granules which 
hold a variety of proteases, and following phagocytosis these granules fuse 
with the phagocytic vesicle and release the cytotoxic granule proteases into 
it. This occurs concurrently with the second major antimicrobial 
mechanism, production of reactive oxygen species (ROS). ROS are 
produced by reduction of molecular O2 during the respiratory burst, which 
is catalysed by the membrane bound NADPH oxidase complex 
43
. These 
granule proteases and ROS act in concert to destroy the pathogen in the 
phagocytic vesicle 
44
. Following pathogen destruction, the neutrophil 
undergoes controlled apoptosis to prevent release of its cytotoxic contents 
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into the extracellular milieu 
5,45
. Apoptotic neutrophils are removed by 
other phagocytic immune cells such as macrophages, to facilitate 
resolution of inflammation 
46
. An overview of this process is shown in 
Figure 1.1, and each stage is discussed in more detail in the following 
sections. 
 
FIGURE 1.1: Overview of neutrophil function in immune response. 
Peripheral blood neutrophils (1.) become tethered to the blood vessel endothelial 
cell lining and roll along the surface (2.) The neutrophil then firmly adheres to the 
vessel wall (3.) and squeezes between gaps in the neighbouring endothelial cells 
to enter the tissue (4.). The neutrophil travels along a chemotactic gradient 
towards the site of infection, and recognises and binds pathogens by virtue of cell 
surface receptors (5.). The neutrophil engulfs the pathogen by phagocytosis (6.) 
and destroys it by releasing granule proteases and ROS into the phagocytic vesicle 
(7.). The neutrophil then undergoes controlled apoptosis (8.). 
In contrast to the crucial role the neutrophil plays in host defence, 
dysregulation of neutrophil function is also implicated in numerous human 
diseases. If neutrophil function is not tightly regulated, this cell has great 
capacity to cause tissue damage due to the cytotoxic products it contains. 
Destructive neutrophil products are major contributors to tissue damage in 
inflammatory diseases such as rheumatoid arthritis 
2,6,11
. 
1.
2.
5.
4.
6.7.
8.
3.
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1.2.2 Priming 
It is essential that neutrophils only respond appropriately to inflammatory 
stimuli, and do not release their cytotoxic products to cause tissue damage. 
To prevent inappropriate activation, neutrophils undergo a two-step 
activation process, initially being primed into a state of heightened 
responsiveness, before becoming fully activated when they encounter a 
stimulus 
3
. Neutrophils circulate in the body in an inactive state, but can be 
primed by a variety of stimuli including bacterial peptides, and cytokines 
such as GM-CSF. The surface expression of a number of plasma 
membrane receptors is increased (either in number or by a change in 
affinity) when neutrophils are primed, and the primed neutrophils exhibit 
enhanced degranulation, phagocytosis and production of ROS in response 
to agonists. Thus, priming greatly enhances bacterial killing 
3,47
. These 
changes occur rapidly, and the speed of response is facilitated by the 
storage of pre-formed receptors and subunits, that can be rapidly mobilised 
to the cell surface independently of de novo protein synthesis. Priming 
does, however, also induce longer-term effects that are dependent on de 
novo protein biosynthesis. These products of de novo biosynthesis include 
proteins that extend the functional life-span of the neutrophil and also a 
wide range of cytokines that act as further mediators of the immune 
response 
17,48
. 
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1.2.3 Adhesion, transmigration and chemotaxis  
For neutrophils to respond to infection they must reach the site of the 
immune challenge, which requires them to leave the circulation and enter 
the tissue. This process involves adhesion to, and transmigration through 
the blood vessel wall, which is mediated by both neutrophil and endothelial 
cell membrane receptors, the expression of which can be differentially 
regulated by cytokines 
49–51
. The adhesion receptors can be grouped into 3 
types that act sequentially; selectins, integrins and immunoglobulin 
receptors. The selectins are responsible for the initial tethering of the 
neutrophil to the endothelium and its subsequent rolling along the vessel 
wall. L-selectin is the major neutrophil selectin and is constitutively 
expressed, whereas P- and E-selectin are expressed on endothelial cells 
51,52
. Transient binding of these receptors to their ligands facilitates rolling 
of the neutrophil onto the endothelium. Following attachment, L-selectin is 
shed and then expression of neutrophil integrins is stimulated by cytokines 
and factors released from endothelial cells 
51,52
. Rolling arrest and firm 
adhesion of the neutrophil to the endothelium is mediated by the neutrophil 
integrins that interact with the endothelial intercellular adhesion molecule 
(ICAM) receptors ICAM-1 and ICAM-2, ICAM-1 expression is 
upregulated by cytokines. Integrin CD11b/CD18 (Mac-1 or CR3) and 
endothelial ICAM-1 cooperate to enable neutrophil crawling to a suitable 
site for neutrophil transmigration where the neutrophil docks 
51–53
. At this 
point, docking of the neutrophil is thought to lead to changes in the 
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endothelial cell morphology to aid neutrophil transmigration between cells, 
in a process known as diapedesis 
52,54
. Paracellular diapedesis is mediated 
by molecules redistributed to endothelial cell junctions, including the 
immunoglobulins PECAM-1, ICAM-1, ICAM-2 and  JAM-A, -B and –C 
51,52
. Different molecules mediate transmigration in a stimulus dependent 
manner, for example ICAM-2, PECAM-1 and JAM-A mediate neutrophil 
transmigration in response to IL-1β but not TNFα 55. In contrast to this 
paracellular transmigration of neutrophils through endothelial cell 
junctions, a minority of emigrating neutrophils undergo transcellular 
migration, usually under conditions of very high ICAM1 expression. 
During transcellular migration, neutrophils migrate through small 
continuous endothelial membrane-associated channels called vesiculo-
vacuolar organelles. This process is mediated by many of the same 
paracellular migration facilitating molecules 
49,56,57
.  
Once neutrophils enter the tissue they continue to move towards the site of 
infection, following a gradient of increasing concentration of 
chemoattractants such as bacterial peptides, complement fragments and 
cytokines including  IL-8 and TNFα 58. Neutrophils exposed to these 
agents change shape and exhibit polarity, with a leading edge and trailing 
end. Migration occurs via extension of actin-rich protrusions, known as 
pseudopodia, from the leading edge of the neutrophil, and contraction of 
the trailing end 
58
. During this process, chemokine receptors cluster at the 
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leading edge of the neutrophil to facilitate detection of the chemotatic 
agents 
59
. 
1.2.4 Pathogen recognition and phagocytosis 
By virtue of various plasma membrane receptors, neutrophils recognise 
pathogens and other particles that have been opsonised by 
immunoglobulins (Ig) and/or complement fragments. The number and 
affinity of these receptors is increased when neutrophils are primed by 
cytokines 
3,48
. One group of receptors recognises and binds the bacterial 
peptide N-formyl-methionyl-leucyl-phenylalanine (fMLP); fMLP is a 
potent chemoattractant and activator of neutrophils and fMLP receptors 
bind this molecule and its analogues. Complement receptors are also 
upregulated during priming; the soluble complement factors C3a and C5a 
initiate neutrophil chemotaxis and secretion, whereas surface-bound 
fragments of C3 coat and opsonise pathogens and stimulate neutrophil 
adhesion and phagocytosis via their receptors CR1 and CR3 (CD11b/CD18 
or Mac-1) 
60,61
. Particles are also opsonised by being coated with 
immunoglobulins to further enhance recognition by neutrophils. 
Neutrophils express a family of immunoglobulin receptors that recognise 
the Fc domain of IgG, called Fcγ receptors. The immunoglobulin receptors 
FcγRII (CD32) and FcγRIII (CD16) are constitutively expressed on the 
surface of neutrophils, whereas FcγRI (CD64) is absent on resting 
neutrophils, but, its surface expression is induced by cytokines, such as 
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interferon-γ (IFNγ) and GM-CSF 62. FcγRI binds monomeric IgG with 
high-affinity, FcγRII will also bind monomeric IgG with low affinity but it 
has a greater affinity for dimers or aggregates of IgG. There are 2 isoforms 
of FcγRIII, FcγRIIIa and -b, but only FcγRIIIb (CD16b) is expressed on 
neutrophils. FcγRIIIb is constitutively expressed at a higher concentration 
than the other Fcγ receptors on the neutrophil surface (100,000–200,000 
molecules per cell). FcγRIIIb is anchored to the membrane via a glycosyl-
phosphatidylinositol (GPI) linkage which enables cleavage of this receptor 
from the cell surface 
1,63
. Shedding, via GPI-cleavage, alongside 
mobilisation of internal stores of this receptor, allows dynamic regulation 
of expression on the neutrophil surface. Stimulation with cytokines such as 
GM-CSF leads to rapid shedding and concurrent replenishment of 
FcγRIIIb on the neutrophil surface 64. 
Neutrophils also express Toll-like receptors (TLR) that recognise 
structurally-conserved pathogen-associated molecular patterns (PAMPs) 
65
. 
TLRs are part of the IL-1/TLR superfamily and neutrophils express all 10 
TLRs (TLR1-10) except TLR3. Expression can be upregulated by priming; 
for example GM-CSF increases expression of TLR2 and TLR9 
66
. This 
facilitates recognition of a variety of bacterial products including 
lipoproteins, lipopolysaccharide (LPS), peptidoglycans, flagellins and 
RNA (which facilitates recognition of viruses) 
67
. TLR agonists activate 
MAPK, and subsequently NF-κB signalling pathways, resulting in 
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initiation of phagocytosis 
68
. TLR receptor engagement also leads to 
increased degranulation, production of ROS and cytokine release 
65,66,69
. 
Once a neutrophil recognises a pathogen by virtue of these receptors, it 
engulfs it by phagocytosis 
70
. There are two major receptor-dependent 
mechanisms by which this occurs; particles coated by opsonins bind to 
complement receptors on the surface of the neutrophil and rapidly sink into 
the cell without stimulating significant surface protrusions 
71,72
. 
Alternatively, activation of immunoglobulin receptors by IgG coated 
particles drives actin polymerisation and the formation of protruding 
pseudopodia that extend around the pathogen and fuse to engulf it. The 
resulting membrane bound vesicle is drawn into the cell and is termed the 
phagosome. This process in disrupted by addition of cytochalasin B in 
vitro 
71,72
. Neutrophil granule proteins and NADPH oxidase activity during 
the respiratory burst then act in concert to create an intra-phagosomal 
environment that can destroy the engulfed pathogen 
44
. 
1.2.5 Degranulation 
Neutrophil granules contain a vast array of antimicrobial substances that 
are delivered to the phagosome during degranulation. However, these can 
also be delivered to the cell surface to facilitate secretion of the molecules 
73
. There are a number of subsets of granules, distinguishable by their 
protein content. All subsets share common structural features, such as a 
phospholipid bilayer membrane and an intragranular matrix containing 
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the granule proteins. It is thought that the protein contents of each granule 
type is determined by the timing of development during neutrophil 
maturation 
74,75
. The types of granules are broadly grouped into 
peroxidase-positive (also known as the azurophilic or primary granules) 
and peroxidase-negative, with the peroxidase-negative group further 
subdivided into the specific (secondary), gelatinase (tertiary) and the 
secretory vesicles 
1
. These granules contain anti-microbial proteins and 
stores of pre-formed receptors; the contents of each type is summarised in 
Table 1.1. The defining protein of the peroxidase positive group is 
myeloperoxidase (MPO). This heme dependent protein oxidises chloride 
(and other halides) and reacts with hydrogen peroxide (H2O2) formed by 
the NADPH oxidase to produce hypochlorous acid (HOCl) 
76
. This 
process is discussed in more detail in section 1.2.6. Another major 
component of these primary granules are the α-defensins, which are 
antimicrobial peptides, and are estimated to constitute 5% of the total 
neutrophil protein content 
77
. Generally, the larger secondary granules are 
richer in antimicrobial proteins than the smaller tertiary granules; these 
antimicrobial products are mobilised to the phagosome or released 
extracellularly and are crucial for killing 
73
. The tertiary granules contain 
a number of matrix-degrading enzymes and pre-formed receptors and are 
more easily exocytosed to provide these products to the cell surface 
78
.  
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Peroxidase Granule Contents 
Positive Azurophillic/Primary Myeloperoxidase 
Defensins 
BPI 
Cathepsin G 
Elastase 
Proteinase 3 
Azurocidin 
Lysozyme 
Alkaline phosphatise 
Hydrolases 
Phospholipase A2, C and 
D 
Negative Specific/Secondary Lysozyme 
Lactoferrin 
fMLP receptor 
MAC-1 (CD11b/CD18) 
Laminin receptor 
Cytochrome b558 
Gelatinase 
Collagenase 
Negative Gelatinase/Tertiary fMLP receptor 
MAC-1 (CD11b/CD18) 
CD45 receptor 
Laminin receptor 
Cytochrome b558 
B2 microglobulin 
Gelatinase 
Diamine oxidase 
H+-ATPase 
Tetranectin 
DAG lipase 
Negative Secretory vesicles fMLP receptor 
MAC-1 (CD11b/CD18) 
LFA-1 (CD11a/CC18) 
Complement receptor-1 
Cytochrome b558 
   TABLE 1.1: Protein contents of neutrophil granules 
1
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The secretory vesicles have the highest propensity for extracellular 
release, and contain a variety of membrane-associated receptors, such as 
CD11b/CD18 and other complement receptors, which are mobilised to 
the cell surface early in the inflammatory response 
78–80
.  
In vitro addition of nanomolar concentrations of agonists such as fMLP 
can stimulate mobilisation of secretory vesicles without significantly 
affecting the other granules 
80
. Thus, the granule contents of neutrophils 
provide components for various stages of neutrophil activity, with the 
anti-microbial peptides of the primary and secondary granules acting 
alongside the oxygen-dependent activity of the NADPH oxidase complex 
to orchestrate bacterial killing 
44
. 
1.2.6 Production of ROS by neutrophils 
Neutrophils produce antimicrobial oxidants that are released into the 
phagosome or extracellularly and act in concert with the granular 
antimicrobial peptides during microbial killing. Reactive oxygen species 
(ROS) are produced by the reduction of molecular O2 by the multi-
component NADPH (reduced nicotinamide adenine dinucleotide 
phosphate) oxidase in a process known as the respiratory burst. The 
primary product of the NADPH oxidase (O2
-
) is relatively inactive but it 
is unstable and it rapidly dismutates into hydrogen peroxide (H2O2). 
Under certain conditions and in the presence of metal salts, these ROS 
can also be converted into the highly reactive hydroxyl free radical (·OH) 
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44
. H2O2 is itself microbicidal at high concentrations but the granule 
enzyme myeloperoxidase can further convert it into hypochlorous acid 
(HOCl), which is a much more potent microbicidal agent 
81
. This process 
is summarised in Figure 1.2. The NADPH oxidase uses the reducing 
power of NADPH to reduce molecular oxygen, resulting in NADP
+
, 
which is subsequently converted back to NADPH via the hexose 
monophosphate (HMP) shunt. The HMP shunt, also known as the 
pentose phosphate pathway, consists of two distinct phases; NADP 
becomes reduced to NADPH during the first (oxidative) phase, when 
glucose-6-phosphate (G6P) is converted into 6-phosphogluconolactone 
(6PGDL) by G6P dehydrogenase (G6PDH). The action of G6PDH is 
allosterically stimulated by NADP. This is followed by the non-oxidative 
phase during which  6PGDL is decarboxylated to produce the 5-carbon 
sugar ribulose-5-phosphate 
82
. In this way neutrophils can regenerate 
NADPH to provide a source of reducing power for the oxidase; however, 
resting neutrophil pools of NADP/H are insufficient to fuel the oxidase, 
and are increased greater than 3-fold upon neutrophil activation with 
fMLP or phorbyl myristate acetate (PMA), requiring new input of 
phosphorylated NAD 
83
. 
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FIGURE 1.2: ROS production in neutrophils. A. i. The NADPH 
oxidase complex uses the reducing power of NADPH to reduce 
molecular oxygen, forming O2
-
. ii. Oxidised NADP
+
 is converted back to 
NADPH during the hexose monophosphate (HMP) shunt iii. O2
-
 is 
relatively unstable and spontaneously forms secondary oxidants. iv. 
Neutrophils contain myeloperoxidase which catalyses production of 
HOCl. v. Under certain conditions and in the presence of transition metal 
salts, O2
-
 and H2O2 may react to form the highly reactive ·OH radical 
(adapted from 
84
).  
 
The core NADPH oxidase consists of the membrane bound p22
PHOX
 
(CYBA) and gp91
PHOX
 (CYBB) subunits that form cytochrome b558, and 
the cytosolic components p40
 PHOX
 (NCF4), p47
 PHOX 
(NCF1), p67
 PHOX 
(NCF2), and is associated with Rac1 or Rac2 which are low-molecular 
weight G proteins of the Rho guanosine triphosphatase (GTPase) family 
85
. The Rac proteins are held in an inactive state by the Rho guanine 
nucleotide dissociation inhibitor (RhoGDI) which binds and prevents 
their association at the membrane 
86
. Upon neutrophil priming, the 
cytosolic components of the oxidase migrate to the membrane to enable 
assembly of the enzyme, that allows a rapid response if the cell is further 
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activated, in a process regulated by phosphorylation 
87
. gp91
PHOX
 binds 
the electron carrying components of the oxidase including the flavin 
adenine dinucleotides (FAD) and two heme molecules, which are 
required for electron transfer from NADPH to molecular oxygen 
88
. 
p22
PHOX
 is the second subunit of the heterodimeric flavocytochrome and 
is associated with gp91
PHOX
 at the membrane. p22
PHOX
 extends a tail into 
the cytoplasm and is bound by p47
PHOX
; this adaptor peptide is 
phosphorylated upon activation and is responsible for bringing the 
cytosolic subunit of the oxidase to the membrane bound catalytic core 
43
. 
This facilitates the association of gp91
PHOX
 with p67
PHOX
 which is 
thought to catalyse the electron transfer to molecular oxygen. p67
PHOX
 
also binds the Rac protein, which is crucial for oxidase assembly 
89
 (Fig. 
1.3). The function of the final oxidase component p40
PHOX
 remains 
unclear; p40
PHOX
 associates with p67
PHOX
 and p47
PHOX
 in the cytosol and 
it has been suggested that it is involved in the regulation of p67
PHOX
 
action due to their tight association. However, this is yet to be confirmed 
and evidence for both positive 
90–92
 and negative 
93,94
 regulatory roles has 
been presented. 
Much of what is known about the function of the oxidase has come from 
the study of the phagocytic cells of patients with chronic granulomatous 
disease (CGD), which is characterised by a variety of genetic defects in 
the oxidase genes 
95,96
, however, no CGD patients have been identified 
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with mutations of p40
PHOX
 
43
. Generally, CGD leads to the inability to 
produce superoxide and is often characterised by severe infections 
97–99
. 
The incidence of infection, however, does differ between patients, and 
some have been documented as having relatively few bacterial infections, 
despite being unable to produce substantial levels of phagosomal 
oxidants, and relying solely on O2 independent microbicidal activities 
100
. 
 
FIGURE 1.3: Assembly of the multi-component NADPH oxidase 
upon neutrophil activation. In resting neutrophils the membrane and 
cytosolic subunits of the NADPH oxidase are not associated with one 
another, and the Rac protein is held in the cytosol by the Rho guanine 
nucleotide dissociation inhibitor (RhoGDI). Upon neutrophil activation, 
various signalling pathways trigger release of the adaptor protein Rac and 
phosphorylation of the p47
PHOX
 subunit, leading to migration of the 
cytosolic subunit to the membrane and its association with the 
flavocytochrome to form the functional oxidase. The oxidase complex 
then catalyses reduction of molecular oxygen using NADPH as a co-
factor. 
 
The neutrophil respiratory burst coincides with degranulation; the oxidant 
species produced during the neutrophil respiratory burst have 
microbicidal activity, as free radicals readily react with organic 
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molecules, and the catalysis of H2O2 to HOCl by the granule protein 
myleoperoxidase is one example of the coordinated nature of the 
neutrophil killing mechanisms 
44
. However, production of ROS also 
changes the conditions within the phagosome to enhance other killing 
mechanisms; the high ROS concentration results in an accumulation of 
anionic charge, and the pH within the phagosome transiently rises from 
pH 6 to around pH 7.8, triggering an influx of potassium ions into the 
phagosome across the membrane. This increase in ionic strength leads to 
activation of cationic granule proteins, including elastase and cathepsin 
G, that act to destroy the bacteria 
101
. Thus, the concerted action of the 
two neutrophil killing mechanisms is important for effective bacterial 
killing. 
1.3 Neutrophil Apoptosis 
It is vitally important that host cells and tissues are protected from the 
cytotoxic molecules that are used by neutrophils to kill pathogens, as they 
have the capacity to cause bystander tissue injury. This is achieved in part 
by the two-stage activation of neutrophils, but it is complemented by the 
tight regulation of neutrophil apoptosis. Neutrophils have a short half-life 
in the circulation and in the absence of pro-inflammatory signals will 
undergo apoptosis 
38
. This constitutive apoptosis is transiently delayed 
during immune challenge to allow neutrophils to carry out their anti-
microbial activities. Controlled neutrophil apoptosis, however, is also 
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crucial for the resolution of inflammation following pathogen killing. If 
neutrophils did not undergo controlled death in this manner, uncontrolled 
death and secondary necrosis would lead to the release of intracellular 
cytotoxic proteases and exacerbate the acute inflammatory state 
45,102
. 
Neutrophil apoptosis is triggered either by the withdrawal of positive 
survival signals or by exposure to negative death signals, which 
respectively trigger the intrinsic and extrinsic apoptotic pathways. 
Morphologically, apoptotic neutrophils are distinct from their healthy 
counterparts. Apoptosis results in condensation of the nuclear chromatin, 
nuclear fragmentation, and degradation of DNA and proteins, leading to 
condensation of the nucleus which loses its characteristic multi-lobed 
shape and becomes more rounded, disappearance of the granules and 
overall cell shrinkage 
42
. Once neutrophils have undergone apoptosis they 
are cleared by other phagocytic immune cells, such as macrophages to 
prevent release of proteases 
46
. 
Neutrophils may be exposed to multiple mediators of inflammation, so 
their fate depends on the balance between pro-survival and pro-apoptotic 
cues. Cell death is facilitated by activation of a cascade of caspase 
(cysteine-aspartic protease) cleavage. Caspases exist in inactive, pro-forms 
in the cell until, following an apoptotic signal, they are sequentially 
cleaved and activated in a cascade mechanism. This cascade culminates in 
the cleavage and degradation of a number of proteins in the cell and 
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ultimately cellular disassembly and death. Caspases are activated via both 
intrinsic and extrinsic apoptotic signalling, and it is reported that their 
function can be further mediated by ROS 
103,104
. 
1.3.1 The intrinsic apoptotic pathway 
Constitutive neutrophil apoptosis in the absence of inflammatory signals is 
achieved by constitutive expression of pro-apoptotic members of the Bcl-2 
family. These proteins, including Bax, Bad, Bak and Bid, have a relatively 
long half-life and their expression is not greatly affected by agents that 
induce or delay apoptosis 
5,105
. Thus, dynamic regulation of neutrophil 
apoptosis is mainly achieved by the anti-apoptotic Bcl-2 family members. 
The anti-apoptotic Bcl-2 family member Mcl-1 plays a key role in 
neutrophil apoptosis. There is some evidence that neutrophils also express 
the other anti-apoptotic Bcl-2 family members A1 (Bfl-1), and possibly to 
a lesser extent Bcl-XL, but not Bcl-2 
105,106
. Mcl-1 is responsive to 
stimulation by pro-apoptotic stimuli such as cytokines, and as such is the 
key protein responsible for the dynamic regulation of neutrophil apoptosis 
38,105
. Mcl-1 is a short lived protein and its rates of transcription and protein 
turnover control the rate of neutrophil apoptosis. Pro-inflammatory 
cytokines, such as GM-CSF and other inflammatory indicators such as 
hypoxia, can stimulate transcription of Mcl-1 in neutrophils, although this 
increase in transcription is modest compared to the change in protein 
levels, suggesting that this may not be the major way cellular levels are 
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controlled 
105,107,108
. Post-transcripitonal splicing can also modulate the 
protein levels, as a short version of the transcript is generated when exon 2 
is removed, forming a protein with pro-apoptotic activity that inhibits the 
action of full-length Mcl-1 
109,110
. The major way in which levels of Mcl-1 
are controlled in neutrophils is via post-translational modifications. Mcl-1 
has a number of phosphorylation sites and its phosphorylation at different 
sites can have a differing effect on its stability; for example 
phosphorylation by ERK stabilises Mcl-1 
111
, whereas phosphorylation at 
alternative sites by Glycogen synthase kinase-3 (GSK3), results in its 
destabilisation 
112,113
, and hyper-phosphorylation of Mcl-1 targets it for 
degradation by the proteosome 
114
. Because of these differing outcomes of 
phosphorylation on its stability,  Mcl-1 has been described as the factor 
that integrates the opposing actions of pro-survival and pro-apoptotic 
signalling pathways 
115
. 
These biological properties of Mcl-1 make it suited for the acute and 
dynamic regulation of apoptosis required for neutrophils; in the absence of 
continued expression, Mcl-1 is rapidly broken down and neutrophil 
apoptosis is triggered. The sensitivity of Mcl-1 to pro-inflammatory 
mediators however, means that its expression can be increased and the 
protein can be stabilised, extending neutrophil life-span to facilitate 
bacterial killing. The naturally short-life span of the protein encourages 
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neutrophil apoptosis, facilitating resolution of inflammation following 
removal of inflammatory stimuli 
38,102,116
. 
The pro-apoptotic Bcl-2 family members mediate apoptosis via the 
intrinsic or mitochondrial pathway by controlling permeabilisation of the 
outer mitochondrial membrane. Assisted by other pro-apoptotic proteins 
such as Bid, Bak and Bax oligomerise and promote formation of pores in 
the mitochondrial outer membrane. This disruption of the membrane leads 
to release of a number of pro-apoptotic factors including cytochrome c. 
Cytochrome c along with its interacting protein, apoptotic protease 
activating factor 1 (APAF1), recruits and activates caspase 9, which goes 
on to activate the downstream effector caspase, caspase 3, culminating in 
cell death 
4,5,117
. Anti-apoptotic Mcl-1 contains three BH3 (Bcl-2 homology 
domains) that allow it to associate with other Bcl-2 proteins 
115,118
. In this 
way,  Mcl-1 can neutralise the pro-apoptotic activity of Bcl-2 family 
proteins, by sequestering them and inhibiting activation of pore-formation 
at the mitochondrial membrane 
38,119,120
. Under conditions of stress, the 
Mcl-1 antagonist NOXA, causes release of the sequestered pro-apoptotic 
Bcl-2 proteins and apoptosis is triggered 
121–123
. 
1.3.2 The extrinsic apoptotic pathway 
Neutrophil apoptosis can also be triggered extrinsically, by engagement of 
death receptors on the neutrophil surface. Engagement of a death receptor 
leads to the activation of the initiator caspases (including caspases 8, 9, 10 
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and 12), which go on to activate the downstream effector caspases 
(including caspases 3, 6 and 7) 
124
. These extrinsically-activated apoptotic 
signalling pathways usually bypass the intrinsic or mitochondrial apoptotic 
pathway, and as such are not regulated by the Bcl-2 family. However, the 
pro-apoptotic Bcl-2 family member Bid can be activated by caspase-8, 
suggesting there is some level of crosstalk between the two pathways 
124,125
. The death receptors are generally transmembrane proteins 
containing an intracellular motif known as a death domain. Upon receptor 
engagement these death domains translate this signal to the intracellular 
apoptotic machinery by association with a variety of apoptotic factors 
126,127
. Two of the most well characterised neutrophil death receptors are 
TNFR1 and Fas (also known as TNFR superfamily member 6), 
engagement of which activates intracellular caspase cleavage cascades via 
initial activation of caspase 8 in a similar manner for both receptors 
127
. Fas 
ligand (FasL) activates the Fas receptor, and TNFα is the receptor for the 
TNFR group, and in both cases binding of the trimeric ligand leads to 
trimerisation and cross-linking of receptors. This results in clustering of the 
intracellular death domains to initiate recruitment of apoptotic adaptor 
proteins; either the Fas-associated death domain-containing protein 
(FADD) or TNFR-associated death domain-containing proteins (TRADD). 
These molecules also contain death effector domains that facilitate 
interaction with apoptotic molecules. FADD associates with the pro-form 
of the initiator caspase, caspase 8 and induces autoprocessing to the active 
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form 
128
. This complex of Fas, FADD and pro-caspase 8 has been termed 
the death-inducing signalling complex (DISC) 
124,129
. TRADD can also 
associate with FADD to initiate apoptosis in this manner 
130
, but TRADD 
alternatively associates with a variety of other secondary adaptor molecules 
that can lead to activation of transcription factors and production of pro-
survival signals 
131,132. At low concentrations, TNFα specifically induces 
expression of the pro-survival protein A1 (Bfl-1) in neutrophils. Thus, 
TNFα has opposing concentration dependent effects on neutrophil 
apoptosis 
133
. 
1.4 Neutrophils in chronic inflammation 
Neutrophils are critically important in host defence,  but due to their 
cytotoxic contents, they have great capacity to cause tissue damage if their 
function and apoptosis are not tightly regulated. The potential of 
neutrophils to exacerbate chronic inflammation is now appreciated, and 
they have been shown to contribute to rheumatoid arthritis (RA), chronic 
obstructive pulmonary disease (COPD) and Behçet’s disease 2,6. 
Neutrophils have been shown to be inappropriately activated in these 
conditions, leading to the release of cytotoxic products, and also cytokines 
and chemoattractants 
2
. One inflammatory disease in which the 
contribution of neutrophils to the inflammatory state is of great interest, is 
RA 
2,6,11
. During active disease, the normally acellular joint becomes 
infiltrated with immune cells, of which neutrophils are by far the most 
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numerous accounting for up to 90% of the cells in the synovial fluid of a 
typical rheumatoid knee joint 
7,8
. The etiology of RA remains incompletely 
understood, but neutrophils are thought to contribute to the characteristic 
inflammation and tissue damage observed in the rheumatoid joint 
2,6,11
. 
1.4.1 Rheumatoid arthritis 
RA is a systemic, autoimmune inflammatory disease, mainly characterised 
by symmetrical polyarthritis of the diarthrodial (free moving) joints, 
especially the small joints of the hands and feet 
14,16
. The onset of the 
disease is subtle, but the predominant symptoms of established disease are 
pain, swelling and stiffness of the peripheral joints. The symptoms can be 
mild and self-limiting in some patients, whereas in others they can rapidly 
lead to severe deformity and loss of function. Further complications of 
systemic inflammation include an increased risk of vasculitis, respiratory 
and cardiac diseases, which can lead to profound morbidity and reduced 
life expectancy 
14,134,135
. Inflammation of the synovium (synovitis) is 
fundamental to the pathophysiology of RA, and correlates with disease 
progression; characteristically a pannus of proliferative and invasive 
synovial tissue forms locally and exacerbates joint erosion 
14,136
. Joint 
destruction resulting from this persistent synovitis is typically rapid, and is 
detectable by radiographic techniques within the first 2 years of onset of 
disease in more than 70% of patients. This predates functional disability by 
a number of years and often once physical deformity is presented, 
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irreversible joint damage has already occurred 
14,136
. Because of this, early 
and effective drug intervention is imperative in RA to prevent 
accumulation of irreversible joint damage.  
1.4.2 Clinical measurements and treatment of RA 
A classification system for diagnosis of RA was developed by the 
American College of Rheumatology. It describes defining criteria of the 
disease, including corporal features evident upon examination, such as 
morning stiffness and swelling of the joints, and those that require further 
investigation, such as radiographic erosions and the presence of 
inflammatory serum markers 
137
. A number of biochemical markers have 
been identified as being of prognostic value in RA; the erythrocyte 
sedimentation rate (ESR) and serum C-reactive protein (CRP) are 
inflammatory markers associated with RA 
138,139
.  However, joint damage 
has been shown to progress in the absence of these inflammatory markers 
16
. More recently, serum levels of the autoantibodies rheumatoid factor 
(RF), and anti-cyclic citrullinated peptide antibodies (anti-CCP) have been 
associated with more severe joint damage, and anti-CCP is reported to be 
more specific for RA 
16,140–143
. However, RA is a very heterogeneous 
disease and the presence or absence of these markers does not always 
correlate with disease activity or progression, making a multifaceted 
diagnosis of prime importance 
16
. 
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Typically, treatment for RA includes a combination of non-steroidal anti-
inflammatory drugs (NSAIDs), disease modifying anti-rheumatic drugs 
(DMARDs) and the newer class of biological-response modifiers 
(biologics) that target specific cytokine mediators of disease 
144–147
. 
Analgesic NSAIDs improve the symptoms of disease, although they do 
little to alter its progression; they generally act by inhibiting 
cyclooxygenase and decreasing production of inflammatory prostaglandins 
145,148
. As their name suggests, DMARDs modify disease, slowing clinical 
and radiographic progression. They are thought to act by either directly or 
indirectly affecting inflammatory pathways mediated by cytokines 
144,148
. 
DMARDs, including methotrexate, hydrochloroquine and sulfasalazine, 
are now used as the first-line therapy for all newly diagnosed cases of RA 
149
. Many patients will remain well-controlled through a combination of 
DMARD therapy and NSAIDs for management of pain and inflammation. 
However, those with more severe disease may be given biologics that 
selectively inhibit specific molecules of the immune system. These include 
inhibitors of cytokines, such as: etanercept, infliximab and adalimumab, 
that target TNFα; anakinra that targets interleukin-1; tocilizumab which 
targets the IL-6 receptor; rituximab an anti-CD20 antibody that targets 
CD20 positive cells, specifically B-cells; and abatacept, a fusion protein 
that inhibits the co-stimulation of T-cells 
144,146,149
. These therapies are very 
effective in the majority of patients but a significant cohort remain 
refractory to treatment or develop resistance 
15,150
. Due to the progressive 
 46 
 
nature of the disease, bringing it under control quickly is vitally important 
to prevent further irreversible joint damage. Hence, research into 
alternative treatment strategies and diagnostic markers of response in RA is 
ongoing. 
A system has been developed for scoring the severity of disease in RA, 
known as the disease activity score or DAS. This combines measurement 
of the ESR, the number of tender and swollen joints and a self-
measurement of pain, into a numerical value. The classification of the 
scoring system is shown in Table 1.2. Generally, patients are only 
prescribed biologic therapies for RA if they sustain a high DAS following 
DMARD therapy. A patient is considered to respond to therapy if they 
show an improvement in their DAS of ≥1.2 151. 
DAS Classification 
≤ 2.6 Remission 
2.7 - 3.2 Low 
3.3 - 5.0 Moderate 
≥ 5.1 High 
TABLE 1.2 DAS score classification system 
151
. 
1.4.3 The immune system in RA 
The etiology of RA remains incompletely understood. However, it is 
thought that genetic factors make individuals more susceptible to 
producing auto-antibodies in response to environmental triggers, such as 
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cigarette smoke. Autoimmunity is thought to be established a number of 
years before the onset of symptoms 
152
. In active disease, a number of 
immune cell types of both the adaptive and innate immune systems 
infiltrate the normally acellular joint. Immune cells such as lymphocytes, 
macrophages and neutrophils infiltrate the synovial lining of the joint and 
the proliferative pannus, comprised of activated synovial fibroblasts 
153,154
. 
Here, the pro-inflammatory mediators secreted by these cell types activate 
osteoclasts at the pannus/cartilage junction, and these cells, together with 
neutrophils and macrophages produce proteases. This is the site of active 
cartilage and bone destruction, and the perpetual recruitment and activation 
of cells, involving many elements of the immune response, alongside the 
production of cytotoxic products leads to the irreversible damage observed 
in the rheumatoid joint 
8,10,155
. 
1.4.4 The neutrophil in RA 
Neutrophils account for up to 90% of the cells in the synovial fluid of a 
typical rheumatoid knee joint 
7,8
 and have been observed at the 
pannus/cartilage junction 
8,10
. A number of animal models of inflammatory 
arthritis also show that in vivo neutrophils are the first immune cell types to 
infiltrate the joint and correlate with early measures of inflammation in 
these models 
156
. The cytokines inappropriately produced during chronic 
inflammation lead to priming of circulating neutrophils and their 
chemotaxis towards the rheumatoid joint, which contains high levels of 
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pro-inflammatory cytokines such as IL-1β, IL-6, GM-CSF and TNFα 157. 
Neutrophils aspirated from rheumatoid joints display an activated 
phenotype such as: increased mRNA expression, for transcripts such as 
those for chemokines, cytokines and destructive proteins such as matrix-
metalloproteinases (MMP); increased ROS production; and increased 
surface expression of markers such as class II major histocompatibility 
complex (MHCII) molecules, and the IgG receptor FcγRI (CD64) 17,158–160. 
Neutrophil apoptosis is also delayed for several days when they enter the 
inflammatory environment of the rheumatoid joint 
12,13
. These primed 
neutrophils, that are present in large numbers, can be activated by 
molecules found within the rheumatoid joint, such as IgG-containing 
immune complexes. Immune complexes in RA are aggregates of 
autoantibodies and antigens that interact with neutrophils via the Fcγ 
receptors. They are the major neutrophil activating factors in the 
rheumatoid joint. Large insoluble immune complexes interact via FcγRII 
and are usually phagocytosed by neutrophils with few side effects; 
however, smaller, soluble immune complexes interact via both FcγRIIIb 
and FcγRII, and stimulate secretion of destructive ROS and granule 
enzymes from primed neutrophils into the extracellular milieu 
161–163
. 
Indeed, comparison of neutrophils from the synovial fluid to those in the 
peripheral blood, suggest that those in the joint had undergone 
degranulation, as they had lower levels of intracellular granule enzymes 
164
. 
Immune complexes can also be deposited onto tissue surfaces, such as the 
 49 
 
pannus, which can stimulate a process known as frustrated phagocytosis. 
During this, the neutrophil releases its cytotoxic products directly at the 
pannus surface, leading to a high localised concentration of damaging 
agents linked to cartilage destruction 
11
. Additionally, increased release of 
ROS from neutrophils is thought to be responsible for oxidative stress in 
the tissue, another hallmark of RA 
160
. Immune complexes and cytokines in 
the joint can also induce expression of further cytokines (such as IL-1β and 
TNFα) and chemoattractants (such as LTB4 and IL-8) from neutrophils, 
recruiting and activating further immune cells and contributing to the 
perpetuation of inflammation in the joint 
17
. 
Taken together, the infiltration of large numbers of activated neutrophils 
into the rheumatoid joint, and the presence of their pro-inflammatory 
products in the extracellular milieu, strongly indicates a role for these cells 
in the pathophysiology of RA. If their function and/or apoptosis are not 
appropriately controlled, these cells have great capacity to cause damage in 
inflamed tissue, due to the release of tissue-damaging proteases, ROS and 
cytokines. As such, neutrophils represent an attractive target in RA, a 
disease in which it is of interest to identify novel molecular targets due the 
high degree of heterogeneity in both the disease and the response to 
treatment. A recent high-level screen of genes expressed by neutrophils in 
a number of inflammatory diseases (RA, Beçet’s disease and scleroderma), 
was carried out (prior to the start of this PhD) with the aim of identifying 
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neutrophil biomarkers of inflammatory disease. A major finding was a 
remarkably high level of transcripts for the NAMPT gene observed in all 
samples (Edwards et al. unpublished data). This gene is of particular 
interest due to its recently defined role in the regulation of neutrophil 
apoptosis 
19
 and its correlation with inflammatory disease 
18,165
. 
1.5 NAMPT 
NAMPT is a highly conserved and ubiquitously-expressed protein with a 
number of described functions. NAMPT is a nicotinamide 
phosphoribosyltransferase enzyme which catalyses a key stage in the 
mammalian NAD salvage pathway, but it has also been described as 
having a signalling function as a cytokine when released from immune 
cells: somewhat controversially, it has also been described as an adipokine 
released from adipose tissue 
23,166
. These multiple functions of NAMPT 
have led to the use of other names for this protein, such as pre-B-cell 
colony stimulating factor (PBEF) and visfatin, the derivation of which are 
described below. The term NAMPT, has now been approved by the 
Human Genome Organisation Gene Nomenclature Committee. The 
following section covers the research history of NAMPT, the discoveries 
of the various proposed functions of this protein, and also NAMPT gene 
and protein structure.  
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1.5.1 NAMPT history 
Human NAMPT was first identified and cloned from activated human 
peripheral blood lymphocytes by Samal and colleagues in 1994 
167
. With 
the aim of identifying new factors involved in early B-cell development, 
Samal et al. screened an activated human peripheral blood lymphocyte 
cDNA library with a degenerate oligonucleotide probe, designed on the 
basis of the similarity of the signal peptidase processing site coding 
sequences of cytokines such as GM-CSF, IL-1β, IL-2, IL-3 and IL-6. 
They identified a novel molecule which functioned to synergise the pre-
B-cell colony forming activity of stem cell factor and IL-7, and 
designated it pre-B-cell colony stimulating factor (PBEF). It was defined 
as a novel cytokine that acts on early B-lineage precursor cells. PBEF 
lacked the characteristic signal peptide necessary for extracellular 
secretion, but more characteristically of a cytokine, it contained multiple 
TATT motifs in the 3' untranslated region and was found to be 
upregulated in response to pokeweed mitogen, cycloheximide and PMA 
in activated lymphocytes and COS cells 
167
.  
It was not until 2001 that another function of PBEF/NAMPT was 
identified from an unrelated field. Martin et al. 
168
 identified that a gene 
they cloned from Haemophilus ducreyi showed significant sequence 
homology to the mammalian PBEF cloned by Samal et al. 
167
. Members 
of the bacterial family Pasteurellaceae can be distinguished, in part, by 
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their ability to synthesise NAD from nicotinamide, known as V-factor 
independence. V-factor dependent strains require NAD supplemented 
media for growth in the laboratory. Martin and colleagues 
168
 cloned the 
gene responsible for this phenotype from H. ducreyi and named it nadV. 
They demonstrated that when transformed into other V-factor dependent 
species of bacteria, nadV conferred NAD independence. Sequence 
analysis of the nadV gene then surprisingly revealed significant 
homology to mammalian PBEF 
168
. Shortly after this, Rongvaux et al. 
30
 
demonstrated that mammalian PBEF also had nicotinamide 
phosphoribosyltransferase activity and was able to confer V-factor 
independent growth to a V-factor dependent strain of bacteria, confirming 
the high degree of evolutionary conservation of this gene. NAMPT 
(nicotinamide (NAM) phosphoribosyltransferase (PT)) has since been 
approved as the official name for this gene. This activity of NAMPT was 
corroborated by Revollo et al. in 2004 
169
 who reconstituted the 
mammalian NAD biosynthesis pathway in vitro using purified 
recombinant NAMPT and NMNAT (nicotinamide mononucleotide 
adenylyl transferase) 
169
. 
In 2005 a further function of NAMPT was proposed when Fukuhara et al. 
31
 identified NAMPT as a novel visceral fat-derived hormone which they 
termed visfatin. They showed that visfatin was highly enriched in visceral 
fat as compared to subcutaneous fat, and that plasma visfatin was 
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elevated in obesity. They also suggested that visfatin exerted insulin 
mimetic effects on its target cells, such as enhanced glucose uptake and 
increased triglyceride synthesis, and that in mice it lowered plasma 
glucose by binding to and activating the insulin receptor at a site distinct 
from insulin. However, subsequent studies have yielded conflicting 
results with regard to the relationship between circulating visfatin, 
obesity and insulin resistance and none have been able to replicate the 
insulin mimetic effects of visfatin 
26,170–172
. It was later demonstrated that 
differences in the detection of visfatin by different immunoassays may be 
responsible for the conflicting observations 
173
. The Fukuhara et al. paper 
was eventually retracted in 2007, and it remains unclear whether 
visfatin/NAMPT is a true adipokine and how it is related to insulin 
sensitivity. 
1.5.2 Current opinion on NAMPT function 
It has been robustly demonstrated, via biochemical and structural analyses, 
that NAMPT functions in NAD biosynthesis 
27,29,168,174,175
.  However, the 
physiological function of this protein is still under investigation. NAMPT 
has been shown to have both intra- and extracellular enzyme activity, 
leading to the terms iNAMPT and eNAMPT respectively. It is suggested 
that eNAMPT acts as a cytokine, but whether this is discernible from its 
role in NAD biosynthesis is yet to be elucidated, and some conflicting data 
have been presented 
22,26,171
. Currently, NAMPT research occurs in a 
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variety of fields, including NAD biology, metabolism and inflammation.  
Current knowledge of the functions of NAMPT in each of these areas is 
discussed in more detail in sections 1.6 - 1.8. 
1.5.3  NAMPT gene and protein structure 
The NAMPT gene is composed of 11 exons and 10 introns, and spans a 
length of 34.7 kb on Chromosome 7. Exon 1 encodes a short 5' 
untranslated region (UTR) and the signal peptide region, while exon 11 
encodes a 3' UTR 
176
. Samal et al. identified 3 NAMPT mRNA transcripts 
by northern blot analysis, of 2.0, 2.4 and 4.0 kb, the 2.4 kb species being 
the most abundant 
167
. The NAMPT gene has two promoter regions, 
proximal and distal, in the 5' flanking region which contain multiple 
transcription initiation sites and multiple binding sites for transcription 
factors such as SP-1, NF-1, AP-1 and -2, STAT and NF-κB (Fig. 1.4). 
Some transcription factor binding sites are constrained to either the 
proximal or distal promoter; for example the SP-1 binding site is found 
solely in the proximal region and the NF-κB site solely in the distal region, 
whereas others, such as the AP-1 and STAT sites, are distributed 
throughout the promoter region. Both promoter regions contain putative 
regulatory elements responsive to hormonal and chemical signals, but the 
distribution has led to the suggestion that the proximal region is more 
susceptible to regulation by phosphorylation and hormones 
23,176
.  
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FIGURE 1.4: Schematic representation of the regulatory  
elements of the NAMPT promoter region. The 5' upstream region can be 
divided into the proximal (–1400 to +1) is more GC-rich, and the distal (–
3200 to –1400) has more AT bases. The line marked nt (nucleotides) 
represents the distance of the regulatory element from the transcription 
initiation site, which is marked by an arrow in exon 1 (adapted from 
23
). 
A number of single nucleotide polymorphisms (SNPs) have been identified 
in the NAMPT gene, but the functional consequences of most of these 
SNPs are yet to be identified. However, a number of studies have linked 
NAMPT SNPs to serum levels of cholesterol, triglycerides, fasting insulin 
and glucose 
177–181
 and also susceptibility to acute respiratory distress 
syndrome (ARDS) 
182,183
. NAMPT is expressed ubiquitously in nearly all 
tissues of the body 
18,20,167,170,184
, and is particularly highly expressed in the 
liver, peripheral blood leukocytes and adipose tissue 
27,31,167,184
. Abnormal 
NAMPT expression has been associated with a number of disorders, 
especially those involving chronic inflammation 
19,32,165,170,172,185–187
. 
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The NAMPT 2.4 kb mRNA species encodes the 491 amino acid, 52 kDa 
NAMPT protein. The three-dimensional structure of mammalian NAMPT 
confirms it is a dimeric type II phosphoribosyltransferase (PRT), and 
despite low sequence identity with other type II PRTs, NAMPT shows 
significant tertiary structural similarity to PRT enzymes in other NAD 
biosynthesis pathways, such as nicotinic acid PRT and (NaPRTase) and 
quinolinic acid PRT (QaPRTase), although the active site topology differs 
between these enzymes 
29,175
. NAMPT functions as a homodimer, with the 
active site formed at the dimeric interface and it binds nicotinamide 
(NAM), which with 5-phosphoribosyl-pyrophosphate (PRPP), is converted 
into nicotinamide mononucleotide (NMN) 
29,175
. This is the rate-limiting 
step in the mammalian NAD salvage pathway 
27,30
, which is discussed in 
more detail in the following section. An inhibitor of NAMPT function, 
FK866 (also known as APO866 and WK175), has been developed which 
binds in a tunnel at the interface of the NAMPT dimer and competes 
directly with the substrate nicotinamide 
28,29
. 
1.6 NAMPT in NAD Synthesis 
NAMPT has been definitively characterised as a nicotinamide 
phosphoribosyltransferase that is crucial in the mammalian NAD salvage 
pathway 
26,30
. NAD is a crucial metabolic coenzyme in redox reactions, and 
also serves as a substrate for NAD-consuming enzymes in a variety of 
biological processes. It remains unclear whether the proposed signalling 
 57 
 
actions of NAMPT are due to a distinct cytokine-like function of this 
protein, or if these functions are attributed to the effects of modulating 
NAD production. 
1.6.1 NAD 
Nicotinamide adenine dinucleotide (NAD) is found in all living cells, as it 
has a central role in cellular metabolism and energy production. NAD and 
its phosphorylated (NADP) and reduced forms (NADH, NADPH) are 
crucial coenzymes in many redox reactions, readily accepting and donating 
electrons, as summarised in the equation below. This often leads to the 
production of ATP in dehydrogenase-catalysed reactions 
188,189
. 
RH2 + NAD
+
 → NADH + H+ + R 
More recently, however, NAD has been shown to be important as a 
substrate for NAD consuming enzymes that are involved in a range of 
biological processes 
188
. They can be grouped into three general classes that 
utilise NAD as a substrate for 1) ADP-ribose transfer, 2) cADP-ribose 
synthesis or 3) protein deacetylation.  
1) ADP-ribose transferases (ARTs) and poly-ADP-ribose polymerases 
(PARPs) cleave NAD-producing NAM and an ADP-ribosyl 
product. The latter is utilised by these enzymes for protein 
modification, which is important in processes including DNA 
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repair, transcriptional control, epigenetic modifications, G-protein 
coupled signalling and apoptosis 
190–192
.  
2) cADP-ribose synthases catalyse production of  cyclic ADP-ribose 
from NAD 
193
 and nicotinate adenine dinucleotide phosphate 
(NaADP) from NADP, both involved in calcium mobilisation 
193,194
.  
3) Mammalian sirtuins are histone deacetylases (HDAC) that function 
in chromatin remodelling, which affects control of transcription. 
Sirtuins simultaneously bind acetylated lysine residues and NAD, 
and can deacetylate the residue by transferring the acetyl group 
onto the ADP-ribose moiety produced when NAD is cleaved 
195,196
. 
In metabolic redox reactions, NAD is interconverted between its oxidised 
and reduced forms without net consumption. However, in these regulatory 
cellular processes where NAD functions a donor of ADP-ribose, it is 
cleaved. Because of this, NAD resynthesis is required to replenish 
intracellular stores. The ART, PARP, cADP ribose synthase and sirtuin 
enzymes that cleave NAD, can also be inhibited by nicotinamide that is 
released during cleavage 
188,197–199
. Therefore, removal or salvage of 
nicotinamide is also a crucial stage in NAD resynthesis. NAD turnover 
within the cell is a dynamic process, as the half-life of the NAD molecule 
is estimated at 1-2 h 
200
. NAD can be phosphorylated by the cytoplasmic 
NAD kinase (NADK), and NADP/H also functions as an electron 
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donor/acceptor in redox reactions, including the respiratory burst of 
neutrophils 
201
. 
1.6.2 NAD Synthesis 
Mammalian NAD is synthesised from a combination of de novo and 
salvage pathways (Fig. 1.5). De novo synthesis occurs in the liver where 
the essential amino acid tryptophan is converted into quinolinic acid via the 
so-called kynurenine pathway, which can then be converted into nicotinic 
acid mononucleotide (NaMN) 
202
. At this point, the de novo pathway 
converges with the NAD salvage pathway(s). NAD can be recycled from 
nicotinic acid (Na) or nicotinamide (NAM). Lower eukaryotes 
predominately use Na as the NAD precursor, via the so-called Preiss-
Handler pathway 
203
, and whilst this pathway exists in mammals they 
primarily synthesise NAD from nicotinamide. NAMPT catalyses the 
condensation of nicotinamide and 5-phosphoribosyl-pyrophosphate 
(PRPP) to form NMN (as summarised in the equation below), which is 
then converted into NAD by NMN adenyltransferase (NMNAT) 
27
. There 
are three distinct isoforms of NMNAT (NMNAT1-3) which are localised 
to different subcellular compartments, namely the nucleus, cytoplasm and 
mitochondrion 
204
. 
NAM + PRPP                      NMN + PPi 
 
NAMPT 
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FIGURE 1.5: Mammalian NAD synthesis pathways.  NAD can be 
synthesised de novo from tryptophan or recycled via the salvage pathways 
from either nicotinic acid (Na), via Na mononucleotide and Na adenine 
dinucleotide; or from nicotinamide (NAM) via nicotinamide 
mononucleotide (NMN). NAMPT catalyses the conversion of NAM to 
NMN, and the cycle is completed by the action of NMN adenyltransferase 
(NMNAT). 
Nicotinamide represents the major source of NAD for most mammalian 
cell types, and the recycling of nicotinamide that is released during NAD 
cleavage by NAD-consuming enzymes, is an important homeostatic 
mechanism. NAMPT is the rate-limiting enzyme in the nicotinamide 
salvage pathway, and as such represents an important mediator of many 
cellular processes. 
1.6.3 NAMPT inhibitor – FK866 
The enzymic action of NAMPT can be blocked by the chemical inhibitor 
FK866 (also known as APO866 and WK175). FK866 was developed as an 
antitumor agent, as it was found to gradually deplete intracellular NAD, 
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which consequently led to apoptosis in the human monocytic cell line 
THP-1 
205
. Later, it was confirmed that FK866 depleted NAD and triggered 
apoptosis in HepG2 liver carcinoma cells, by inhibiting the NAMPT 
enzyme with an IC50 of approximately 1 nM. This study also calculated the 
inhibitor constants of 0.4 nM for the enzyme/substrate complex (Ki) and 
0.3 nM for the free enzyme (Ki'), respectively 
206
. This inhibition is specific 
to NAMPT and the nicotinamide salvage pathway, and FK866 does not 
affect the action of the closely-related enzymes nicotinic acid 
phosphoribosyltransferase (NaPRTase) and quinolinic acid 
phosphoribosyltransferase (QaPRTase) 
28,206
. Kinetic studies led to the 
initial suggestion that FK866 inhibited NAMPT in a non-competitive 
manner 
206
, however more recently resolution of the crystal structures of 
NAMPT alone and in complex with the reaction product (NMN) or FK866 
indicated that FK866 should compete directly with the nicotinamide 
substrate 
28
. The authors suggest that the Ki of FK866 of 0.3 nM indicated 
that it may have a very slow dissociation rate from the enzyme, and that 
FK866 essentially functions as an irreversible inhibitor of NAMPT 
28
. The 
resolution of the NAMPT crystal structure also confirmed that NAMPT 
functions as a dimer, as the active site is located in the dimer interface with 
residues from both monomers contributing to recognition of the substrate. 
The two monomers interact closely, with 4,000 Å
2
 of the surface area of 
each in contact at the interface of the dimer. The dimer forms a tunnel at 
the monomer interface in which the active site is located. This tunnel is 
 62 
 
about 15 Å and is also narrow, decreasing to 6 Å in places; this may 
account for the relatively slow dissociation of the inhibitor form the 
enzyme observed 
28
. 
FK866 has recently completed phase II clinical trials for a number of solid 
and hematologic malignancies, and tumour cells are thought to be 
particularly sensitive to the effects of NAD depletion by FK866 due to 
their increased metabolic requirements. The use of this compound in vitro 
and in in vivo models has allowed manipulation of NAD turnover, and has 
increased understanding of the role of the NAD salvage pathway in many 
cellular processes. More recent work with FK866 has indicated that it also 
shows promise as an anti-inflammatory agent 
19,33,34
, suggesting that NAD 
is a key regulator of immune cell function. 
1.6.4 Role of NAMPT as a NAD biosynthetic enzyme in human diseases 
Dysregulation of NAD homeostasis can be causative or indicative of 
numerous disorders, as NAD(P) participates in a wide array of metabolic 
and other fundamental cellular pathways. As NAMPT is the major enzyme 
that controls the rate of NAD synthesis, it is also implicated in many key 
cellular processes. In fact dysregulation of NAMPT function has been 
implicated in a number of human diseases and conditions, such as acute 
respiratory distress syndrome 
182,183
, aging 
204,207
, atherosclerosis 
185
, 
inflammatory bowel disease 
20
, cancer 
206,208,209
, diabetes 
172,210
, sepsis 
19
 
and rheumatoid arthritis 
18,32,33,165
. Although NAMPT acting as a cytokine 
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has been implicated in many of these disorders, its effect on many, if not 
all, of these conditions can also be attributed to availability of NAD either 
for specific NAD-consuming enzymes, such as the sirtuins (in aging and 
PARPs in DNA repair and cancer), or for metabolic processes such as the 
respiratory burst of immune cells. The role of NAMPT as an enzyme in 
inflammatory disease, specifically rheumatoid arthritis, will be covered in 
section 1.8. 
1.7 NAMPT as a Cytokine 
NAMPT is a ubiquitously-expressed protein, and has been reported to 
exert a variety of effects on a number of cell types. It is purported to have a 
cytokine-like function, and was initially identified by the sequence 
similarity in its coding region to that of other cytokines 
167
. Exogenous 
NAMPT can stimulate expression of cytokines, chemokines and matrix-
degrading enzymes from synovial fibroblasts and monocytes 
18
, and it 
delays the apoptosis of neutrophils and macrophages 
19,22
. However, the 
mechanism by which NAMPT is released from cells is still a matter of 
debate 
211,212
, and no cell surface receptor for NAMPT has been identified. 
It was suggested that NAMPT can bind to the insulin receptor at a site 
distinct from that of insulin 
31
, although this has not been reconfirmed to 
date 
26
. The proposed role of NAMPT as a cytokine in inflammatory and 
metabolic diseases is discussed in this section. 
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1.7.1 NAMPT expression and release 
NAMPT is essential for development, as it has been shown that NAMPT 
gene knockouts are embryonic lethal in mice 
26,31,174
. NAMPT is 
ubiquitously expressed in the body, although it is particularly highly-
expressed in the liver, adipose tissue and immune cells. It is well-validated 
that NAMPT expression can be upregulated in a number of immune cells 
in response to endotoxin and inflammatory cytokines 
20
. The expression of 
NAMPT in response to these stimuli, in a variety of cell types, is 
summarised in Table 1.3. 
NAMPT is detected at relatively high levels in the circulation (~90 ng/mL), 
at a concentration around 9 times that of other common adipokines such as 
leptin, adiponectin and resistin 
165; cytokines such as TNFα and IL-6 are 
generally observed to be around 10-20 pg/mL in the serum 
214
. NAMPT is 
reported to be significantly elevated during inflammation 
18,32,165
, obesity 
and diabetes 
31,172
, amongst other conditions. However, it is still not well 
understood how NAMPT is released from cells, and some argue that it is 
released solely through cell death and lysis 
171,212
. NAMPT does not 
contain a putative N-terminal signal sequence, commonly-seen in other 
secreted cytokines 
167,176
, but it has been suggested that NAMPT is 
actively-secreted by the 3T3-L1 adipocyte cell line during culture, in 
similar ways as other adipokines are secreted.  
211
. This secretion was 
independent of the endoplasmic reticulum (ER)-Golgi system, as it was not  
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STIMULUS CELL TYPE REFERENCE 
TNFα 
Monocytes Dahl et al., 2007 
185
 
Macrophages 
Iqbal & Zaidi, 2006 
213
 
Neutrophils Jia et al., 2004 
19
 
Amniotic epithelial cells 
Ognjanovic et al., 
2001 
176
 
Lung microvascular endothelial 
cells 
Ye et al., 2005 
182
 
IL-1β 
Neutrophils Jia et al., 2004 
19
 
Amniotic epithelial cells 
Ognjanovic et al., 
2001 
176
 
Lung microvascular endothelial 
cells 
Ye et al., 2005 
182
 
IL-6 
Amniotic epithelial cells 
Ognjanovic et al., 
2001 
176
 
Synovial fibroblasts Nowell et al., 2006 
32
 
IL-8 Neutrophils Jia et al., 2004 
19
 
GM-CSF Neutrophils Jia et al., 2004 
19
 
Oncostatin-M Synovial Fibroblasts Nowell et al., 2006 
32
 
Endotoxin/LPS 
Neutrophils Jia et al., 2004 
19
 
Amniotic epithelial cells 
Ognjanovic et al., 
2001 
176
 
Lung microvascular endothelial 
cells 
Ye et al., 2005 
182
 
TABLE 1.3: Expression of NAMPT induced by inflammatory 
mediators in a number of cell types. Adapted from 
23
. 
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blocked by addition of inhibitors of this pathway, and microvesicles 
secreted by these cells contained very little NAMPT.  Thus, it was 
suggested that secretion occurs via a non-classical pathway, consisting of 
several discrete secretory machineries 
211
. One study has addressed the 
expression and release of NAMPT from neutrophils; it was shown that 
NAMPT mRNA transcripts were upregulated by exposure to LPS, TNFα 
and IL-1β, and conversely decreased by addition of pro-apoptotic stimuli 
(anti-CD95 antibody and heat-killed Candida albicans). NAMPT protein 
was also detected in the culture supernatant of LPS stimulated neutrophils 
19
. 
1.7.2 NAMPT signalling 
It has been shown that exogenous NAMPT can activate expression of IL-
1β, IL-6 and TNFα in monocytes in a p38- and MEK-1-dependent manner; 
inhibition of p38 MAPK abrogates this NAMPT-induced cytokine 
expression 
20
. It is also reported that exogenous NAMPT can activate NF-
κB signalling in endothelial cells; NAMPT-mediated expression of matrix 
metalloproteinase-2/9 (MMP-2/9) from these cells was abrogated by 
addition of an NF-κB inhibitor 215. In many of these studies of NAMPT 
cytokine-like activity, the role of NAMPT as an enzyme is not specifically 
addressed. Others, however, have attempted to reconcile these two 
supposed functions. For example, mutant recombinant NAMPT protein 
(with no enzyme function) was shown to stimulate expression of IL-8, IL-
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16 and CCR3 in human pulmonary epithelial cells but did not trigger NAD 
biosynthesis. It was identified that the transcription factor, AP-1, was 
required to mediate these effects, and MAPK and JNK inhibitors 
attenuated the activity 
21
. In other studies, the enzyme function of NAMPT 
did appear to be crucial for signalling. For example,  in human vascular 
smooth muscle cells, NAMPT was shown to induce sustained activation of 
NF-κB and biphasic activation of ERK1/2, leading to enhanced iNOS 
production. The activation of these signalling pathways by NAMPT was 
abrogated by addition of the NAMPT enzyme inhibitor FK866, and was 
mimicked by addition of the NAMPT enzyme product nicotinamide 
mononucleotide (NMN) 
216
. 
Exogenous NAMPT is also reported to have an anti-apoptotic effect on 
neutrophils and macrophages 
19,22
. This anti-apoptotic effect resulted in 
decreased activation of caspases-3 and -8, but not caspase-9, suggesting 
that NAMPT targets the extrinsic apoptotic pathway. It was shown that 
endogenous intracellular NAMPT was required for this process, but the 
role of NAMPT as an enzyme in this process was not discussed 
19
. In 
macrophages, NAMPT was shown to block ER-stress induced apoptosis 
via a two-step process that involved initial rapid induction of IL-6 
secretion, followed by IL-6 mediated activation of STAT3. This effect was 
not altered by addition of the NAMPT enzyme inhibitor FK866, or by use 
of site-directed mutant NAMPT proteins 
22
. 
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Current opinion still favours the dual-role hypothesis of NAMPT, 
activating cells like a cytokine in some circumstances and affecting cellular 
function via mediation of NAD biosynthesis and metabolism in others. It is 
clear that exogenous NAMPT can induce stimulatory effects on various 
cell types, but whether this is due to NAMPT induced expression of other 
cytokines and subsequent autocrine/paracrine activation of signalling 
pathways, is yet to be determined. 
1.8 NAMPT in Inflammatory Disease 
NAMPT expression is increased in a number of acute and chronic 
inflammatory diseases, including sepsis 
19
, inflammatory bowel disease 
20,217
, acute lung injury 
182
, atherosclerosis 
185
 and rheumatoid arthritis (RA) 
18,32,165,218
. A number of studies have recently described the potential of 
NAMPT inhibition (with FK866) to modulate the immune response, and it 
has shown promise in alleviating the symptoms in mouse models of 
inflammatory arthritis 
33,34
. 
1.8.1 NAMPT in rheumatoid arthritis 
It is well established that NAMPT expression is elevated in the serum and 
synovial fluid of RA patients 
18,165,218
, and levels are significantly higher 
than those seen in osteoarthritis (OA) patients 
32
.  It is also elevated in other 
inflammatory conditions, such as Beçhet’s disease, and juvenile idiopathic 
arthritis (JIA) 
219
. Serum NAMPT is associated with radiological joint 
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damage in RA, even when other inflammatory mediators such as TNFα, 
IL-6 and CRP are considered 
18,165,220,221
, suggesting that NAMPT is 
independently associated with RA. Some studies suggest that NAMPT 
correlates with clinical measurements of disease in RA, such as serum CRP 
and DAS 
18
, but others did not find a correlation with DAS 
220
. 
NAMPT is elevated in synovial tissue during inflammation in RA 
218
, 
specifically in a number of structural cells of the synovial joint, including 
chondrocytes, synovial fibroblasts, endothelial cells and fibroblast- and 
macrophage-like synoviocytes  
18,32,34
. It has been demonstrated that 
NAMPT is highly expressed in fibroblast-like synoviocytes, specifically 
localised at points of invasion into the synovial lining and cartilage 
18
. 
Some studies suggest that synovial lining fibroblasts and synovial 
lymphoid aggregates may provide the major source of NAMPT expression 
in the joint 
18,32
. Expression of NAMPT in cells of the rheumatoid joint can 
be regulated by exposure to cytokines, for example IL-1β stimulates 
NAMPT expression in chondrocytes 
222
, and it is stimulated in synovial 
fibroblast-like cells by addition of IL-6 and its soluble receptor sIL-6R, in a 
STAT3-dependent manner 
32,34
. Addition of exogenous NAMPT has also 
been shown to activate NF-κB and AP-1 in synovial fibroblasts, 
subsequently promoting expression of IL-6, IL-8, CCL2 and MMP-1 and -
3 
34
. 
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NAMPT is also expressed by a number of the immune cell types involved 
in inflammatory arthritis, such as neutrophils, monocytes 
19
, macrophages, 
dendritic cells 
33
, and T and B lymphocytes 
167,223
 (Table 1.3). During 
inflammation, it is suggested that peripheral blood leukocytes are a major 
source of circulatory NAMPT, as serum NAMPT correlated with white 
blood cell count in one study of children 
184
. Another study (in RA adults) 
confirmed that serum NAMPT correlated with mRNA expression from 
PBMCs 
218
, and it is considered one of the only universal markers of 
inflammation in these cells 
217
. Lymphocytes and macrophages are also 
major sources of NAMPT during chronic inflammation, and its expression 
is upregulated in response to inflammatory mediators. Continuous 
activation of these cells during chronic inflammation leads to a high level 
of NAMPT in the circulation and in the joints infiltrated by these immune 
cells during RA. 
Exogenous NAMPT activates a number of immune cell types and 
stimulates expression other cytokines and chemokines, perpetuating the 
immune response. For example, monocytes stimulated with NAMPT are 
activated to secrete a variety of inflammatory mediators such as TNFα, IL-
6 
18
, IL-1β, IL-1Ra and IL-10, alongside an increase in the surface 
expression of CD40, CD54 and CD80 
20
. Neutrophils are the most 
abundant cell type found in the rheumatoid joint, and have the greatest 
capacity for tissue damage 
11
.  Transcription of NAMPT is induced in 
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neutrophils by IL-1β 19 and NAMPT has been described as exacerbating 
the pro-inflammatory action of these cells in a number of ways. One study 
suggests that NAMPT primes neutrophils for an augmented respiratory 
burst via partial assembly of the NADPH oxidase complex, leading to 
production of ROS upon further stimulation 
224
. NAMPT has also been 
shown to delay neutrophil apoptosis, exacerbating the inflammatory state 
further. In fact, antisense oligonucleotide knock-down of NAMPT 
expression abolishes the anti-apoptotic action of TNFα, GM-CSF, IL-1β 
and IL-8 suggesting that NAMPT is crucial to the regulation of neutrophil 
apoptotic mechanisms 
19
. 
Considering the evidence, it appears that NAMPT is involved in the 
dysregulated immune response observed during chronic inflammation and 
joint destruction in RA. As the concentration of NAMPT in the inflamed 
synovial joint correlates with rheumatoid joint damage, it likely contributes 
to the destructive inflammatory process, either directly through activation 
of immune cells or by stimulating expression of other pro-inflammatory 
cytokines. Analysis of RA tissues lends credence to this hypothesis and 
together this evidence has led to the proposal that NAMPT may be an 
attractive therapeutic target in inflammatory disease. 
1.8.2 Effects of NAMPT inhibition on the inflammatory process 
A number of studies have expanded upon the potential of NAMPT as a 
therapeutic target in inflammatory disease, by investigating the effects of 
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NAMPT inhibition on these processes. Existing therapies for rheumatoid 
arthritis have been shown to impact NAMPT concentration in the 
circulation; RA and JIA patients showed decreased circulatory NAMPT 
following both anti-TNF (infliximab) and methotrexate treatment 
225,226
, 
and B-lymphocyte depletion therapy for RA causes a similar decrease in 
serum NAMPT 
227
. New ideas for therapies are emerging that target the 
actions of this molecule directly, by inhibiting its function as an enzyme of 
the NAD biosynthetic pathway. The role of NAMPT in NAD biosynthesis 
may also be important in inflammation, as NAMPT regulates the function 
of the sirtuin proteins which are involved in the transcriptional control of 
many cellular processes including the cellular response to cytokines 
169
. 
Van Gool et al. 
35
 identified that NAMPT is responsible for the 
upregulation of intracellular TNFα via the NAD-dependent enzyme Sirt6. 
They, amongst others, also confirmed that an accumulation of nicotinamide 
(the substrate of NAMPT) efficiently down-regulated cytokine production 
when not converted to NMN by NAMPT 
228
. FK866 also inhibited the 
NAMPT-induced increase in expression of MMP3, CCL2 and IL-8, and 
decreased the activity of MMP3, CCL2 and RANKL 
34
. Activated T-
lymphocytes are also acutely affected by NAMPT inhibition, undergoing 
significant NAD depletion and decreased expression of IFNγ and TNFα, 
before undergoing autophagic cell death 
223
. In vitro, FK866 significantly 
decreased the secretion of TNFα, IL-1β and IL-6 from monocytes upon 
stimulation with bacterial agents, which was reversed by addition of the 
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NAMPT enzyme product NMN 
33
. FK866 has also been reported to 
decrease production of ROS by monocytes in response to stimuli 
229
, and 
this may be attributed to the effects of NAD depletion on the action of the 
NADPH oxidase. However, it has also been shown that accumulation of 
nicotinamide, the substrate of NAMPT, has the potential to suppress 
production of reactive oxidants 
230
. 
Due to the proposed down-regulation of immune cell activation, 
production of inflammatory mediators and release of tissue-damaging 
products, NAMPT inhibition is an attractive option for treatment of chronic 
inflammatory disease. Two studies have assessed the potential of FK866 to 
modulate disease in the collagen-induced arthritis (CIA) mouse model. 
Busso et al. 
33
 reported that injection of FK866 into CIA mice decreased 
serum TNFα levels and the severity of the arthritis, to an extent comparable 
to the anti-TNF drug etanercept 
33
. In a similar study by Evans et al. 
34
, 
early intervention with FK866 in CIA mice inhibited synovial 
inflammation and leukocyte infiltration, and protected against bone 
erosion. These mice also showed decreased serum hyaluronic acid, a 
marker of systemic inflammation. Joint extracts showed that FK866 
treatment decreased expression of MMP-3 and -13 and markers of cartilage 
erosion. In mice with established disease FK866 treatment led to decreased 
synovial inflammation and cartilage destruction and also prevented bone 
erosion 
34
. Both of these studies in mice reported no adverse toxicity of 
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FK866. Interestingly they both reported that FK866 treatment had no effect 
on the levels of autoantibodies against type II collagen, suggesting that the 
impact of FK866 is mainly mediated through the local disruption of the 
destructive processes in the joint 
33,34
. These beneficial effects may be due 
to the initial down-regulation of cytokines and destructive enzymes in the 
joint. Studies into the feasibility of NAMPT inhibition as a viable therapy 
for RA are ongoing, but these early results showing a concurrent decrease 
in pro-inflammatory molecules and in the destructive processes within the 
joint, appear promising. FK866 has recently completed phase II clinical 
trials for the treatment of solid and haematological malignancies, and has 
demonstrated a good safety profile, suggesting that it may be a viable 
future treatment option in RA, either alone or alongside existing therapies 
231,232
.  
1.9 Summary 
Neutrophils have a pathologically important role in the progression of RA. 
Inappropriately primed neutrophils infiltrate rheumatoid joints in vast 
numbers and become activated, resulting in delayed apoptosis and release 
of tissue damaging products 
2,6,11
. RA is a progressively degenerative 
inflammatory joint disease, so targeting the cells that mediate the damage 
would be expected to be beneficial. 
During a transcriptomics screen for potential inflammatory biomarkers in 
neutrophils, high levels of NAMPT mRNA expression were identified in 
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neutrophils from patients with inflammatory disease. NAMPT has been 
previously implicated in inflammatory disease, and correlates with clinical 
measurements of disease in RA 
18
. It is unclear if one particular function of 
NAMPT, which is proposed to act both as a cytokine and as an enzyme in 
NAD biosynthesis, is important in inflammation. However, the ability of 
NAMPT to activate immune cells, stimulating expression of cytokines and 
destructive enzymes, coupled with a role in mediating neutrophil apoptosis,  
place NAMPT as an important mediator of inflammation 
19–24
. This, 
alongside the down-regulation of key inflammatory mediators, and 
alleviation of disease severity observed in mouse models of inflammatory 
arthritis reported with NAMPT inhibition (with FK866) 
33–35
, suggest that 
NAMPT is an attractive therapeutic target in RA. 
1.10 Research Aims 
The overarching aim of this research was to better understand the role of 
neutrophils in inflammation, using RA as a model disease. Previous work 
has identified NAMPT as a potential biomarker of inflammation in 
neutrophils, so more specifically the aim of this thesis was to understand 
the role of NAMPT in neutrophil functions and gene expression. One 
particular aim was to evaluate whether this molecule could be a viable 
therapeutic target in inflammatory disease. 
The specific aims of the research were to: 
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1. Evaluate whether the role of NAMPT in NAD production is of 
importance to neutrophil function; to determine the level of NAD, and its 
phosphorylated and reduced forms in the cell, and observe the effects of 
NAMPT enzyme inhibition and NAD depletion on neutrophil function and 
apoptosis. 
2. Determine whether exogenous NAMPT is capable of priming 
neutrophils and augmenting their function in a manner similar to that of 
other cytokines. 
3. Investigate the expression and release of NAMPT in both resting 
neutrophils and in response to key inflammatory cytokines, and comparing 
this to NAMPT expression from the neutrophils of RA patients. 
4. Determine the effects of both NAMPT stimulation and NAMPT 
inhibition on neutrophil intracellular signalling pathways and mRNA 
expression profiles. 
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CHAPTER 2: Materials and Methods 
2.1 Materials 
Cytokines, Stimulants and Inhibitors Supplier 
Recombinant human TNFα Calbiochem (Nottingham, UK) 
Recombinant Human GM-CSF (50,000 
U) 
Roche Diagnostics Ltd. (East 
Sussex, UK) 
Recombinant human IL-8 
Recombinant human IL-1β 
Invitrogen (Paisley, UK) 
Recombinant human NAMPT* 
Cytochalasin B (CB) 
N-formylmethionyl-leucyl-
phenylalanine (fMLP) 
Phorbol 12-myristate 13-acetate (PMA) 
Recombinant human IL-6 
Bacterial lipopolysaccharide (LPS) 
Sigma (Poole, UK) 
FK866 
BAY-11-7082 
Cambridge Bioscience 
(Cambridge, UK) 
TABLE 2.1 
*Full length recombinant NAMPT was expressed in E. Coli and following 
purification was determined by Sigma to be of  ≥95% purity by HPLC and 
SDS-PAGE analysis. The endotoxin level was also determined to be ˂0.1 
EU per µg of NAMPT (LAL test). 
Media and Chemicals Supplier 
Glycerol 
Sodium dodecyl sulphate 
Tris 
Fisher Scientific 
(Loughborough, UK) 
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Hanks balanced salt solution (HBSS) 
RPMI 1640 ( + 25 mM HEPES, 2 mM 
L-glutamine) 
Trizol
®
 reagent 
Gibco (Paisley, UK) 
MTS reagent (Cell titer non-radioactive-
proliferation assay kit) 
Promega (Southampton, UK) 
Phosphate buffered saline (PBS) tablets Oxoid Ltd (Basingstoke, UK) 
30% Hydrogen peroxide (H2O2) 
Ammonium chloride (NH4Cl) 
Ammonium persulphate (APS) 
Bovine serum albumin (BSA) 
Dethylpyrocarbonate (DEPC) 
Dithiothreitol (DTT) 
Dimethyl sulfoxide (DMSO) 
Ethanol (general laboratory grade) 
Ethylenediaminetetracetic acid (EDTA) 
Ferri-cytochrome c 
Glycine 
Horseradish peroxidise (HRP) 
Human pooled AB serum 
Isoluminol 
Luminol (disodium salt) 
Paraformaldehyde 
Sodium azide 
Tetramethylethylenediamine (TEMED) 
Tween-20 
Sigma (Poole, UK) 
Hydrochloric acid (HCl) 
VWR International 
(Leicestershire, UK) 
Polyacrylamide 
Severn Biotech (Kidderminster, 
UK) 
TABLE 2.2 
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Antibodies, dyes and probes Supplier 
HRP-conjugated donkey anti-rabbit IgG 
Amersham Life Sciences 
(Bucks, UK) 
Fluorescein isothiocynate (FITC)-
conjugated mouse anti-human CD16 
FITC-conjugated anti-human CD32 
BD Biosciences (Cowley, 
UK) 
Rabbit anti-human lactoferrin 
Sheep anti-human myeloperoxidase 
Biodesign International 
(Kennebunk, USA) 
HRP-conjugated rabbit anti-sheep IgG Dako (Glostrup, Denmark) 
FITC-conjugated Annexin V Invitrogen (Paisley, UK) 
Allophycocyanin (APC)-conjugated rat 
anti-human CD11b 
Miltenyi Biotec (Surrey, UK) 
Bromophenol blue 
HRP-conjugated sheep anti-mouse IgG 
Ponceau S 
Propidium iodide (PI) 
Sigma (Poole, UK) 
Mouse anti-human Actin  Abcam (Cambridge, UK) 
Mouse anti-human extracellular  TNFα-
FITC 
FITC-conjugated anti-human L-selectin 
R&D Systems (Abingdon, 
UK) 
TABLE 2.3 
Other Materials Supplier 
Enhanced chemiluminescence hyperfilm Amersham Life Sciences 
Polymorphprep™ AxisSheild (Cambs, UK) 
dNTPs Bioline (London, UK) 
Biotinylated protein ladder detection pack 
Cell-Signalling Technology 
(Massachusetts, USA) 
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Primers 
Eurofins MWG Operon 
(Ebersberg, Germany) 
Lithium heparin vacutainers 
Grenier Bio-one 
(Gloucestershire, UK) 
Rapid Romanowsky stain HD Supplies (Aylesbury, UK) 
Superscript III first strand cDNA 
synthesis kit 
RNase OUT 
Invitrogen (Paisley, UK) 
Immobilon western chemiluminescence 
HRP-substrate 
Polyethylene Terephthalate (PET) 
millicell 3 µm hanging inserts 
Polyvinylidene fluoride (PVDF) 
membrane 
Millipore (Hertfordshire, UK) 
Random primers Promega (Southampton, UK) 
RNeasy mini kit 
Quantitect SYBR green PCR kit 
Qiagen (Crawley, UK) 
Staphylococcus aureus   
Donated by department of 
Medical Microbiology, 
University of Liverpool, UK 
Marvel non-fat powered milk Tesco 
Slide-A-lyzer 10 k dialysis cassettes (3-5 
mL) 
BCA protein assay 
Pierce Technology 
(Northumberland, UK) 
TABLE 2.4  
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2.2 Methods 
2.2.1 Neutrophil isolation from whole blood 
Ethical approval for the study of neutrophils from healthy control 
individuals was obtained from the University of Liverpool Committee for 
Research Ethics (CORE), reference RETH000398. Ethical approval for the 
study of neutrophils from patients was obtained from the North West 3 
(Liverpool East) Research Ethics Committee, study number 07/Q1502/4. 
All blood donors gave informed consent. Blood was collected into 
heparinised vacuette tubes, by venupuncture of healthy volunteers and RA 
patients. Heparin was included to prevent red blood cell coagulation, as red 
blood cells are crucial to the generation of a density gradient during 
neutrophil isolation with Polymorphprep. Since neutrophils are short-lived 
and should be used within a few hours of collection, a fast and reliable 
method of separating them from other blood cells is desirable, to enable 
robust assay of neutrophil function in vitro. Polymorphprep is currently the 
only commercially available medium capable of separating PBMC and 
neutrophils from whole blood in one step. Other methods such as dextran-
sedimentation followed by Ficoll-Paque isolation are much more time-
consuming. However, the efficacy of the Polymorphprep method requires 
fresh blood, <2 h from collection 
233
. Polymorphprep relies on an 
isoosmotic density barrier that separates the mononuclear cells and 
neutrophils into two distinct bands during centrifugation, whilst the red 
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blood cells settle to the bottom of the solution
233
. This allows immediate 
aspiration of the neutrophil layer. Here, Neutrophils were isolated from 
whole blood by one-step centrifugation with Polymorphprep (as described 
in the manufacturer’s instructions). Briefly, blood was layered onto 
Polymorphprep at a 1:1 to 1.5:1 ratio, and centrifuged at 500 g for 35 min. 
Granulocytes were removed and resuspended in RPMI 1640 media then 
centrifuged at 500 g for 5 min. Cells were resuspended in media and 
contaminating erythrocytes were removed by ammonium chloride lysis 
(155 mM NH4Cl4, 13.4 mM KHCO3, 97 µM EDTA, pH 7.6); red blood 
cell membranes are permeable to ammonium chloride, and it causes cell 
lysis due to an imbalance in the osmotic pressure. Neutrophils are widely 
reported to be unaffected by ammonium chloride treatment, but some 
affects on iodination have been reported over time, so here lysis was 
performed for 3 min 
234
. Any red blood cells remaining following 
centrifugation were at the top surface of the neutrophil pellet and so were 
washed away with a rinse of medium. Neutrophils were resuspended in 
RPMI 1640 (with 25 mM HEPES, 2 mM L-glutamine), and adjusted to a 
final concentration of 5 x 10
6
 cells/mL (unless otherwise stated) using a 
Multisizer 3 cell counter (Beckman Coulter). Final neutrophil purity was 
routinely greater than 97% by cytospin. Cells were incubated with gentle 
agitation at 37°C, and where indicated 10% AB serum was added for 
incubations >4 h. Cytokines and inhibitors were added as indicated.  
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2.2.2 Assay of neutrophil NAD content 
Neutrophils in culture at 5 x 10
6
 cells/mL were centrifuged at 1000 g for 3 
min then lysed with 250 µL of 1% Triton/PBS (v/v) per 5 x 10
6
 cells, for 
15 min on ice. Samples were then centrifuged at 5000 g for 3 min to 
remove cell debris, and supernatant was aspirated for use in the NAD(P)H 
assay. Cellular NAD(P)H content was assayed using the Amplite™ 
Colormetric NAD/H or NADP/H assay kit from AAT Bioquest as per 
manufacturer’s instructions. Briefly, 50 µL of sample or NAD(P)H 
standard was mixed with the corresponding 50 µL NAD(P)H reaction 
mixture in a 96-well white (clear bottom) microtitre plate, and incubated 
for 1 h protected from light. The absorbance was assayed on a Bio-Rad 
3550 microplate reader at 570 nm with the reference wavelength set at 620 
nm. The cellular NAD(P)H concentration was determined by comparison 
to NAD(P)H standards of known concentration and adjusted for the 
number of cells. 
The CellTiter 96
®
 AQueous Non-Radioactive Cell Proliferation Assay 
(Promega) was also used as an indirect measure of total cellular NAD(P)H. 
Briefly, 100 µL neutrophils (5x10
6
 cells/mL) in culture medium were 
added to 20 μL of CellTiter 96® AQueous One Solution Reagent in a 96-
well microtitre plate, and incubated for 4 h in a humidified 5% CO2 
atmosphere protected from light. Relative NAD(P)H content was assayed 
by absorbance at 490 nm. 
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2.2.3 Flow cytometric analysis of neutrophil surface marker expression 
For measurement of neutrophil surface marker expression, 1 x 10
6
 cells 
were fixed in 2% (w/v) paraformaldehyde (PFA) for 10 min at room 
temperature. Where indicated, cells were then permeabilized with 0.04% 
(w/v) saponin with PBS (0.1% (w/v) BSA), and 0.1 M glycine. Following 
washing with PBS/BSA, the cells were incubated for 30 min at 4°C with 5 
µL of the indicated fluorescently-conjugated antibody. 150 µL of 
PBS/BSA was then added to the cells, and the total volume was added to a 
96-well microtitre plate for flow cytometry. All samples were analysed 
using the Guava Easycyte flow cytometer (Miltenyi Biotech), and a 
minimum of 5000 gated events were collected. 
2.2.4 Flow cytometric analysis of neutrophil apoptosis 
Neutrophil apoptosis was quantified by flow cytometry as the percentage 
of cells exhibiting external expression of membrane phosphatidylserine, 
detected by annexin V binding, and necrosis was quantified by propidium-
iodide (PI) uptake due to membrane permeabilisation. 1 x 10
5
 cells in 100 
µL HBSS were incubated with 1 µL annexin V for 30 min at room 
temperature, protected from light in a 96-well microtitre plate. Following 
this, 1 µL PI (1 µg/mL) was added just prior to analysis by flow cytometry. 
Neutrophil viability was also quantified using the Guava Viacount Reagent 
(Millipore), according to the manufacturer’s instructions. The Viacount 
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reagent contains two DNA binding dyes of differing cell membrane-
permeability. All nucleated cells are stained by the membrane-permeable 
dye, but the membrane-impermeable dye stains only cells with increased 
membrane permeability, indicating apoptotic or dying cells 
235
. Briefly, 
200 µL of the assay reagent was added to 10
6
 cells in a 96-well microtitre 
plate, and immediately subjected to flow cytometry. 
 2.2.5 Neutrophil transmigration assay 
A model of neutrophil transmigration was set up using Millipore Hanging 
Cell Culture plate inserts with a 3 µm pore-size filter at their base. To 
prevent neutrophil adherence following transmigration, 24-well tissue 
culture plates were coated with 400 µL poly-hema (12 mg/mL) in ethanol, 
which was left to evaporate at 37°C for at least 24 h. For the assay, 800 µL 
of culture medium plus the indicated chemoattractant was added into each 
well. The hanging cell inserts were then suspended in the media and left to 
equilibrate for 10 min at 37°C. Following this, 1 x 10
6
 freshly isolated 
neutrophils in 200 µL culture media were added into the hanging insert, 
and incubated for 1 h at 37°C (Figure 2.1). The inserts were then removed, 
and the cells that had migrated through the membrane into the well beneath 
were counted using the Multisizer 3 cell counter (Beckman Coulter) 
following a 1:1000 dilution with Isoton II. Chemotaxis was determined as 
the number of migrated cells calculated as a percentage of the total number 
of cells added. 
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FIGURE 2.1: Hanging insert assay for neutrophil chemotaxis. 
2.2.6 Preparation of neutrophil lysates for analysis of protein 
Following culture, cells were sedimented at 1000 g for 3 min, and the cell 
pellet was rapidly lysed in reducing 1x Laemmli buffer, containing 10% 
(v/v) glycerol, 100 mM DTT, 3% (w/v) SDS, 0.001% (w/v) bromophenol 
blue and 1 M Tris-HCl (pH 6.8), to a final concentration of 5 x 10
4
 
cells/µL. For assessment of proteins released during culture, boiling 5x 
Laemmli buffer was added to the aspirated culture medium at a ratio of 5:1 
supernatant to buffer. All samples were boiled for 3 min with occasional 
vortexing, and stored at -20°C until use. For concentration of low 
abundance proteins from the culture supernatant, 4 volumes of cold (-
20°C) acetone were added to the supernatant and proteins were precipitated 
for at least 1 h at -20°C. The protein was sedimented by centrifugation at 
13,000g for 10 min, and resuspended in 25 µL Laemmli buffer. 
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2.2.7 Western blotting 
Whole cell extracts were loaded to into 8-12% polyacrylamide gels 
(dependent on molecular weight of target protein) to an equivalent of 0.5-2 
x 10
6
 cells per well, along with a biotinylated protein molecular weight 
marker and subjected to SDS-PAGE. Electrophoresis was performed for 1 
hour at a constant voltage of 200V using BioRad Mini Protean II 
Electrophoresis Apparatus. Following this, proteins were electrotransferred 
to a PVDF membrane at a constant voltage of 100V for 90 min using the 
BioRad Mini Protean II Transfer Apparatus. Successful transfer of proteins 
was confirmed using Ponceau S staining (0.01% (w/v) in 5% (v/v) acetic 
acid). To prevent non-specific binding of the antibody, PVDF membranes 
were incubated with blocking buffer containing 5% (w/v) non-fat dried 
milk in wash buffer (Tris buffered saline (TBS) 1 mM Tris, 15 mM NaCl, 
pH 8.0, 0.075% (v/v) Tween-20), for at least 1 h at room temperature. 
Membranes were then incubated with the required primary antibody in 
blocking buffer at the indicated concentration (Table 2.5) overnight at 4°C. 
Following washing, the membranes were incubated with the appropriate 
HRP–conjugated secondary antibody in blocking buffer, for at least 1 h at 
room temperature. The membranes were washed again then bound 
antibodies were detected using enhanced chemiluminescence (ECL) 
reagents (Millipore) and exposure to Hyperfilm in the dark. Densitometry 
of blots was performed with AQM Advanced 6 Kinetic Imaging System. 
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Levels of β-actin were measured to confirm equivalent loading of protein 
in neutrophil samples. 
Target protein Primary antibody Secondary antibody 
Nampt 
Rabbit anti-human Nampt 
(1:2500) 
HRP-conjugated donkey 
anti-rabbit IgG (1:10000) 
Myeloperoxidase 
Sheep anti-human MPO 
(1:10000) 
HRP-conjugated rabbit 
anti-sheep IgG (1:10000) 
Lactoferrin 
Rabbit anti-human 
lactoferrin (1:10000) 
HRP-conjugated donkey 
anti-rabbit IgG (1:10000) 
Mcl-1 
Rabbit anti-human Mcl-1 
(1:1000) 
HRP-conjugated donkey 
anti-rabbit IgG (1:10000) 
CD16b 
Mouse anti- human FcγIIIb 
(3G8 cell line) (1:100) 
HRP-conjugated sheep 
anti-mouse IgG (1:10000) 
ph-NF-κB 
Rabbit anti-human 
phospho-p65 (1:1000) 
HRP-conjugated donkey 
anti-rabbit IgG (1:10000) 
ph-ERK1/2 
Mouse anti-human 
phospho- p44/p42 (1:1000) 
HRP-conjugated sheep 
anti-mouse IgG (1:10000) 
ph-STAT3 
Mouse anti-human 
phospho- STAT3 (1:1000) 
HRP-conjugated sheep 
anti-mouse IgG (1:10000) 
IκBα 
Rabbit anti-human IκBα  
(1:1000) 
HRP-conjugated donkey 
anti-rabbit IgG (1:10000) 
β-Actin 
Mouse anti-human actin 
(1:10000) 
HRP-conjugated sheep 
anti-mouse IgG (1:10000) 
Biotin n/a HRP-linked anti-biotin 
TABLE 2.5 Western Blot Antibodies 
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2.2.8 Isolation of neutrophil mRNA and cDNA synthesis 
1 x 10
7
 (3 x 10
7
 for transcriptome sequencing) cells were sedimented at 
1000 g for 3 min and lysed with 1 mL Trizol reagent. The pellet was 
disrupted by pipetting until a homogenous solution was obtained, which 
was then incubated for at least 5 min at room temperature. Following this, 
200 µL of chloroform was added to the samples and mixed by inversion 
for 15 s, before incubating for 2-3 min at room temperature. The samples 
were then centrifuged at 10,000 g for 15 min at 4°C, and the resulting 
aqueous phase containing the RNA was removed, and mixed with an equal 
volume of isopropanol to precipitate the RNA, either for 20 min at room 
temperature or at -20°C overnight. The samples were then centrifuged at 
10,000 g for 30 min at 4°C, to pellet the precipitated RNA, which was then 
washed in 70% ethanol, and resuspended in 100 µL RNase-free water. The 
RNA samples were cleaned to remove remaining contaminants using the 
Qiagen RNeasy kit according to the manufacturer’s instructions, and 
genomic DNA was removed by a 15 min on-column digestion with Qiagen 
DNase. RNA was then eluted in 30 µL RNase-free water. The RNA 
content was quantified using the Nanodrop ND-1000 spectrophotometer. 
RNA samples were stored at -80°C until use.  
cDNA synthesis was performed using the Superscript III First Strand 
cDNA Synthesis kit (Qiagen) and RNase OUT (Qiagen), according to the 
manufacturer’s instructions, as per Table 2.6. RNA samples were adjusted 
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to the same concentration (<10 ng/µL) within each experiment prior to 
cDNA synthesis. cDNA samples were stored at -20°C until use. 
Reagents Added 
Temperature 
(°C) 
Time 
(min) 
RNA (<10 ng/µL) 11 µL 
Random Primers (20 µM) 1 µL 
dNTPs (10 mM) 1 µL 
60 5 
0 (Ice) >1 
First-Strand buffer 5 µL 
RNase OUT  1 µL 
DTT (0.1 M) 1 µL 
Superscript III reverse transcriptase 1 µL 
25 5 
50 60 
70 15 
TABLE 2.6 cDNA Synthesis Procedure 
2.2.9 Quantitative PCR 
qPCR was performed using the QuantiTect SYBR Green detection kit 
(Qiagen), according to the manufacturer’s instructions. 10 µL of 
QuantiTect was added to 1 µL cDNA along with 0.4 µM of forward and 
reverse primers, in a total reaction volume of 15 µL. Each sample was 
prepared in triplicate, and PCR was performed using the Roche 
LightCycler 480 qPCR machine. Relative amounts of mRNA were 
checked by comparison to the Ct value of the reference gene cyclophilin A 
using the Pfaffl method 
236
. The cycling protocol is shown in Table 2.7 and 
primer sequences in Table 2.8. 
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Step Purpose 
Temperature 
(°C) 
Time 
(min) 
Cycles 
1 Taq Activation 95 15 1 
2 
Denaturation 95 1 
45 Primer Annealing 55 0.5 
Elongation 72 0.5 
3 Melt Curve Analysis 60 0.5 1 
TABLE 2.7 qPCR Cycling Procedure 
Target Gene Forward Sequence (5'-3') Reverse Sequence (5'-3') 
Cyclophilin A gctttgggtccaggaatgg gttgtccacagtcagcaatggt 
NAMPT gccagcagggaattttgtta tgtcaccttgccattcttga 
TNFα cagagggcctgtacctcatc ggaagacccctcccagatag 
CD16 gggggcaagcatcctgggaaa gtgggtgggtgtgccccctt 
IL-8 aaaagccaccggagcactccat agagccacggccagcttgga 
IL-1β gggcctcaaggaaaagaatc aagtggtagcaggaggctga 
ICAM1 aggggtgcatgtgttctagg ctgacaagttgtgggggagt 
TABLE 2.8 qPCR Primer Sequences 
2.2.10 Whole transcriptome sequencing 
RNA was isolated as described in 2.2.8 from at least 3 x 10
7
 neutrophils 
and the RNA integrity was confirmed using the Agilent 2100 Bioanalyzer 
system. The total RNA concentration at this stage was routinely > 1 µg and 
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the RIN (RNA integrity number) was routinely >8. Following this, samples 
were prepared and sequenced externally, briefly, samples were enriched for 
mRNA using poly-A selection, and standard Illumina protocols were used 
to generate 50 bp read libraries, that were sequenced using the Illumina 
HiSeq 2000 Analyser sequencing platform at the Beijing Genomics 
Institute (BGI). Bioinformatic analysis was carried out in-house by H. 
Wright and H. Thomas, briefly, raw data was mapped to the human 
genome using TopHat (v1.4.1) 
237
 and gene annotation and calculation of 
RPKM expression values (the number of reads assigned to the transcript 
divided by the transcript length) was carried out using Cufflinks (v1.3.0) 
238
, with differential expression analysis carried out using the Cuffdiff tool 
239
. The following analyses were carried out by the author; functional 
analyses were generated by Ingenuity Pathway Analysis (IPA) 
240
. 
Canonical pathways from the IPA Knowledge Base were identified as 
regulated by treatment if molecules participating in the pathway set were 
changed < 1.5 fold from the comparison data set. The significance of the 
association between the data set and the identified pathway was expressed 
as the ratio of the number of molecules in the data set present in the 
pathway, divided by the total number of molecules in the pathway, and 
Fisher’s exact test was used to calculate the probability that the association 
between the data set and the canonical pathway was significant. 
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2.2.11 Preparation of Immune Complexes 
Synthetic immune complexes were prepared using human serum albumin 
(HSA) and anti-HSA antibody (dialysed in PBS to remove sodium azide). 
The concentrations of each were determined using the BCA protein assay 
(Qiagen), and both were then adjusted to a concentration of 5 mg/mL with 
PBS. 500 µg of anti-HSA antibody was added to 4 wells of a 96-well 
microtitre plate, and to each well a different concentration of HSA was 
added (10, 30, 40 or 50 µg) and made up to 200 µL with PBS. This plate 
was incubated for 1 h at 37°C with agitation, before determining the 
absorbance at 450 nm using a Bio-Rad 3550 microplate reader. The highest 
absorbance value obtained represented the point of equivalence where 
insoluble immune complexes (IIC) formed, and soluble immune 
complexes (SIC) formed at an antigen concentration six-times that of IIC. 
Larger volumes of IIC and SIC were then prepared by incubating the 
appropriate concentration of HSA and antibody determined by this method. 
Following this, the IIC were washed 3 times in PBS and any contaminating 
IIC in the SIC preparation was removed by centrifugation and aspiration of 
the SIC 3 times. The immune complexes were then stored at 4°C for up to 
1 month. 
2.2.12 Measurement of neutrophil ROS production 
Total production of ROS (primary and secondary oxidants) from 
neutrophils was measured by luminol-dependent chemiluminescence. 10 
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µM luminol was added to 1 x 10
6
 neutrophils in HBSS (37°C). The 
respiratory burst was induced in a receptor-independent manner, by 
addition of the phorbol-ester PMA (0.1 µg/mL), and measured as photon 
emission using a LKB 1251 tube luminometer over 40 min. The respiratory 
burst was also stimulated in a receptor-dependent manner using fMLP or 
immune complexes. Neutrophils (5 x 10
6
/mL) were primed for 30 min with 
GM-CSF (50 U/mL), then 10 µM luminol was added to 2 x 10
5
 cells and 
the respiratory burst was stimulated with 1 µM fMLP or 20% (v/v) 
immune complexes, with HBSS in a total volume of 200 µL in a 96-well 
white, opaque microtitre plate. The oxidants produced over 40 min were 
measured using a Perkin Elmer Victor plate reader. The rate of production 
of solely extracellular reactive oxidants, produced at the cell membrane, 
was assayed in a similar manner, using 1 µM isoluminol in place of 
luminol. The signal produced with isoluminol is weaker, so it was 
enhanced by addition of HRP (4 U/mL). In this case, the respiratory burst 
was stimulated with 1 µM fMLP, and the oxidants produced over 10 min 
were assayed using the FLUOstar Omega plate reader from BMG Labtech. 
The rate of extracellular production of O2
-
 via the neutrophil NADPH 
oxidase, can be measured by O2
-
 mediated reduction of ferri-cytochrome c 
(λmax 550 nm). 75 µM ferri-cytochrome c was added to 5 x 10
6
 neutrophils 
in a total volume of 1 mL HBSS (37°C), and PMA (0.1 µg/mL) was added 
to stimulate the respiratory burst. Reduction of ferri-cytochrome c was 
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measured spetrometrically at 550 nm using the Perkin-Elmer Lambda 5 
spectrophotometer, as compared to a reference cuvette with no PMA. 
Absorbance at 550 nm was recorded at 1 min intervals over 10 min. The 
rate of O2
-
 secretion was calculated, using the millimolar extinction 
coefficient of cytochrome c (19.1), and expressed as nM/min/10
6
 cells. 
2.2.13 Preparation of S. aureus 
10 mL of sterile LB broth was inoculated with a single S. aureus colony 
(from an LB agar streak plate) and incubated overnight at 37°C with 
agitation. A subculture was then prepared from this overnight culture and 
grown to mid-exponential growth phase. At this point, the culture was 
serially diluted, the absorbance was recorded at 540 nm, and viable counts 
were taken by plating onto LB agar plates. A calibration curve was then 
constructed so that the number of bacterial cells could be determined 
spectrometrically at 540 nm. For each experiment, an overnight culture 
was prepared from a streak plate as above, and the cells were adjusted to a 
concentration of 1 x 10
10
 cells/mL in LB broth. 
2.2.14 Assessment of neutrophil killing capacity 
For assay of neutrophil killing capacity, live S. aureus were prepared as 
described above, and then opsonised with 30% (v/v) human AB serum in 
PBS at 37°C with agitation. After 20 min, the cells were washed twice in 
PBS to remove the serum. Alongside this, freshly isolated neutrophils were 
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incubated for 30 min with media alone or 100 nM FK866 at 37°C with 
agitation. The opsonised bacteria were then added to the neutrophils at a 
ratio of 10:1 and incubated for 1 h at 37°C with gentle agitation. Following 
this, the neutrophils were lysed in ddH2O, and the remaining bacteria were 
serially diluted in PBS before plating onto LB agar plates at a 
concentration yielding 30-300 colonies. The plates were incubated 
overnight at 37°C, and the killing capacity of the neutrophils was assessed 
by comparing the number surviving bacteria (cfu) not killed by the 
neutrophils in culture. Cultures without neutrophils were prepared 
alongside to determine the total number of bacteria. 
2.2.15 Assessment of neutrophil phagocytosis and respiratory burst 
For assay of neutrophil phagocytosis, S. aureus were prepared as described 
above, then 1 x 10
10
 bacteria were heat killed by incubating at 60°C for 30 
min. Bacteria were then washed and resuspended in 1 mL PBS with 30 µM 
PI, and incubated in the dark at 4°C for 2 h. The bacteria were then washed 
3 times in HBSS (0.1% gelatine), prior to opsonisation with 30% human 
AB serum for 1 h at 37°C with agitation. Following this, bacteria were 
washed and resuspended in PBS at a concentration of 1 x 10
10
 cells/mL, 
and stored at 4°C for up to 1 month. Freshly isolated neutrophils (1 x 
10
6
/mL) were incubated in media alone (control) or in the presence of 100 
nM FK866 for 30 minutes at 37°C with agitation, before bacteria were 
added at a ratio of 10:1 bacteria to neutrophils. The cells were incubated 
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for 15 min, before 5 µM DHR123 was added for a further 15 min, 
alongside the appropriate untreated controls. Following this, the cells were 
resuspended in 2 mL HBSS, and a 200 µL aliquot was added to a 96-well 
microtitre plate for flow cytometry. 
2.2.16 Inhibition of NAMPT with FK866 
The NAMPT inhibitor FK866 was reconstituted in DMSO, preliminary 
experiments using DMSO alone confirmed it had no effect on the 
neutrophil functions tested. NAMPT was inhibited using a range of 1-1000 
nM FK866, with 100 nM used in the majority of the experiments. The IC50 
of FK866 is 1 nM, however some studies have identified that this dose is 
ineffective in certain cell lines 
241
. FK866 was developed as an anti-cancer 
agent that causes a gradual depletion in cellular NAD content and 
eventually leads to cell death after a number of days 
206
. However, 
neutrophils are relatively short-lived cells, and the functional capacity of 
these cells quickly declines in culture; this necessitated the length of 
incubation for most functional assays performed in this thesis to be 1 hour 
or less. NAMPT inhibition had the greatest effect when time was allowed 
for NAD(P)H depletion to occur prior to stimulation of function. Where 
possible, neutrophils were pre-treated for 1 h, however for many functional 
tests that relied on membrane receptor expression, control neutrophils 
became less responsive after a >30 min pre-incubation time. The limited 
incubation time, and early experiments demonstrating the effect of FK866 
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on neutrophil NAD content and the respiratory burst led to the conclusion 
that FK866 would be used at a range of 50-100 nM. 
2.2.17 Statistical analysis 
Data was judged for significance using a combination of parametric and 
non-parametric statistical tests. Paired data was analysed using the 
parametric Student’s t-test, making the assumption that the data was 
normally distributed. When comparing non-normally distributed data that 
were matched but not necessarily from the same sample or analysed at the 
same time, a non-parametric test such as the Wilcoxon signed-rank test 
was used (as indicated in the text). Data are displayed ± SEM unless 
otherwise stated, and differences were considered significant if p≤0.05. 
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CHAPTER 3: Effects of NAMPT Inhibition on Neutrophil Function 
3.1 Introduction 
In addition to the ability of exogenous NAMPT to regulate neutrophil 
functions, such as priming and apoptosis 
19,224
, this molecule is also 
expressed by neutrophils 
19
. Intracellularly, NAMPT catalyzes the 
conversion of nicotinamide (NAM) to nicotinamide monophosphate 
(NMN). This is the rate-limiting step of NAD biosynthesis in the NAD 
salvage pathway 
23,26
. By controlling NAD recycling, NAMPT can 
impact cellular energetics and also the activity of NAD-dependent 
enzymes, such as the NADPH oxidase of phagocytes, assembly and 
activation of which represents the first stages of the neutrophil respiratory 
burst.  
The enzymatic activity of NAMPT can be blocked by the inhibitor 
FK866. Inhibition of NAMPT significantly decreases secretion of TNFα, 
IL-1β and IL-6 from inflammatory cells in vitro, while in vivo this 
inhibition decreases serum TNFα and the severity of mouse models of 
inflammatory arthritis 
33,34
. The ability of NAMPT to stimulate 
expression of cytokines, such as IL-1β, and destructive enzymes, such as 
MMPs, coupled with its role in mediating neutrophil apoptosis, identify 
this protein as a potentially important mediator of inflammatory disease.  
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In view of the anti-inflammatory potential of NAMPT inhibitors and the 
role of neutrophils in the pathogenesis of inflammatory diseases, it is 
important to define the role of NAMPT in neutrophil functions. Inhibition 
of NAMPT activity in neutrophils could decrease their pro-inflammatory 
activity, but could also impair their ability to combat bacterial infections. 
The latter could have severe consequences on morbidity and mortality of 
patients treated with NAMPT inhibitors. 
3.2 Aims  
The aims of this chapter were to determine the effects of NAMPT 
inhibition on NAD(P)H levels in neutrophils, and how this might affect 
neutrophil activities relevant in inflammation. It was hypothesized that 
inhibition of NAMPT, and thus the NAD salvage pathway, would 
decrease the availability of NAD/H and possibly NADP/H, which may 
affect redox reactions and the action of NAD(P) consuming enzymes, 
including the NADPH oxidase. Therefore, a variety of neutrophil 
functions were tested following NAMPT inhibition, using FK866 alone, 
and in combination with priming agents such as GM-CSF and TNFα. 
These experiments would determine if inhibition of this pathway could 
disrupt inflammatory processes, and provide the first experiments 
investigating the role of this enzyme in neutrophil function. 
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3.3 Results 
3.3.1 NAMPT inhibition depletes intracellular NAD(P)H 
NAMPT is reported to play a key role in the salvage pathway by 
catalyzing the production of NMN from nicotinamide and PRPP 
26
. 
Therefore, inhibition of NAMPT by FK866 may be predicted to decrease 
intracellular NAD levels and this may affect neutrophil viability and 
functions that directly or indirectly depend on this molecule. Cellular 
NAD(P)H content was initially measured using the CellTiter 96
®
 AQueous 
Non-Radioactive Cell Proliferation Assay or the  MTS assay (Promega). 
MTS is a tetrazolium salt that can be reduced to a water soluble fomazan 
product by intracellular dehydrogenases in the presence of NADH and 
NADPH. The rate of formazan production is directly related to the 
production of NADH and NADPH, and can be assayed at A490 
242
. 
Control neutrophils were incubated for 4 h with increasing concentrations 
of the NAMPT inhibitor, FK866, and then a further 2 h with the MTS 
reagent. Relative NAD(P)H content was assayed at A490, and cell 
viability was measured alongside using the Viacount assay. Under these 
experimental conditions, FK866 triggered a dose-dependent decrease in 
intracellular NAD(P)H, by up to 40% at the highest concentration tested 
(1000 nM,  p<0.01), but had no effect on the viability of the neutrophils, 
as determined by the Viacount assay. A significant (25%, p<0.05) 
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decrease in intracellular NAD(P)H was detected at concentrations of 
FK866 as low as 10 nM (Fig. 3.1A). 
The decrease in intracellular NAD(P)H with FK866 was confirmed in 
another assay, using the Amplite™ Colormetric NAD/H or NADP/H 
assay kit (AAT Bioquest), which allows the absolute concentration of 
NAD/H and NADP/H to be determined by comparison to a standard 
curve. 5 x 10
6
 cells were incubated at 37°C either with media alone, GM-
CSF (50 U/mL), or FK866 (50 or 100 nM), for the indicated time periods. 
Cells were also pre-treated for 1 h with the inhibitor or media alone prior 
to stimulation with either GM-CSF or PMA (0.1 µg/mL) for a further 1 h. 
Figure 3.1B shows that the concentration of NAD/H increased over time 
in culture in untreated cells. This increase was abrogated by NAMPT 
inhibition; the NAD/H concentration was significantly lower than in 
resting cells after 2 h incubation with 50 nM FK866 (41% p<0.05) and 
after 1 h with 100 nM FK866 (19% p<0.05). NADP/H concentration 
appeared to increase over time in culture (63 % over 4 h), and again 
FK866 at 50 nM (64% decrease at 4 h) and 100 nM (53% decrease at 4 h) 
abrogated this increase, but this did not reach statistical significance. 
To observe the changes in intracellular NAD/H and NADP/H that occur 
during the typical incubation used for the following experiments, 
neutrophils were incubated in the absence or presence of 100 nM FK866  
 103 
 
 
FIGURE 3.1: NAMPT inhibition with FK866 depletes resting 
neutrophil intracellular NAD(P)/H. A. Cellular NAD content was 
assayed indirectly at 4 h by MTS assay and compared to cell viability by 
the Viacount flow cytometric assay. Data represent mean ±SEM of 5 
independent experiments. GM - GM-CSF B. Neutrophil NAD/H and 
NADP/H contents were measured alternatively using a colorimetric assay 
at the indicated timepoints with either 50 or 100 nM FK866 as indicated, 
data represent mean ±SEM of 5 independent experiments, and statistics 
are calculated as change from 0 nM. *p<0.05, **p<0.01. 
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for 1 h and then stimulated with either GM-CSF or PMA for a further 1 h 
or 5 min respectively. Both PMA and GM-CSF induced a modest 
increase in NAD/H (3.2A,B), however, PMA induced a much larger 
increase in NADP/H (3.2C,D), likely due to stimulation of the respiratory 
burst via the NADPH oxidase. Pre-treatment with the NAMPT inhibitor 
prior to stimulation, abated the upregulation of both NAD/H and 
NADP/H in response to these stimulants (Fig. 3.2). 
Because many neutrophil functions directly or indirectly require NAD, it 
was then necessary to determine the effects of NAMPT inhibition on the 
properties of these cells. 
3.3.2 Effects of NAMPT inhibition on the neutrophil respiratory burst 
The neutrophil respiratory burst that results in the generation of a series 
of reactive oxygen species (ROS) is triggered via activation of the 
NADPH oxidase to initially generate O2
-
 
243
. As the respiratory burst 
requires electrons transferred from NADPH to O2, it was necessary to 
determine if inhibition of NAMPT and disruption of the NAD salvage 
pathway, would negatively affect the activity of this NADPH oxidase and 
hence the ability of neutrophils to generate ROS. 
Neutrophils were incubated for 1 h in the absence and presence of 
increasing concentrations of FK866, and the respiratory burst, triggered 
by the addition of the phorbol ester, PMA, was measured by luminol- 
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FIGURE 3.2: NAMPT inhibition with FK866 decreases neutrophil 
intracellular NAD(P)/H in response to priming and stimulation. 
Neutrophil NAD/H and NADP/H content was measured using a 
colorimetric assay. Neutrophils were pre-incubated with 100 nM FK866 
as indicated (FK) for 1 h, then for either a further 1 h with GM-CSF (50 
U/mL) (GM), or a further 5 min with PMA (0.1 µg/mL). Data represent 
mean ±SEM of 4 independent experiments, *p<0.05. 
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dependent chemiluminescence. Fig. 3.3A shows that under these 
conditions, FK866 resulted in a dose-dependent inhibition of the 
respiratory burst, with over 50% inhibition observed at a concentration of 
the inhibitor of 100 nM. As well as being concentration-dependent, this 
inhibition of the respiratory burst was also time-dependent (Fig. 3.3B): at 
a concentration of 10 nM FK866, inhibition of the respiratory burst was 
significant by 30 min pre-incubation with the inhibitor, and this 
inhibitory effect was greater as the pre-incubation period increased. 
Representative traces of this inhibition of respiratory burst activity are 
shown in Fig. 3.3C, and this inhibitory effect of FK866 was also 
observed when NADPH oxidase activity was measured as the rate of O2
-
 
secretion using the cytochrome c reduction assay (Fig. 3.3D). 
PMA activates the neutrophil respiratory burst by directly activating 
protein kinase C via a mechanism that is independent of receptor-coupled 
signalling 
244
. However, neutrophil function is usually activated in vivo 
by receptor-linked signalling 
48
. Therefore, the effects of FK866 on 
activation of the respiratory burst triggered by a number of ligands of 
patho-physiological importance were also determined. 
Neutrophil activation in vivo is usually regulated by prior exposure to 
cytokines, such as GM-CSF, that can prime the cells into a state of 
enhanced responsiveness 
3
. The effects of NAMPT inhibition on  
 107 
 
 
 
 
FIGURE 3.3: FK866 inhibits the neutrophil respiratory burst in a 
time- and dose- dependent manner in response to PMA. Neutrophils 
were incubated for 60 min with the indicated concentration of FK866 (A) 
or for the indicated time with 10 mM FK866 (B) total ROS were 
measured by luminol-enhanced chemiluminescence in response to PMA 
(0.1 µg/mL). Data represent mean ±SEM of 5 independent experiments, 
representative trace shown in C. D, the rate of neutrophil extracellular 
release of O2
-
 was measured spectrophotometrically by O2
-
 mediated 
reduction of ferri-cytochrome c (λmax 550 nm). Data represent mean 
±SEM of 3 independent experiments, *p<0.05. 
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unprimed and GM-CSF primed neutrophils were also determined in these 
experiments, to assess if NAMPT was involved the priming response. 
In these experiments neutrophils were incubated for 30 min in the 
absence or presence of 100 nM FK866 and then for a further 30 min in 
the absence or presence of GM-CSF. Unprimed neutrophils generated 
only low levels of reactive oxidants when stimulated by fMLP, but this 
low level of ROS production was significantly decreased (p<0.05, n=8) in 
the presence of the NAMPT inhibitor. Priming by GM-CSF significantly 
increased ROS production stimulated by fMLP, and this primed response 
was also inhibited by FK866 (Fig. 3.4A). In inflammatory disorders such 
as rheumatoid arthritis, primed neutrophils can be inappropriately 
stimulated to produce ROS in response to soluble and insoluble immune 
complexes 
163
. We therefore determined the effects of priming and 
NAMPT inhibition on activation of ROS production triggered by immune 
complexes. Previous work 
161,245
 has shown that soluble and insoluble 
immune complexes can activate neutrophils by different signalling 
pathways. Both the unprimed and GM-CSF primed ROS production, 
triggered by either type of immune complex, were similarly decreased in 
the presence of FK866 (Fig. 3.4B,C). 
Neutrophils produce ROS both inside the phagosome and at the cell 
surface, neutrophils can also be stimulated to secrete ROS; bystander 
tissue injury can occur when ROS are released extracellularly. To  
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FIGURE 3.4: FK866 inhibits the neutrophil respiratory burst in 
response to fMLP and immune complexes, in both primed and 
unprimed cells. Neutrophils were pre-incubated in the absence (-) and 
presence (FK) of 100 nM FK866 for 30 min, then incubated for a further 
30 min in the absence or presence of GM-CSF (GM). The respiratory 
burst was then stimulated with either 1 µM fMLP (A), or 20% insoluble 
(IIC) (B), or soluble immune complexes (SIC) (C), and measured by 
luminol-enhanced chemiluminescence. Data (left panel) represent mean 
±SEM of 8 independent experiments, and representative traces are shown 
in the right panel, *p<0.05, ***p<0.001. 
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determine whether the inhibition of ROS affects both intra- and 
extracellular ROS production, ROS were measured using the membrane 
impermeable isoluminol alongside the membrane permeable luminol. 
Neutrophils were pre-incubated as previously in the absence or presence 
of 100 nM FK866 for 30 min and then incubated for a further 30 min in 
the presence and absence of GM-CSF. The respiratory burst was then 
stimulated with either fMLP (1µM) or PMA (0.1µg/mL) and measured 
using either luminol- or isoluminol-enhanced chemiluminescence. The 
level of ROS produced extracellularly is below the level of detection with 
isoluminol alone, so HRP was included to enhance the fluorescence. 
Extracellular ROS were decreased in an equal manner to total ROS 
produced, and it can be seen that FK866 appears to have a greater 
inhibitory effect on receptor-mediated production of ROS, than that 
stimulated synthetically (Fig. 3.5). 
3.3.3 Effect of FK866 on the expression of neutrophil cell surface 
receptors 
Immune complexes activate the neutrophil respiratory burst via Fcγ 
receptors 
162,245. The expression of the major Fcγ receptor on neutrophils, 
CD16b (FcγIIIb), is dynamically regulated by its rate of shedding, its rate 
of mobilization to the plasma membrane from intracellular stores and 
possibly by its rate of biosynthesis 
64,246,247
. We therefore measured the 
effects of NAMPT inhibition on the regulation of this receptor in both  
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FIGURE 3.5: FK866 inhibits the production of both intracellular or 
extracelluar ROS. Neutrophils were pre-incubated in the absence (-) and 
presence (FK) of 100 nM FK866 for 30 min, then incubated for a further 
30 min in the absence or presence of GM-CSF (GM). The respiratory 
burst was then stimulated with either 1 µM fMLP or 0.1 µg/mL PMA, 
and measured by either luminol- or isoluminol-enhanced 
chemiluminescence. Data represent mean ±SD of 2 independent 
experiments and representative isoluminol traces are shown. 
  
 112 
 
control and GM-CSF treated cells, this was firstly assessed by 
immunoblotting for CD16b shed from the cell surface into the culture 
supernatant. No significant changes in cellular expression of CD16b were 
observed (Fig. 3.6A). The cell culture supernatants were probed for 
CD16b cleaved from the surface of the cell, and there was a significant 
increase in CD16b shedding following GM-CSF treatment (Fig. 3.6A). 
However, NAMPT inhibition, prior to stimulation, abrogated the GM-
CSF induced shedding (Fig. 3.6A). 
Flow cytometry was then used to determine the levels of cell surface and 
intracellular CD16b following NAPMT inhibition. Neutrophils were pre-
incubated for 1 h with FK866 (100 nM), then a further 1 h with GM-CSF, 
alongside the appropriate no treatment controls. Incubation of neutrophils 
with 100 nM FK866 alone resulted in very little change in the surface 
expression of CD16b, but a statistically-significant decrease in the total 
cellular level of this receptor, due to a significant decrease in the 
intracellular receptor pool (Fig. 3.6B): a similar effect was seen with GM-
CSF treatment. Previous work 
64
 has shown that GM-CSF results in an 
increase in shedding of CD16b from the cell surface and a concurrent 
mobilization of the receptor from internal stores, maintaining cell surface 
expression. This was confirmed in Figure 3.6B where a statistically-
significant decrease in the intracellular pool of CD16b was observed, but 
the surface expression remained unchanged from control. This effect was  
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FIGURE 3.6: FK866 inhibits GM-CSF induced shedding of CD16b, and decreases 
intracellular pools, but does not significantly affect its expression on the neutrophil 
surface. A. Neutrophils were incubated for 1 h with 100 nM FK866 (FK) or medium 
alone (-), then a for further 1 h in the presence and absence of GM-CSF (GM), total 
cellular CD16b and CD16b shed into the culture supernatant were then assessed by 
immunoblotting. Densitometry represents the mean ±SEM of 3 independent experiments 
and representative blots are shown below. B. Surface expression and intracellular stores 
of CD16b were measured by flow cytometry of neutrophils treated in the same way, 
then fixed and permeabilized. Data represent mean ±SEM of 5 independent experiments 
and representative traces are shown below, *p<0.05. 
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compounded when cells were treated with GM-CSF and FK866 in 
combination, and there was a further decrease in intracellular CD16b 
compared to GM-CSF treatment alone (Fig. 3.6B). Thus, NAMPT 
inhibition affects the dynamics of CD16b synthesis and shedding in 
neutrophils, but cell surface expression is maintained, and as such is 
unlikely to have an adverse effect on receptor mediated events, such as 
activation of the respiratory burst. 
NAMPT inhibition (1 h, 100nM) had no effect on the surface expression 
of other key neutrophil surface markers tested in the presence and 
absence of GM-CSF priming. CD11b on the surface of neutrophils is 
normally up-regulated by GM-CSF 
48,50,60,248
, and this cytokine-
dependent up-regulation was not affected by NAMPT inhibition (Fig. 
3.7A). Similarly, NAMPT inhibition alone did not alter CD11b 
expression in non-cytokine treated cells. In contrast to the cytokine-
dependent up-regulation of CD11b expression, GM-CSF triggers the 
shedding of L-selectin (Fig. 3.7B). Again, NAMPT inhibition by FK866 
did not affect either the expression of L-selectin on resting neutrophils, or 
the cytokine-induced shedding of this receptor. Similarly, neither the 
resting levels of expression of the Fcγ receptor, CD32, nor the levels of 
expression of this receptor observed after GM-CSF treatment, were 
affected by NAMPT inhibition (Fig. 3.7C). Therefore, under these  
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FIGURE 3.7: FK866 does not affect the surface expression of other 
key neutrophil surface receptors. Neutrophils were incubated for 1 h 
with 100 nM FK866 or media alone (-), then a further 1 h in the presence 
and absence of GM-CSF (GM), and surface expression of CD11b (A), L-
selectin (B) and CD32 (C) was measured by flow cytometry. Data 
represent mean ±SEM of 4 independent experiments (left panel) and 
representative traces are shown on the right, *p<0.05 
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experimental conditions, NAMPT inhibition did not affect the level of 
cell surface expression of any of these important neutrophil receptors. 
3.3.4 Effect of NAMPT inhibition on phagocytosis and degranulation 
Having shown that NAMPT inhibition decreased the ability of 
neutrophils to generate ROS production in response to soluble agonists, it 
was then necessary to determine if it also affected ROS production during 
phagocytosis of bacteria. In the first sets of experiments, the rates of 
phagocytosis of PI-stained (heat-killed) serum-opsonised S. aureus were 
measured. FK866 did not affect phagocytosis of these serum-opsonised 
bacteria (Fig. 3.8A), in line with its lack of effect on the surface 
expression of receptors likely to be involved in opsono-phagocytosis. The 
rate of intraphagosomal ROS production during phagocytosis of S. 
aureus, was then measured with the same FK866 pre-treatment, using 
Dihydrorhodamine (DHR) 123 and flow cytometry. DHR123 is a cell-
permeable dye that becomes fluorescent once oxidised by ROS 
249
. In 
contrast to its lack of effect on phagocytosis, and in agreement with the 
effects observed previously, the NAMPT inhibitor significantly decreased 
intraphagosomal ROS production (Fig. 3.8A). Under these experimental 
conditions (100 nM FK866; 30 min pre-incubation), intraphagosomal 
ROS production was decreased by approximately 65% (p<0.01, n=5). 
Following phagocytosis, neutrophils release granule enzymes, alongside 
ROS. To investigate whether NAMPT inhibition affects this process, the 
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FIGURE 3.8: FK866 inhibits production of ROS in response to S. aureus, but does 
not affect phagocytosis or release of granule proteins. A. Neutrophils were pre-
incubated with 100 nM FK866 (FK) or media alone (-) for 30 min, then with opsonised 
S. aureus (SA) either unlabelled or labelled with PI (SA/PI) for 30 min; uptake was 
measured by flow cytometry. B. Alternatively, following 15 min incubation with S. 
aureus, or media alone, DHR123 was added to samples for 15 min to measure 
intraphagosomal ROS production. Data represent the mean ±SEM of 5 experiments with 
representative traces. C. Neutrophils were pre-incubated for 1 h with 100 nM Fk866, 
then 30 min in the presence and absence of GM-CSF (GM). All samples were then 
treated with cytochalasin B for 10 min and 1 µM fMLP for a further 10 min to stimulate 
degranulation. Total cellular myeloperoxidase (MPO) and lactoferrin (LF) and that 
released into the culture supernatant was assayed by immunoblotting. Densitometry 
represents the mean ±SEM of 4 experiments with representative blots, **p<0.01. 
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release of two of these granule proteins, myeloperoxidase (MPO) 
(primary granules) and lactoferrin (LF) (secondary granules), was 
measured in response to fMLP, following pre-incubation with media 
alone or FK866. Neutrophil preparations were also treated with 
cytochalasin B, which disrupts the actin cytoskeleton, and allows release 
of the granule enzymes into the culture supernatant following stimulation. 
MPO and LF in the culture supernatant were then measured by 
immunoblotting. Pre-incubation with FK866 (100 nM for 1 h) had no 
significant inhibitory effect on the release of these granule enzymes (Fig. 
3.8B). 
3.3.5 FK866 does not affect neutrophil chemotaxis towards fMLP 
It was investigated whether inhibition of NAMPT affected the ability of 
neutrophils to transmigrate towards fMLP. Hanging culture well inserts 
with a 3 µm polycarbonate filter were suspended in a culture plate 
containing media and the indicated chemoattractant. Following this, 1 x 
10
6
 neutrophils, either untreated or following 30 min with FK866, were 
added into the hanging well inserts, and incubated at 37°C for 1 h. The 
cells that had migrated through the filter towards the chemoattractant 
were counted using a Multisizer 3 cell counter. 10 nM fMLP was used as 
a positive control for chemotaxis. Around 50% (p<0.05) of the cells 
transmigrated through the membrane towards fMLP, and this was 
unaffected by pre-treatment with FK866 (Fig. 3.9). 
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FIGURE 3.9: FK866 does not affect neutrophil chemotaxis towards 
fMLP. Neutrophils were incubated for 30 min with 100 nM FK866, then 
added into a hanging well insert with a 3 µm membrane suspended above 
media alone (-) or media containing 10 nM fMLP for 1 h. The neutrophils 
that had migrated through the membrane were then counted using a cell 
counter. Data represent mean ±SEM of 7 independent experiments, 
**p<0.01, ***p<0.001. 
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3.3.6 Effect of NAMPT inhibition on bacterial killing. 
Activation of the neutrophil NADPH oxidase is a key event in regulating 
bacterial killing within the phagosome 
1
. In view of the inhibitory effects 
of FK866 on ROS production, particularly intraphagosomal ROS 
production following phagocytosis of bacteria, its effects on bacterial 
killing were determined. Neutrophils (5 x 10
6
) were pre-incubated for 30 
min in the absence (control) or presence of 100 nM FK866 and then for a 
further 1 h in with serum-opsonised S. aureus (at a bacteria:neutrophil 
ratio of 10:1). Following this, the neutrophils were lysed in water, and the 
remaining bacteria were serially diluted and spread onto agar plates. 
Following incubation overnight at 37°C, the number of colony forming 
units (cfu) were counted, and compared to neutrophil free cultures. Under 
these conditions, control neutrophils killed approximately 40% of the 
bacteria (Fig. 3.10), but inhibition of NAMPT by FK866 had no 
significant effect on bacterial killing. Therefore, in spite of the large 
decrease in ROS production following NAMPT inhibition, this did not 
affect the efficiency of bacterial killing. 
 
3.3.7 Effect of NAMPT and FK866 on neutrophil apoptosis 
Previous work has shown that the addition of exogenous NAMPT to 
neutrophils can delay their rate of apoptosis 
19
. Previous work 
38
 has also 
shown a key role for the anti-apoptotic protein, Mcl-1 in regulating the  
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FIGURE 3.10: Inhibition of ROS production with FK866 does not 
have any effect on neutrophil killing of opsonised S. aureus. 
Neutrophils were pre-incubated with 100 nM FK866 or media alone (-) 
for 30 min, prior to mixing with opsonised S. aureus for 1 h. Following 
this neutrophils were lysed and the number of bacteria killed was assayed 
by comparing the cfu remaining following different neutrophil treatments 
and compared to a no neutrophil control (media). Data represent mean 
±SEM of 4 independent experiments, **p<0.01, ***p<0.001, N.S. – not 
significant. 
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rate of neutrophil apoptosis. The addition of exogenous NAMPT to 
neutrophils (100 ng/mL) significantly delayed their apoptosis over a 17 h 
incubation period and maintained Mcl-1 protein levels at 5 h (Section 
4.3.4). However, intracellular NAMPT inhibition by FK866 had no 
significant effect on apoptosis at 17 h (Fig. 3.11A), neither decreasing nor 
increasing viability. Also, NAMPT inhibition had no effect on 
degradation of Mcl-1; Mcl-1 was significantly decreased in control cells 
undergoing high rates of apoptosis by 5 h, and this was unchanged by 
addition of FK866 (Fig. 3.11B). 
3.4 Discussion 
NAMPT functions intracellularly in the regulation of NAD biosynthesis, 
and NAMPT inhibitors have been shown to have anti-inflammatory 
potential in in vivo models of inflammation 
33,34
. NAD is required for 
cellular metabolism and is an essential co-factor for enzymes, such as 
sirtuins (protein deacetylases), and poly (ADP-ribose) polymerases 
(PARP). These proteins are involved in the transcriptional control of 
many cellular processes, including the response to cytokines 
169,250
. 
Inhibition of NAMPT-mediated NAD biosynthesis with FK866, down-
regulates cytokine production from inflammatory cells in vitro, and is 
reversed by addition of the enzyme product nicotinamide mononucleotide 
(NMN) 
33
. Moreover, accumulation of nicotinamide (NAM) (the 
substrate of NAMPT) has also been shown to decrease cytokine  
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FIGURE 3.11: NAMPT inhibition with FK866 has no effect on 
neutrophil apoptosis or turnover of Mcl-1. A. Neutrophils were 
incubated for 17 h with media alone (-), GM-CSF (GM) or 100 nM 
FK866, before apoptosis was quantified by annexin V binding and PI 
uptake measured by flow cytometry. Results are representative of 6 
experiments. B. The effect of NAMPT and its inhibition on turnover of 
Mcl-1 was assayed by immunoblotting, neutrophils were assayed at 0 h 
and 5 h with the treatments listed previously. Densitometry represents the 
mean ±SEM of 6 independent experiments and a representative blot is 
shown above, *p<0.05. 
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production 
35,228
. No studies have yet specifically addressed the effect of 
NAMPT inhibition on neutrophil function. Here, it is shown that FK866 
depletes neutrophil NAD/H and NADP/H stores, which leads to a 
decrease in the reactive oxidants secreted by these cells in response to 
receptor-dependent and -independent stimulation. However, this does not 
cause a concomitant decrease in neutrophil phagocytosis or bacterial 
killing. 
FK866 inhibits the first step in the respiratory burst, reduction of 
molecular O2 by the NADPH oxidase complex. O2
-
 is then converted into 
a variety of secondary oxidants, spontaneously, and by the action of other 
cellular enzymes 
1,243
. The NADPH oxidase uses the reducing power of 
NADPH to reduce oxygen, resulting in NADP
+
; which is converted back 
to NADPH via the hexose monophosphate (HMP) shunt. Neutrophil 
pools of NADP/H are insufficient to fuel the oxidase, and are increased 
greater than 3-fold upon neutrophil activation with fMLP or PMA 
83
, 
requiring new input of phosphorylated NAD. However, FK866 inhibits 
intracellular production of NAD and NADP, and in this way FK866 may 
also impede the production of reactive oxidants. These findings are 
supported by the recent results of Schilling et al. 
229
 who demonstrated a 
decrease in ROS from monocytes with FK866 treatment, although they 
found that exogenous NAD did not restore this function, and suggest that 
FK866 may directly affect NADPH oxidase activity. It has been shown 
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previously that accumulation of NAM, the substrate of NAMPT, has the 
potential to suppress production of reactive oxidants 
230
, so if NAM were 
to accumulate as a consequence of NAMPT inhibition, it could affect 
production of oxidants in this manner. 
CD16b (FcγRIIIb) is a member of the Fcγ receptor family, which is  
responsible for the binding and endocytosis of soluble antibody-antigen 
complexes and IgG coated particles 
1,246
. The CD16b isoform is 
expressed only on neutrophils, where it is present on the cell surface in 
large numbers of 100,000-200,000 molecules per cell 
1,64
. It is attached to 
the cell membrane via a glycosylphosphatidylinositol (GPI) linkage, 
which can be easily cleaved by metalloproteinases. The receptor is 
cleaved during apoptosis, and also during neutrophil activation by 
cytokines such as GM-CSF 
64,251
. However, during activation with such 
agents, sub-cellular stores of pre-formed receptors can be mobilised, 
replenishing surface levels 
247
. This is confirmed here by flow cytometry, 
in which GM-CSF treatment resulted in an increase in shedding and a 
decrease in the intracellular stores of CD16b, whilst overall the surface 
levels remained unchanged. In this study, FK866 decreased both GM-
CSF-induced shedding, and the intracellular stores of CD16b.  However, 
this did not appear to affect surface expression of the formed receptor. 
Translocation of pre-formed receptors allows for rapid response to stimuli 
in neutrophils, and in these experiments depletion of the CD16b stores 
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did not affect the ability of the cells to maintain surface expression of the 
receptor, but may have led to a down regulation of shedding to conserve 
the depleted pre-formed receptor stores. In this way, NAMPT inhibition 
would not be expected to affect neutrophil receptor function, which 
corresponds with the observation that FK866 does not affect neutrophil 
phagocytosis of bacteria. 
The decrease in reactive oxidants produced by neutrophils, following 
FK866 treatment, could be beneficial to decrease the tissue damage 
caused by these cytotoxic products in inflammatory diseases 
2
. However, 
production of ROS is a crucial component of the anti-microbial action of 
neutrophils, and down-regulation of this system could potentially render 
patients more susceptible to infections. It was investigated whether 
inhibition of NAMPT with FK866, had an adverse effect on neutrophil 
functions important in host defence, and it was shown that FK866 did not 
decrease neutrophil phagocytosis or killing of S. aureus. In view of the 
importance of ROS in bacterial killing, this lack of inhibition of bacterial 
killing by FK866, when the inhibitor significantly decreases ROS 
production, appears difficult to reconcile. However, there is precedent for 
this in neutrophils of patients with chronic granulomatous disease (CGD), 
which is a disorder of the neutrophil phagosomal oxidase 
97–99
. Patients 
have impaired ability to generate a respiratory burst, and as such, oxygen 
dependent microbicidal activity is repressed, rendering neutrophils unable 
 127 
 
to kill many microorganisms, leading to recurrent infection. The X-linked 
form of the disease is the most severe and often patients with this form of 
the disease have a severe defect of NADPH oxidase activity and severe 
problems with infections 
98
. However, the autosomal recessive form of 
the disease is more variable and some patients with this form of CGD are 
only identified by chance or by genetic studies 
95,96
. Often, such patients 
have significantly impaired NADPH oxidase activity, but no problems 
with infections: i.e. the residual oxidase activity, although decreased 
compared to healthy controls, is sufficient to sustain intra-phagosomal 
killing, alongside non-oxidative processes 
100,252,253
. In this study, 
presumably, the residual intra-phagosomal activity of the NAPDH 
oxidase in NAMPT-inhibited cells was sufficient to create an anti-
microbial environment, and alongside O2 independent killing 
mechanisms such as release of granule proteases, sufficient bacterial 
killing was maintained. 
In conclusion, these data show that inhibition of NAMPT-catalysed NAD 
biosynthesis can down-regulate neutrophil activities that have the 
potential to cause tissue damage in inflammatory disease, without 
compromising their microbicidal action and thus host defence. These 
findings, alongside previous work showing that FK866 can decrease 
production of inflammatory cytokines 
33,34
, suggest that NAMPT is a 
potential therapeutic target in inflammatory disease. However, inhibition 
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of NAD biosynthesis could have wide ranging effects on many cell types, 
so it will be of interest to monitor the progress of this drug following the 
recent completion of phase II clinical trials for the treatment of cancer 
231,232
. 
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CHAPTER 4: Effects of NAMPT on Neutrophil Functions 
4.1 Introduction 
Whilst it has previously been reported that NAMPT regulates neutrophil 
apoptosis 
19
, the full range of effects of this molecule on other neutrophil 
functions has not yet been determined. NAMPT expression is upregulated 
in a variety of acute and chronic inflammatory diseases including RA 
18,32,165
, and it may contribute to the perpetuation of the inflammatory 
state in this disease via inhibition of neutrophil apoptosis 
19
. There is 
accumulating evidence that NAMPT acts as an extracellular cytokine-like 
molecule and growth factor that can stimulate immune cells 
independently of its enzyme activity 
21,22,167
. In vitro, exogenous 
recombinant human NAMPT (rhNAMPT) has been shown to stimulate 
cells involved in inflammation to express a number of cytokines, such as 
TNFα, IL-1β, IL-1ra, IL-6 and IL-10 20. 
4.2 Aims 
The aims of this chapter were to characterize the in vitro responses of 
control neutrophils to recombinant human (rh)NAMPT, at concentrations 
observed in inflammatory diseases such as RA. A variety of neutrophil 
functions were tested to establish whether exogenous NAMPT could, like 
many other cytokines, prime these cells. This would evaluate whether 
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NAMPT contributes to the inflammatory potential of neutrophils in 
chronic inflammatory disease. 
4.3 Results 
4.3.1 NAMPT does not affect neutrophil surface marker expression 
Neutrophil priming, by agents such as GM-CSF, affects the expression of 
cell surface receptors that facilitate many neutrophil functions, including 
transmigration and pathogen recognition 
50,64,254
. Therefore, expression of 
some key markers was measured on resting neutrophils, and compared 
with cells stimulated with either GM-CSF or rhNAMPT (100 ng/mL) for 
1 h. The neutrophils were fixed and stained with the appropriate 
fluorescently-conjugated antibodies before surface receptor expression 
was assayed by flow cytometry. As observed in the previous chapter, 
GM-CSF induced significant shedding of L-selectin (p<0.05) (Fig. 4.1A) 
as well as a significant increase in expression of CD11b (p<0.01) (Fig. 
4.1B). However, NAMPT had no effect on the extracellular expression of 
these receptors (Fig. 4.1A, B). Neither GM-CSF nor NAMPT caused a 
significant change in the surface expression of CD16 or CD32 
48
 (Fig. 
4.1C,D)  
4.3.2 NAMPT is not a neutrophil chemoattractant 
One of the features of RA is massive leukocyte infiltration into affected 
joints, via processes that are controlled by the presence of neutrophil  
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FIGURE 4.1: NAMPT does not affect the surface expression of key 
neutrophil receptors. Neutrophils were incubated for 1 h with 100 
ng/mL NAMPT (N), GM-CSF (G) or media alone (-) and surface 
expression of L-selectin (A), CD11b (B), CD16b (C) and CD32 (D) was 
measured by flow cytometry. Data represent mean ±SEM of 4 
independent experiments, *p<0.05, **p<0.01. 
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chemoattractants in the joint 
7,8,10
. It is well established that NAMPT is 
elevated in the synovial fluid of RA patients 
18,165,218
, so it was 
investigated whether rhNAMPT, at patho-physiological concentrations, 
was capable of inducing neutrophil chemotaxis. Hanging culture well 
inserts with a 3 µm polycarbonate filter were suspended in a culture plate 
containing media and the indicated chemoattractant. Following this, 1 x 
10
6
 neutrophils were added into the hanging well inserts, and incubated at 
37°C for 1 h. The cells that had migrated through the filter towards the 
chemoattractant were counted using a Multisizer 3 cell counter. 10 nM 
fMLP was used as a positive control for chemotaxis. Around 50% 
(p<0.05) of the neutrophils transmigrated through the membrane towards 
fMLP. However, no more cells migrated towards NAMPT at 50 or 100 
ng/mL, than were observed to move due to random migration alone (~ 
5% migration) (Fig. 4.2). 
4.3.3 NAMPT does not prime neutrophils for the respiratory burst 
Neutrophils may be primed by exposure to cytokines prior to producing 
reactive oxidants in response to stimuli 
3
. In inflammatory diseases, 
neutrophils can become inappropriately primed by high levels of 
circulating cytokines 
11
. Priming stimulates the assembly of the NADPH 
oxidase complex, which catalyses the first step in oxidant production 
255
. 
To examine whether NAMPT, like other cytokines, is capable of priming 
neutrophils for the respiratory burst, 5 x 10
6
 cells were primed with either  
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FIGURE 4.2: NAMPT is not a neutrophil chemoattractant. 
Neutrophils were added to a 3 µM filter chamber suspended above media 
containing the indicated concentration of NAMPT or fMLP (10 nM) as a 
positive control for chemotaxis, and incubated for 1 h. The number of 
migrated Data represent mean ±SEM of 4 independent experiments, 
***p<0.001. 
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TNFα (10 ng/mL) for 15 min, or GM-CSF (50 U/mL) for 45 min, 
alongside the indicated concentrations of rhNAMPT for the same time 
period. Following this incubation, the respiratory burst was stimulated 
with fMLP (1 µM) and the production of reactive oxidants was measured 
by luminol-dependent chemiluminescence. 
fMLP stimulated oxidant production from neutrophils increased 7.1-fold 
(p<0.01) with 15 min TNFα priming and 4.5-fold (p<0.01) with 45 min 
GM-CSF priming, but there was no significant increase in the capacity of 
neutrophils to produce oxidants in response to fMLP following NAMPT 
treatment for either 15 or 45 min (Fig. 4.3). 
4.3.4 NAMPT delays neutrophil apoptosis and stabilizes Mcl-1 
Neutrophil apoptosis can be transiently delayed, the major way in which 
this is controlled in neutrophils is by decreases in the turnover rate of the 
anti-apoptotic protein Mcl-1 
38
. Pro-inflammatory cytokines, such as GM-
CSF, decrease the rate of Mcl-1 turnover by altering the phosphorylation 
state of the protein 
38,108
. Jia et al. (2004) 
19
 have demonstrated that 
rhNAMPT delays neutrophil apoptosis in a dose-dependent manner in 
vitro. This is corroborated here, as 100 ng/mL rhNAMPT significantly 
delayed neutrophil apoptosis at 17 h (control 51% ± 4.6%: NAMPT 37 % 
± 4.2%, p<0.05, n=6), measured by flow cytometry of annexin V binding 
and uptake of PI (Fig 4.4A). As Mcl-1 turnover is the major controlling 
factor in neutrophil apoptosis, it was then investigated whether  
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FIGURE 4.3: NAMPT does not prime neutrophils for the respiratory 
burst. Neutrophils were incubated for 15 min with the indicated 
concentration of NAMPT or TNFα (10 ng/mL) as a positive control for 
priming (A), or for 45 min with NAMPT (200 ng/mL) alongside GM-
CSF (50 U/mL) as a positive control for priming (B). Production of ROS 
was stimulated with fMLP (1 µM) and measured by luminol-enhanced 
chemiluminescence, displayed as total area under the curve. Data 
represent mean ±SEM of 3 (A) or 4 (B) independent experiments, 
**p<0.01. 
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rhNAMPT affected the stability of this protein. Figure 4.4B shows that 
the degradation of Mcl-1 over time (measured at 5 h) is delayed by 100 
ng/mL rhNAMPT in a manner comparable to GM-CSF. 
4.4 Discussion 
NAMPT is elevated in the serum and synovial fluid of RA patients, and 
has been demonstrated to have a cytokine-like effect on immune cells 
18,23,165
. Neutrophils contribute to the inflammatory process in diseases 
such as RA, and thus it is of interest to indentify factors that can lead to 
their activation and/or delay their apoptosis 
2
. NAMPT has been shown 
previously to delay constitutive neutrophil apoptosis 
19
, so it was 
investigated whether it exerts any other pro-inflammatory effects on these 
cells. NAMPT, at the range of serum concentrations observed in 
inflammatory disease, was found to have little effect on neutrophil 
functions, but it did delay neutrophil apoptosis by delaying the turnover 
of Mcl-1. 
NAMPT did not stimulate any changes in the surface expression of the 
key cell surface markers tested, suggesting that these cells are not primed 
by NAMPT. Further evidence that NAMPT is unable to prime 
neutrophils came from the inability of NAMPT treated cells to mount a 
respiratory burst. Neutrophils pre-treated with rhNAMPT alone produced 
no more ROS in response to fMLP than unprimed cells, in comparison to 
a large upregulation observed with GM-CSF or TNFα priming.  
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FIGURE 4.4: NAMPT delays neutrophil apoptosis and the turnover 
of anti-apoptotic Mcl-1. A. Neutrophils were incubated with 100 ng/mL 
NAMPT (N) or GM-CSF (G) as an anti-apoptotic control for 17 h, then 
apoptosis was quantified by flow cytometry as binding of annexin V and 
uptake of PI. Data represent mean ±SEM of 4 independent experiments. 
B. Turnover of Mcl-1 was quantified by immunoblotting; neutrophils 
were incubated in either media alone (-), or with 100 ng/mL NAMPT (N) 
or GM-CSF (G) for 5 h. Relative Mcl-1 expression was quantified by 
comparison to Actin. Data represent mean ±SEM of 6 independent 
experiments, *p<0.05, **p<0.01. 
A 
B 
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Neutrophil priming facilitates assembly of the multi-component NADPH 
oxidase complex at the plasma membrane, in readiness to mount a 
respiratory burst when a stimulus is encountered. Malam et al., (2011) 
224
, 
suggested that rhNAMPT does prime (but not activate) neutrophils for 
the respiratory burst, by promoting translocation of two of these enzyme 
subunits, p40 and p47, to the cell membrane via phosphorylation of p40. 
In their study, the generation of ROS was assayed using isoluminol, 
which measures extracellular oxidant production only, whereas here 
luminol was used to measure total intra- and extracellular oxidant 
production. The extracellular oxidant portion enhanced with isoluminol is 
reported to constitute less than 22% of the total cellular oxidants, and 
there is precedent for the two parts of the chemiluminescence signal 
being differentially modified by the same treatment 
256
. This may go 
some way to explain why Malam et al. 
224
 observed a priming effect with 
rhNAMPT that was unable to be reproduced here. 
It was also concluded that NAMPT does not act as a neutrophil 
chemoattractant at patho-physiologically relevant concentrations. This is 
in disagreement with the work of Hong et al. (2008) 
257
, as they found 
rhNAMPT to be a rat neutrophil chemotactic factor in vitro. Hong et al. 
labeled rat peritoneal neutrophils with calcein AM, and assayed 
transmigration towards rhNAMPT (10 ng/µL) through a bovine albumin 
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coated filter. The number of transmigrated cells was assayed via 
fluorescence emission at 517 nm 
257
. They suggested that rhNAMPT at 
10 ng/µL acts as a rat neutrophil chemotactic agent, however, this 
concentration is 100 times that observed during inflammation in vivo 
18,165,218
. The discrepancy between these findings and the experiments in 
this report may be accounted for by the high concentration of rhNAMPT 
used and by the cross-species experimentation. 
In contrast to the lack of effect on other neutrophil functions tested, 
NAMPT significantly delayed neutrophil apoptosis by delaying turnover 
of the anti-apoptotic protein Mcl-1. Pro-inflammatory cytokines such as 
GM-CSF decrease the rate of Mcl-1 turnover by altering the 
phosphorylation state of the protein, transiently delaying neutrophil 
apoptosis 
38,108
. Control of this process is crucial for effective resolution 
of inflammation, and deregulated neutrophil apoptosis has been 
implicated in numerous chronic inflammatory conditions such as RA 
2,133
. 
Jia et al. (2004) 
19
 have also demonstrated that rhNAMPT delays 
neutrophil apoptosis in a dose dependent manner in vitro. They suggest 
this is due to decreased activity of caspases-8 and -3. This cascade of 
caspase activity is initiated by death receptor engagement, and brings 
about apoptosis of the cell, which includes cleavage of Mcl-1 by caspase-
3. Thus the decrease in caspase activation in response to NAMPT 
observed by Jia et al. corresponds with the observation here that NAMPT 
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delays the turnover of Mcl-1 in neutrophils. NAMPT may contribute to 
the dysregulation of neutrophil apoptosis observed in chronic 
inflammation, which exacerbates the damage caused in inflammatory 
diseases such as RA. Thus, although here NAMPT appeared to have little 
stimulatory effect on pro-inflammatory neutrophil functions, it may 
contribute to the perpetuation of inflammation by delaying neutrophil 
apoptosis, when present at high concentrations such as those observed in 
the rheumatoid joint 
18
. 
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CHAPTER 5: Dynamics of NAMPT Expression by Neutrophils 
5.1 Introduction 
Until recently, neutrophils were considered to be terminally differentiated 
cells with little capacity for active gene expression. However, it is now 
understood that activated neutrophils express a variety of cytokines and 
chemokines 
17,258,259
. NAMPT has been shown to be upregulated in 
neutrophils in response to IL-1β, TNFα and LPS 19, and it is also 
upregulated in a number of other immune cells in response to endotoxin 
and a variety of inflammatory cytokines 
23
. The NAMPT gene contains a 
binding site for the transcription factor NF-κB 176, which is activated by 
pro-inflammatory cytokines, such as TNFα and IFNγ 260. The NF-κB 
binding site is located at the distal NAMPT promoter alongside NF-1 
binding sites, whereas AP-2 binding sites are located at the proximal 
promoter, with AP-1 binding sites found throughout both regions 
176
. 
NAMPT protein is detectable in the circulation and correlates with 
leukocyte counts 
184
, and it is elevated in the serum and synovial fluid of 
patients with rheumatoid arthritis 
18,32,165
. It is suggested that NAMPT can 
be secreted from cells, and this has been termed extracellular or 
eNAMPT. The mechanism by which secretion occurs is not well 
understood, and as NAMPT lacks an identifiable signal peptide sequence 
that is commonly seen in hematopoietic cytokines and necessary for 
extracellular secretion 
167
, it has been suggested that eNAMPT may be 
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released during cell death and lysis 
171,212
. However, it has been shown 
that NAMPT is secreted by the 3T3-L1 adipocyte cell line during culture, 
via a non-classical pathway that is independent of the endoplasmic 
reticulum (ER)-Golgi system or microvesicles 
211
. 
5.2 Aims 
NAMPT is expressed by a number of immune cells, including neutrophils, 
can be dynamically regulated in response to cytokines and is found in the 
circulation. It has been suggested that NAMPT acts as an extracellular 
signalling molecule, but the mechanism of NAMPT secretion is yet to be 
elucidated 
23
. The aims of this chapter were to characterise expression of 
NAMPT RNA and protein by neutrophils, and to investigate whether 
NAMPT protein is secreted from neutrophils in vitro. The effects of 
cytokine stimulation on NAMPT expression by neutrophils were also 
investigated. 
5.3 Results 
5.3.1 Effects of cytokine stimulation on NAMPT RNA expression from 
neutrophils 
It has been shown previously that neutrophils express NAMPT mRNA 
transcripts in response to the inflammatory stimuli LPS, TNFα and IL-1β, 
and that NAMPT protein expression is similarly induced by stimulation 
with LPS 
19
. Here, it was investigated whether other pro-inflammatory 
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cytokines are capable of inducing transcription of NAMPT in healthy 
neutrophils in vitro. Neutrophils were incubated with the indicated stimuli 
for 1 h at 37°C with gentle agitation. Following this the cells were lysed 
with Trizol for isolation of RNA (as described in section 2.2.9). NAMPT 
RNA transcripts were quantified following conversion to cDNA and 
subsequent qPCR (as described in 2.2.10). Figure 5.1 shows a modest, but 
significant increase in NAMPT RNA transcripts in response to all of the 
cytokines tested, namely GM-CSF, IL-1β, IL-6, IL-8 and TNFα, and also 
with bacterial LPS. rhNAMPT did not induce expression of NAMPT 
mRNA by neutrophils. 
5.3.2 Effects of cytokine stimulation on NAMPT protein expression from 
neutrophils 
The dynamics of NAMPT protein expression, quantified by western blot, 
showed more variability between donors than NAMPT mRNA expression 
when cells were treated with the same inflammatory stimuli. Neutrophils 
were incubated with the indicated stimuli at 37°C with gentle agitation, and 
then lysed in boiling Laemmli buffer at the indicated time-points. Samples 
were then subjected to SDS-PAGE and immunoblotting for NAMPT. 
NAMPT expression generally appeared to increase over time in 
neutrophils (Fig. 5.1B), although this did vary between donors. NAMPT 
protein expression in response to stimuli was also highly variable, and no  
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FIGURE 5.1: NAMPT mRNA transcript is increased by exposure to cytokines, but 
protein levels are variable and not significantly altered. A. Neutrophils were 
incubated for 1 h with the indicated cytokine or NAMPT (N) alongside media alone (-) 
and NAMPT expression was assayed by qPCR. Data represent mean ±SEM of 6 
independent experiments. B. Neutrophils were incubated with the indicated cytokine for 
the indicated time alongside media alone (-), then NAMPT protein expression was 
analysed by immunblotting. Results shown as percentage expression compared to 
control. Data represent mean ±SEM of at least 3 independent experiments, *p<0.05, 
**p<0.01. 
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cytokine tested induced a significant upregulation in NAMPT protein, 
although IL-1β appeared to increase NAMPT expression at 2 h (Fig. 5.1B).  
5.3.3 NAMPT expression is under the control of transcription factor NF-
κB in neutrophils 
The NAMPT gene encodes a binding site for the transcription factor NF-
κB alongside others 176. Therefore, the selective NF-κB inhibitor Bay11 
was used to investigate the dynamics of NAMPT expression from 
neutrophils by this transcription factor. Bay11 inhibits NF-κB activity by 
inhibiting phoshorylation of IκBα induced by TNFα, but it does not affect 
constitutive IκBα phosphorylation 261. Inhibition of NF-κB activity with 
this agent induced a down-regulation of constitutive NAMPT protein 
expression in neutrophils with little protein detectable by 6 h (Fig. 5.2). 
This suggests neutrophils do constitutively express NAMPT de novo over 
time and that despite the presence of numerous transcription factor binding 
sites in the NAMPT promoter, NAMPT gene expression is primarily 
induced via NF-κB. 
5.3.4 NAMPT secretion from neutrophils 
NAMPT is expressed by neutrophils and it is suggested that NAMPT can 
be secreted; however the mechanism by which this occurs is not well 
understood. Here, neutrophil culture supernatants, alongside cell pellets, 
were immunoblotted for NAMPT in the presence of the priming agent 
GM-CSF and cytochalasin B (CB). CB disrupts the cellular actin  
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FIGURE 5.2: NF-κB inhibition decreases constitutive expression of 
NAMPT from neutrophils. Neutrophils were incubated for the indicated 
time (h) (x axis) in the absence and presence of the NF-κB inhibitor 
BAY-11, before cell lysates were subjected to immunoblotting for 
NAMPT. Representative blot and densitometry shown. 
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cytoskeleton and facilitates degranulation, one of the major mechanisms 
by which neutrophils secrete proteins. NAMPT was not detected in the 
supernatant from these samples; however, GM-CSF and CB in 
combination decreased the amount of intracellular NAMPT. This 
decrease may be due to degradation of the protein upon the co-release of 
NAMPT and intracellular proteases, as indicated by the increase in 
immune-reactive lower molecular weight products. The supernatant was 
also probed for the granule protein myeloperoxidase (MPO) as a positive 
control (Fig. 5.3A). To detect whether NAMPT was released from 
neutrophils at levels below the detection limit of the western blot assay, 
protein was precipitated from the neutrophil culture supernatants using 
ice cold acetone and then re-suspended in Laemmli buffer. This was done 
for samples incubated over the indicated time period with GM-CSF and 
TNFα priming. Figure 5.3B shows that 52 kDa NAMPT was detected 
albeit faintly, but a more intense signal was detected at 30 kDa. This may 
be a degradation product, as lower molecular weight, immune-reactive 
bands were also present in proteins isolated from cell lysates, and were 
decreased in intensity by addition of the serine protease inhibitor AEBSF. 
This 30 kDa species was only detected in culture supernatant and not 
observed in neutrophil whole cell lysates, although it was also present in 
low levels the 0 h samples.  
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FIGURE 5.3: Whole NAMPT is only detected in concentrated 
culture supernatants at very low levels. A. Neutrophils were incubated 
for 2h in the presence and absence of both cytochalasin B (CB) and GM-
CSF, the cell lysates and the culture supernatant were then subjected to 
immunoblotting for NAMPT, immunoblotting for MPO was also carried 
out as a positive control for degranulation. B. Neutrophils were incubated 
for the indicated time (shown above blot) in the presence and absence of 
either TNFα or GM-CSF. The protein content of the culture supernatant 
was precipitated with acetone, and re-dissolved in 50 µL Laemmli buffer; 
this was subjected to immunoblotting for NAMPT alongside the cellular 
protein contents. I – intracellular, E – extracellular. Representative blots 
shown. 
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5.3.5 NAMPT expression in neutrophils from patients with rheumatoid 
arthritis 
NAMPT has been reported to be elevated in the serum and synovial fluid 
of RA patients, and serum NAMPT correlates with disease activity 
18,32,165
. Here it was investigated whether expression of NAMPT from 
neutrophils correlated with changes in disease activity (measured by 
DAS) during treatment and also whether NAMPT expression correlated 
with the expression of the key inflammatory cytokine TNFα, known to be 
expressed by inflammatory neutrophils. RNA was isolated from the 
peripheral blood neutrophils of 5 RA patients (RA1-5) referred for anti-
TNF therapy, prior to the commencement of treatment and for 3 of these 
patients (RA1-3), again at a time point at least 6 months following 
commencement of treatment. Table 5.1 gives the disease activity data for 
each patient before and after treatment along with the European League 
against Rheumatism (EULAR) response classification. RNA was also 
isolated from the peripheral blood neutrophils of 2 patients with newly 
diagnosed RA, samples were collected at first appointment following 
diagnosis, before the commencement of DMARD therapy (Table 5.2). 
Expression of neither NAMPT nor TNFα correlated with the patient 
disease activity, measured by DAS. However pre-treatment, the 
expression of NAMPT does significantly correlate with the expression of 
TNFα from neutrophils (p<0.05 Pearson r2=0.78). Although post-
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treatment, this correlation does not hold (Fig.5.4A). The expression of 
both NAMPT and TNFα from neutrophils increased slightly post-
treatment in this small sample set, although this was not significant and 
the effect did vary between patients (Fig. 5.4B). A comparison between 
the expression of these molecules from the blood neutrophils of early 
arthritis patients and those with more established disease was carried out; 
there was no difference in the average NAMPT expression between these 
groups, and very little difference in the expression of TNFα (Fig. 5.4C). 
Patient 
DAS 
EULAR 
response 
Notes Pre-
treatment 
Post-
treatment 
RA1* 6.86 5.99 None 
Etanercept non-responder. 
Switched to Rituximab 
RA2* 6.95 1.55 Good 
Maintained on 
Adalimumab 
RA3* 6.69 5.23 Moderate 
Injection site reaction to 
Etanercept, switched to 
Adalimumab but did not 
respond well. Now on 
Rituximab 
RA4 4.02 3.57 n/a 
Maintains good response to 
Sulfasalazine 
RA5 6.19 2.64 Good Maintained on Etanercept 
TABLE 5.1: RA patients qualifying for anti-TNF treatment from 
whom samples were analysed (*sample pre- and post-treatment) 
Patient 
Treatment 
Current DAS Notes 
At sample Current 
eRA1 NSAID Methotrexate 4.03 In remission 
eRA2 NSAID Methotrexate 3.21 In remission 
TABLE 5.2: Early RA patients, samples collected following diagnosis 
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FIGURE 5.4: Comparison of NAMPT and TNFα expression from the 
blood neutrophils of RA patients at different stages of disease. RNA 
was isolated from peripheral blood neutrophils and analysed for 
expression of NAMPT and TNFα by qPCR. A. Samples were collected 
from RA patients (n=5 RA1-5) referred for anti-TNF therapy prior to 
commencement of treatment, and then at a time point >6 months post 
start of treatment for 3 patients (RA1-3). Expression of NAMPT 
correlated with the expression of TNFα pre-treatment (p<0.05 Pearson 
r
2
=0.78), but not at the post-treatment timepoint. The expression of 
NAMPT and TNFα did not correlate with the DAS of the patients. B. The 
average expression of NAMPT and TNFα was increased slightly post 
treatment (n=3 not significant). Data represent mean ±SEM of at least 3 
independent samples C. Blood neutrophils were collected from newly 
diagnosed RA patients (early), and NAMPT and TNFα expression was 
compared to that of patients with more established disease (later) (from 
A. and B.), there were no significant changes in expression. Data 
represent mean ±SD of 2 independent samples. 
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The concentration of NAMPT is reported to be higher in the synovial 
fluid than in the serum of RA patients 
18
. To investigate whether this 
increase in NAMPT concentration in synovial fluid is mirrored by 
increases in cellular content in synovial fluid neutrophils, neutrophils 
from paired synovial fluid and peripheral blood samples were lysed and 
the contents subjected to immunoblotting for NAMPT. Figure 5.5 shows 
that NAMPT expression in neutrophils isolated from synovial fluid was 
significantly higher than in cells isolated from the peripheral blood of the 
same patients (30-fold increase, n=8 p<0.01 by Wilcoxon signed-rank 
test). However, the magnitude of this increase did vary between patients. 
5.4 Discussion 
NAMPT expression by immune cells in response to cytokines is well 
documented 
19,32,176,185,186,213,262
, and it has been shown that NAMPT 
expression can be induced in neutrophils by IL-1β, TNFα and LPS 19; 
these authors suggest that induction of expression by LPS occurs via 
initial expression of IL-1β, and subsequent stimulation of NAMPT. As 
with the data presented here, these increases in NAMPT expression 
appear to be more apparent at the mRNA level than they do at the protein 
level. Here, I have found that the degradation of the NAMPT protein and 
the large variation in expression between individuals makes it difficult to 
draw conclusions about NAMPT protein expression in neutrophils. 
Cytokine treatment does induce significant upregulation of NAMPT  
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FIGURE 5.5: NAMPT expression is increased in neutrophils isolated 
from synovial fluid of RA patients as compared to paired peripheral 
blood neutrophils. Protein was isolated from the peripheral blood (B) 
and synovial fluid (SF) of RA patients and subjected to immunoblotting 
for NAMPT. NAMPT expression was significantly elevated in the 
synovial fluid neutrophils (A.) p<0.01 by Wilcoxon signed-rank test. 
Data represent mean ±SEM of 8 independent samples and a 
representative blot is shown in B. (1, 2 and 3 represent individual 
patients). 
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transcripts, but only to a maximum of 2-fold, and it does not appear to be 
mirrored by changes in protein expression of NAMPT. Although it does 
not appear to be dynamically regulated by exposure to cytokines, 
NAMPT is constitutively expressed by healthy donor neutrophils, and as 
such it is likely that it is important for neutrophil function. NAMPT 
expression increased over time in culture, and could be blocked by 
inhibition of the transcription factor NF-κB, which binds to the distal 
promoter of the NAMPT gene. Although the NAMPT gene contains 
binding sites for a number of other transcription factors, namely NF-1 
and AP-1 and -2, it appears that blocking activation of NF-κB alone is 
sufficient to almost completely ablate NAMPT protein expression by 6 h. 
This indicates that this is the major transcription factor for constitutive 
NAMPT expression in neutrophils. 
There is conflicting data published about the secretion of NAMPT from 
various cell types, and it is suggested that because NAMPT lacks a signal 
sequence for secretion 
167
, extracellular NAMPT is only released upon 
cell death and lysis 
171,212
. However, one study showed that NAMPT is 
actively secreted from a 3T3-L1 adipocyte cell line, and this was not 
blocked by addition of (ER)-Golgi-dependent secretion inhibitors, nor 
was it thought to be secreted via microvesicles: thus, it was concluded 
that secretion occurs via a non-classical pathway, using a number of 
distinct secretory  mechanisms 
211
. It has been shown that NAMPT has 
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extracellular nicotinamide phosphoribosyltransferase activity 
26,27
, and 
that it can act as an extracellular cytokine in the absence of its enzymatic 
function. It has been proposed that monomers and enzymatically inactive 
forms of NAMPT are capable of stimulating expression of IL-6 and 
promoting survival of macrophages 
22
. Monomeric NAMPT has a relative 
molecular mass of 52 kDa, and so it is unlikely that the 30 kDa product 
detected in the neutrophil supernatant is capable of dimerisation or has 
any enzyme activity. However, if monomeric NAMPT is capable of 
signalling in the absence of enzyme activity, then this isoform of 
NAMPT may also have signalling function. However, given the 
abundance of proteases within neutrophils, it is likely that the lower 
molecular weight mass detected by immunoblotting are non-specific 
degradation products. 
Given the high level of NAMPT expression by other cell types 
19,32,176,185,186,213,262
, and the lack of extracellular NAMPT detected in 
neutrophil culture supernatants, it may be concluded that neutrophils are 
not major contributors to the high concentration of NAMPT observed in 
the serum and synovial fluid of RA patients 
18,32,165
. However it has been 
observed that serum NAMPT correlated with leukocyte counts in 
children, suggesting that in vivo autocrine or paracrine signalling may 
stimulate secretion from these cell types 
184
. NAMPT is constitutively 
expressed in healthy donor neutrophils, and adding cytokines to 
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neutrophil cultures in isolation had little effect on this expression here. 
However, in this preliminary study of RA patient neutrophils, the mRNA 
expression of NAMPT did correlate with that of TNFα from the 
peripheral blood neutrophils of RA patients whose disease was currently 
not well controlled (those referred for anti-TNF therapy). TNFα is an 
inflammatory cytokine expressed by neutrophils, known to play a crucial 
role in the progression of inflammatory arthritis, and the drugs that target 
this molecule are very successful at treating RA in the majority of 
patients 
146,147,150
. This suggests that NAMPT may play a similarly pivotal 
role in these processes. Although, conversely the expression of neither 
NAMPT nor TNFα from neutrophils correlated with disease activity 
(DAS) in these patients, and the expression of both molecules was 
slightly increased following commencement of a successful treatment 
regimen. RA is a heterogeneous disease, driven by a variety of 
inflammatory cytokines, and the mechanisms of chronic inflammation 
and its abatement by various disease modifying drugs (DMARDs) is 
incompletely understood. Often even those patients whose disease is 
successfully modified by anti-TNF therapy do not show a decrease in 
their serum TNFα concentration 263, and it has been suggested that 
membrane bound TNFα on the surface of cells is more important to the 
progression of RA than that released into the circulation 
264
.  
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In this study NAMPT was however significantly elevated in the synovial 
fluid neutrophils of RA patients compared to paired peripheral blood 
cells. Suggesting that in the multi-cellular inflammatory environment the 
combination of stimuli can lead to upregulation of NAMPT in activated 
neutrophils. Synovial fluid neutrophils have been previously primed by 
exposure to cytokines and undergone transmigration towards the 
inflammatory site, and it has been shown that transmigration itself can 
affect the neutrophil expression profile (Lam et al., unpublished 
observation). This small scale investigation of NAMPT expression in RA 
patient neutrophils, suggests that NAMPT is regulated in a similar 
manner to TNFα, and that NAMPT expression may be increased during 
neutrophil activation. However this preliminary study would require 
expansion before any firm conclusions could be drawn about the 
contribution of NAMPT to the function of neutrophils during 
inflammatory disease. 
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CHAPTER 6: Effects of NAMPT and NAMPT inhibition on the 
Neutrophil Expression Profile 
 
6.1 Introduction 
It is proposed that NAMPT can be considered as a cytokine because it is 
released by immune cells and can stimulate other immune cells. It has 
been shown that dimeric, extracellular (e)NAMPT maintains its 
nicotinamide phosphoribosyltransferase activity 
26,196
, but there is also 
convincing evidence for NAMPT acting as a monomeric extracellular, 
cytokine-like molecule in the absence of this enzymatic activity 
21,22
. 
However, it is unclear whether the proposed cytokine-like activities of 
NAMPT are independent of its role in NAD biosynthesis, and no 
NAMPT receptor has yet been identified 
18,19
. It is now appreciated that 
neutrophils undergo active gene expression in response to stimulation and 
up-regulated gene products include regulators of inflammation together 
with cytokines and chemokines that can all enhance and regulate the 
immune response 
258,259
. Circulating NAMPT is elevated during 
inflammation, but little has been published about the effects of NAMPT 
on neutrophil gene expression. It is unknown (a) whether NAMPT, like 
many other cytokines, can activate neutrophil intracellular signalling 
pathways leading to activated gene expression, or (b) if its role in NAD 
biosynthesis is important for these processes. The functions of a number 
of key enzymes involved in chromatin remodelling and control of 
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transcription (such as sirtuins and PARPs) are NAD-dependent, and I 
have demonstrated previously that inhibition of NAMPT depletes 
neutrophil intracellular NAD (Chapter 3). Thus, it may be hypothesised 
that inhibition of NAMPT and the subsequent decrease in intracellular 
NAD availability, would affect gene expression in neutrophils. 
6.2 Aims 
The aims of this chapter were to characterise the effects of NAMPT 
inhibition on cytokine-induced intracellular signalling leading to gene 
expression, in order to better understand the requirement of NAD in the 
activation of transcription in these cells. A secondary aim of this chapter 
was to investigate whether exogenous rhNAMPT is capable of activating 
intracellular signalling and transcription in neutrophils, even though a 
surface receptor for this molecule has not yet been identified.  
6.3 Results 
6.3.1 Effects of NAMPT and NAMPT inhibition on TNFα expression in 
neutrophils 
Expression of the key inflammatory cytokine TNFα by neutrophils is 
induced by a number of pro-inflammatory factors, including bacterial 
LPS and TNFα itself. Elevated expression of TNFα is observed in 
inflammatory diseases such as RA 
265,266
 and this observation is the basis 
for the therapeutic use of TNF inhibitors. It has been reported that, in a 
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mouse model of inflammation, NAMPT inhibition decreased circulating 
TNFα levels and the severity of arthritis, and also down-regulated  the 
secretion of TNFα (plus IL-1β and IL-6) from human monocytes 33. To 
identify whether FK866 also affected TNFα expression in neutrophils, 
mRNA was isolated from healthy control neutrophils treated for 1 h with 
FK866 (100 nM) or media alone, and cDNA generated was subjected to 
quantitative PCR (qPCR) to measure expression of TNFα. Neutrophils 
treated with FK866 expressed significantly less TNFα mRNA in response 
to 1 h treatment with either TNFα itself (n=5, p<0.001) or LPS (n=3, 
p<0.01). TNF-induced expression of TNFα was decreased to near basal 
levels when NAMPT was inhibited (Fig. 6.1A). However, adding 
exogenous rhNAMPT to neutrophils for 2 h had no effect on expression 
of TNFα mRNA, or the mRNA expression of other cytokines tested (IL-
1β, IL-8 and ICAM1) (Fig. 6.1B). 
6.3.2 Effects of NAMPT and NAMPT inhibition on activation of NF-κB 
TNFα expression is under the control of the NF-κB signalling pathway, 
and NAMPT has been shown to activate the transcription factor NF-κB in 
other cells such as macrophages and endothelial cells 
24
. It was investigated 
here whether NAMPT could stimulate this pathway in neutrophils, and 
whether inhibition of NAMPT affected TNFα expression via this pathway 
in neutrophils. Activation of NF-κB was determined by immunoblotting 
 
 161 
 
 
FIGURE 6.1: Effects of NAMPT and NAMPT inhibition on 
expression of TNFα and other cytokines in neutrophils. A. qPCR 
measured expression of TNFα from neutrophils either untreated (-) or 
stimulated by TNFα (n=5) or bacterial LPS (n=3) over 1 h is significantly 
decreased by a 1 h pre-incubation with 100 nM FK866 (FK). Data 
expressed as a percentage of TNFα or LPS stimulated expression and 
represents mean ±SEM of multiple independent samples as indicated  B. 
1 h TNFα but not rhNAMPT (N) (100 ng/mL) significantly induced 
expression of TNFα, IL-1β and ICAM1 (n=3). 1 h GM-CSF (GM) 
significantly induced expression of IL-8, and rhNAMPT did not (n=4). 
Data expressed as fold change in expression from untreated (-) and 
represents mean ±SEM of multiple independent samples as indicated 
*p<0.05, **p<0.01, ***p<0.001. 
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for the phosphorylated form of the p65 subunit of the transcription factor. 
In initial experiments, neutrophils were stimulated for 5 min or 45 min 
with rhNAMPT (100 ng/mL) or TNFα (10 ng/mL) as a positive control.  
At 5 min TNFα significantly induced a 15-fold increase in phosphorylation 
of p65; there was a trend towards increased phosphorylation by NAMPT, 
although this was variable (Fig 6.2A left panel). Following 45 min of 
culture greater constitutive phosphorylation of p65 was observed and the 
response to TNFα was also more varied; the small stimulatory effect of 
NAMPT seen at 5 min did not occur at 45 min (Fig 6.2A right panel). It 
has been demonstrated previously that the product of the NAMPT enzyme 
reaction, NMN, can also stimulate NF-κB phosphorylation in macrophages 
24
, suggesting that NAMPT enzymatic activity is important for NF-κB 
activation in this cell. Due to the effects of NAMPT inhibition on 
expression of TNFα shown in Figure 6.1A, it was investigated whether 
inhibition of NAMPT with FK866 could affect the phosphorylation of p65 
in neutrophils. Pre-incubating neutrophils for 30 min with FK866 (100 
nM), led to a marked decrease in the phosphorylation of p65 in response to 
a 5 min stimulation with TNFα (10 ng/mL) (Fig. 6.2B). This supports the 
observation that NAMPT enzyme activity is required for activation of 
TNFα expression. 
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FIGURE 6.2: Effects of NAMPT and NAMPT inhibition on 
activation of NF-κB in neutrophils A. rhNAMPT (N) induced a small 
increase in phosphorylation of NF-κB (p65) at 5 min but this was not 
eveident by 45 min, measured by immunoblotting, B. 30 min pre-
treatment with FK866 (FK) prevented phosphorylation of p65 in response 
to TNFα (5 min). Data displayed as relative expression compared to 
untreated (-), and represents mean ±SEM of 3 independent samples. 
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6.3.3 Effects of NAMPT and NAMPT inhibition on activation of other key 
signalling molecules 
Due to the effect of NAMPT and NAMPT inhibition on the activation of 
the NF-κB pathway, it was then investigated whether NAMPT is similarly 
involved in other key signalling pathways in neutrophils, especially those 
activated by the cytokine GM-CSF. The effects of NAMPT and FK866 on 
the neutrophil JAK/STAT and MAPK signalling pathways were 
investigated by immunoblotting for phosphorylation of the signalling 
molecules STAT3 and ERK1/2 (p44/p42), respectively. In experiments 
where GM-CSF (50 U/mL) was used as a positive control for activation of 
these pathways, rhNAMPT (100 ng/mL) did not induce significant 
phosphorylation of STAT3 or ERK, although there did appear to be a small 
increase in phosphorylation of the STAT3 molecule (Fig. 6.3A, B). Next, it 
was investigated whether inhibition of NAMPT with FK866 could affect 
the GM-CSF induced phosphorylation of these signalling molecules. 
Neutrophils were treated for 30 min with FK866 (100 nM) prior to GM-
CSF stimulation for 5 min, alongside the appropriate no treatment controls. 
Pre-incubation with FK866 decreased the GM-CSF induced 
phosphorylation of both ERK and STAT3 (Fig. 6.3C, D). Phosphorylation 
of STAT3 was significantly decreased to unstimulated levels when the 
cells were treated with FK866 prior to GM-CSF stimulation (Fig. 6.3D). 
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FIGURE 6.3: Effects of NAMPT and NAMPT inhibition on activation of signalling 
molecules STAT3 and ERK1/2 by immunoblotting. A. GM-CSF induced 
phosphorylation of ERK1/2 (p44/p42) over 5 min, rhNAMPT (100 ng/mL) did not 
(n=8). B. rhNAMPT (N) induced a slight increase in phosphorylation of STAT3 at 5 
min, but this was not to the same magnitude as that induced by GM-CSF (GM) (n=5). 
Data displayed as relative expression compared to untreated (-) C. 30 min pre-
incubation of neutrophils with FK866 (FK) (100 nM) decreased the phosphorylation of 
ERK1/2 and STAT3 induced by GM-CSF (5 min) (n=3). Data displayed as percentage 
expression of GM-CSF treated group. All data represents mean ±SEM of multiple 
independent samples as indicated, *p<0.05. 
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6.3.4 Whole transcriptome sequencing to investigate TNFα induced gene 
expression inhibited by FK866 
Having shown that NAMPT inhibition decreases TNFα-induced 
phosphorylation of NF-κB, and GM-CSF induced phosphorylation of 
STAT3 and ERK1/2, and also expression of the downstream NF-κB 
transcriptional target TNFα, it was then investigated whether NAMPT 
inhibition in neutrophils had an effect on the wider transcriptional profile 
of neutrophils. Whole transcriptome sequencing of healthy control 
neutrophils was conducted to compare gene expression between 
unstimulated cells and those stimulated with TNFα (10 ng/mL) alone, or 
following a 1 h pre-incubation with the NAMPT inhibitor FK866 (100 
nM). RNA was isolated as described previously (2.2.9) from at least 30 x 
10
6
 neutrophils for each condition, and the RNA integrity number (RIN) 
was confirmed to be greater than 8 for all samples. Samples were then 
prepared and sequenced externally using the Illumina HiSeq 2000 
Analyser sequencing platform at the Beijing Genomics Institute (BGI). 
Mapping and annotation of the sequencing data was performed by H. 
Thomas and H. Wright, as described in 2.2.11. TNFα upregulated many 
cytokines and transcription factors that are well validated in the literature; 
for example TNFα, IL-1α and IL-1β, and genes involved in NF-κB 
signalling. Inhibition of NAMPT for 1 h prior to TNFα stimulation, altered 
the TNFα induced regulation of many neutrophil genes, and expression 
levels most changed by addition of FK866, both negatively and positively, 
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are shown in Tables 6.1 and 6.2 (Appendix), respectively. Of the 17,499 
genes identified as being expressed by neutrophils in at least one of the 
treatment groups, 5046 were down-regulated when cells were pre-
incubated with FK866 prior to TNFα stimulation, and the fold decrease 
from TNFα alone to FK866 plus TNFα was greater than 1.5 in 1310 of 
these genes (greater than 2 in 402 genes). The numbers of mapped genes in 
each treatment category, and the change in expression induced by each 
treatment is summarised in Tables 6.3 and 6.4 below. 
Group Number of mapped genes 
Total 17,499 
Control 16,389 
TNFα 16,238 
FK866 + TNFα 16,188 
TABLE 6.3: Number of mapped genes in each treatment group. 
 
Change 
from Treatment 
Change in expression 
(<1.5 fold) 
Number of 
mapped genes 
Control 
TNFα  
Increase 340 
Decrease 280 
FK866 + 
TNFα 
Increase 864 
Decrease 1569 
TNFα  
FK866 + 
TNFα  
Increase 1075 
Decrease 1310 
TABLE 6.4: Number of genes with altered expression in each 
treatment group.  
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The fold difference in expression between TNFα and FK866 plus TNFα 
was less than 2 for all of the housekeeping genes investigated, and the 
average fold change across these 5 housekeeping genes was -0.66 (Table 
6.5; appendix). It was then investigated whether there was any 
relationships between the genes whose TNFα induced expression was 
inhibited by FK866. The software programme Ingenuity Pathway Analysis 
(IPA) was used to compare the canonical pathways that were statistically 
most likely to be regulated by the treatment in each sample. Figure 6.4 
shows the top 20 pathways predicted to be activated by TNFα stimulation; 
a number of TNFα receptor pathways are shown, many of which involve 
NF-κB signalling, which is known to be activated by engagement of TNFα 
receptors. Figure 6.5 shows the top 20 pathways predicted to be regulated 
by the change in expression from control cells to those treated with FK866 
and TNFα; this shows a very different profile of pathways than those 
shown to be regulated by TNFα alone. In fact, only 6 of these 20 pathways 
are common between the two treatments. It is of interest to note that the 
pathway predicted to be regulated by FK866 pre-treatment with the most 
confidence is the NRF2-mediated oxidative stress response, which is 
activated by ROS. It can be seen in Figure 6.6 that expression of many of 
the participating molecules in this pathway are down-regulated in the 
samples pre-treated with FK866, as compared to those treated with TNFα 
alone, consistent with the observation that FK866 inhibits production of 
ROS by neutrophils. 
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FIGURE 6.4: IPA predicted canonical pathways differentially regulated from control with TNFα or FK866 plus TNFα 
treatment in neutrophils. From IPA the 20 pathways considered by to be statistically most likely to be differentially regulated 
from control with TNFα treatment. Genes down-regulated from control - green bar, upregulated – red bar, unchanged - grey and 
no expression - empty bar. The orange line represents the statistical likelihood (p-value) that the indicated canonical pathway is 
regulated by the treatment. 
 
A
B
TNFα – Fold change from control
FK866 + TNFα – Fold change from control
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FIGURE 6.5: IPA predicted canonical pathways differentially regulated from control when pre-treated with FK866 prior 
to TNFα treatment in neutrophils. From IPA the 20 pathways considered by to be statistically most likely to be differentially 
regulated from control with FK866 plus TNFα treatment. Genes down-regulated from control - green bar, upregulated – red bar, 
unchanged - grey and no expression - empty bar. The orange line represents the statistical likelihood (p-value) that the indicated 
canonical pathway is regulated by the treatment. 
A
B
TNFα – Fold change from control
FK866 + TNFα – Fold change from control
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FIGURE 6.6: The NRF2-mediated oxidative stress response pathway is 
down-regulated by addition of FK866 compared to TNFα signalling 
alone. This IPA NRF2-mediated stress response pathway is overlaid with the 
fold changes (>1.5) in expression with FK866 pre-treatment prior to 
stimulation with TNFα. (change from TNFα alone). Green – decrease; red – 
increase; grey – no change; white – no expression. 
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Using IPA it can be predicted which transcription factors are likely to have 
been affected by each treatment, by comparing the regulation of their 
downstream targets. Table 6.6 (appendix) shows the 15 transcription 
factors statistically most likely to be activated by TNFα (as fold change 
from control), many of these were involved in NF-κB signalling. Of these 
15 transcription factors 9 (Table 6.7; appendix) were also predicted by IPA 
as being statistically most likely to be down-regulated by FK866 pre-
treatment prior to TNFα stimulation (as fold change from TNFα alone); 
again many of these were involved in the NF-κB pathway. Similarly, 6 
transcription factors were predicted by IPA to be down-regulated from 
control by TNFα treatment, and 3 of these were also predicted with most 
certainty to be upregulated when cells were pre-treated with FK866 
(Tables 6.8 and 6.9; appendix). Taken together, this preliminary analysis of 
the data suggests that pre-incubation with FK866 abrogates much of the 
TNFα induced gene expression in neutrophils.  
The differential expression of genes involved in the NF-κB pathway was 
explored in more detail alongside genes involved in neutrophil apoptosis, 
the NADPH oxidase complex and those coding for inflammatory cytokines 
and chemokines, based on the previously observed effects of NAMPT 
inhibition on neutrophil functions. 
6.3.5 Effects of NAMPT inhibition on the TNFα induced expression of 
components of the NF-κB pathway in neutrophils 
TNFα stimulated expression of many of the genes encoding components of 
the NF-κB pathway, but especially the inhibitors of NF-κB (IκB) and A20 
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(TNFAIP3), the product of which is responsible for the termination of 
TNFα induced activation of NF-κB. However, some genes involved in 
TNFα signalling of neutrophils were down-regulated following TNFα 
stimulation, including the TNF receptor 1 (TNFRSF1A), FADD, and the 
components of the NF-κB specific MAP kinase complex, NIK/MEKK1 
(Fig. 6.7). This represents the TNFα/NF-κB negative feedback response. 
Pre-incubation with the NAMPT inhibitor prior to TNFα stimulation 
resulted in >2-fold decreased transcripts for 10 out of the 26 NF-κB related 
genes, when compared to TNFα stimulation alone (Fig. 6.7). A summary 
of the change in expression of genes involved in NF-κB signalling is 
shown in Figure 6.8; 6.8A shows that many elements of the pathway are 
upregulated (red) by TNFα stimulation in contrast to 6.8B where many of 
the genes are down-regulated (green) compared to TNFα when samples 
were first pre-treated with FK866 prior to stimulation. 
6.3.6 Effects of NAMPT inhibition on the TNFα induced expression of 
cytokines and chemokines from neutrophils 
It was also investigated whether NAMPT inhibition affected events 
downstream of signalling pathway activation, by examining the effect of 
FK866 on expression of inflammatory cytokines. TNFα is known to 
stimulate cytokine expression from neutrophils, but pre-treatment with 
FK866 abrogated the TNFα induced upregulation of the transcripts for a 
number of pro-inflammatory cytokines and chemokines including IL-1α, 
IL-1β, IL-1 receptor agonist (RA), CCL3 (MIP1α), CCL4 (MIP1β), 
CXCL2 (GROβ) and TNFα (Fig. 6.9). A summary of the effects of 
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FIGURE 6.7: Genes differentially expressed in the NF-κB pathway between neutrophils stimulated with TNFα alone or those pre-
incubated with FK866 prior to TNFα stimulation. The fold change in expression of key components of the NF-κB signalling pathway from 
control (untreated) cells, to those either treated with TNFα alone (TNF – grey bars) or pre-treated with FK866 prior to TNFα stimulation (FK 
– black bars). Numbers >1 indicate a change in expression (red line). FK866 decreases the TNFα induced expression of a number of NF-κB 
pathway genes. 
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FIGURE 6.8: Genes differentially expressed in the NF-κB pathway between neutrophils stimulated with TNFα alone or those pre-incubated with FK866 prior to 
stimulation.  NF-κB pathway from IPA is overlaid with the fold changes (<1.5 fold) induced by A. TNFα (fold change from control) or B. FK866 pre-treatment plus 
TNFα (fold change from TNFα alone). Green – down-regulated, red – upregulated, grey – no change, white – no expression 
TNFα - Fold change from control FK866 + TNFα - Fold change from TNFαA B
 176 
 
NAMPT inhibition prior to TNFα stimulation on cytokine and chemokine 
signalling networks is shown in Figure 6.10. 
6.3.7 Effects of NAMPT inhibition on the TNFα induced expression of 
regulators of apoptosis from neutrophils 
FK866 was developed as a pro-apoptotic agent, although no effects on 
neutrophil apoptosis were seen in this study (Chapter 4). Here, the effects 
of this inhibitor in combination with TNFα on the expression of apoptosis-
related genes were investigated, to establish whether the effects on gene 
expression indicated a pro-apoptotic effect. At the concentration used in 
this study (10 ng/mL), TNFα is anti-apoptotic for neutrophils, although at 
higher concentrations (>10 ng/mL) it can induce apoptosis 
133. TNFα 
stimulation had a range of effects on the expression of both pro- and anti-
apoptotic genes. However, it did induce down-regulation of expression of 
over half of the TNFα death receptor domain encoding genes expressed 
(CRADD, DAPK1, FADD, TNFRSF1A and TNFRSF1B). Pre-incubation 
with FK866 prior to TNFα stimulation led to an increase in death receptor 
expression in 6 out of the 9 genes investigated (Fig. 6.11A). The products 
of the genes whose TNF stimulated expression was most changed by 
addition of FK866 exert both pro-and anti-apoptotic affects. Additionally, a 
>2fold change in expression of 34/64 apoptosis-related genes was observed 
following incubation with FK866 prior to TNFα stimulation, compared to 
TNFα alone (Fig. 6.11A-C). Inhibition of NAMPT appeared to have an
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FIGURE 6.9: The effects of NAMPT inhibition on the TNFα induced expression of genes encoding cytokines and chemokines in 
neutrophils. The fold change in expression of key neutrophil cytokines and chemokines from control (untreated) cells, to those either treated 
with TNFα alone (TNF – grey bars) or pre-treated with FK866 prior to TNFα stimulation (FK866 – black bars). Numbers >1 indicate a change 
in expression (red line). FK866 decreases the TNFα induced expression of a number of genes encoding cytokines and chemokines. 
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FIGURE 6.10: NAMPT inhibition decreaes the TNFα induced activation of cytokine and chemokine pathways. Key neutrophil cytokines and chemokines (A.) and 
the canonical chemokine signalling pathway (B.) from IPA were overlaid with the fold change (<1.5 fold) induced by FK866 pre-treatment plus TNFα (fold change from 
TNFα alone). Green – down-regulated, red – upregulated, grey – no change, white – no expression. 
A B
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overall pro-apoptotic effect on the expression of the Bcl-2 family members. 
The Bcl-2 family of proteins mediate the intrinsic apoptotic pathway by 
controlling release of apoptotic agents from the mitochondria. This group 
can be further divided into subfamilies with pro- and anti-apoptotic action. 
Pre-incubation with FK866 reversed the TNFα induced increase in 
expression of anti-apoptotic Bcl-2 subfamily members MCL1 and A1 to 
below control levels, and it also reversed the TNFα induced decrease in 
expression of pro-apoptotic BH3 subfamily members BIK, BINP3 and 
BIML, increasing their expression above control (Fig. 6.11B). Figure 6.12 
shows a comparison of the genes expressed in the apoptotic signalling 
pathways when cells were stimulated with TNFα or FK866 and TNFα in 
combination. FK866 appeared to cause an overall down-regulation of 
expression, especially on members of the NF-κB signalling pathway as 
discussed previously. However, NAMPT inhibition increased expression 
of the pro-apoptotic regulators BIM and BAX, whilst it decreased 
expression of anti-apoptotic regulators such as members of the cIAP 
(cellular inhibitor of apoptosis) complex and Mcl-1. 
6.3.8 Effects of NAMPT inhibition on the TNFα induced expression of 
components of the neutrophil NADPH oxidase complex 
Due to the significant inhibition of the neutrophil respiratory burst with 
NAMPT inhibition, the effects of FK866 on the expression of transcripts 
coding for components of the NADPH oxidase and related proteins were 
also examined. The core NADPH oxidase consists of the membrane bound 
p22
PHOX
 (CYBA) and gp91
PHOX
 (CYBB) subunits that form cytochrome 
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FIGURE 6.11: The effects of TNFα and FK866 pre-treatment on the expression of genes involved in the regulation of apoptosis in neutrophils. The fold change in 
expression of death receptor (A.), Bcl-2 family (B.) and other apoptosis regulating genes (C.) is shown from control (untreated) cells, to those either treated with TNFα 
alone (TNF – grey bars) or pre-treated with FK866 prior to TNFα stimulation (FK866 – black bars). Numbers >1 indicate a change in expression (red line). FK866 altered 
the TNFα induced expression of a number of genes in the Bcl-2 family representing a more pro-apoptotic profile (B.) 
-4.5
-3
-1.5
0
1.5
3
C
R
A
D
D
D
A
P
K
1
FA
D
D
TN
FR
SF
1
0
A
TN
FR
SF
1
0
B
TN
FR
SF
1
A
TN
FR
SF
1
B
TN
FR
SF
2
5
TR
A
D
D
TNF
FK866
-2
-1
0
1
2
3
B
C
L2
B
C
LX
L
M
C
L1 A
1
B
A
X
B
A
K
B
A
D
B
ID B
IK
B
N
IP
3
B
IM
L
Bcl-2 (anti) Bax (pro) BH3 (pro)
TNF
FK866
-4
-2
0
2
4
6
R
IP
K
2
B
IR
C
3
C
A
SP
5
C
A
SP
1
A
PA
F1
TR
A
F2 FA
S
C
YC
S
D
IA
B
LO
P
YC
A
R
D
N
O
D
1
C
A
SP
4
C
A
SP
2
C
A
SP
9
A
K
T1
C
A
SP
1
0
C
FL
A
R
B
FA
R
C
A
SP
3
IG
F1
R
G
A
D
D
4
5
A
B
N
IP
2
N
A
IP
B
IR
C
2
TN
FS
F1
0
TN
FS
F8
D
FF
A
A
IF
M
1
TN
FR
SF
9
B
IR
C
6
B
A
G
1
X
IA
P
C
A
SP
8
LT
B
R
TR
A
F3
B
R
A
F
TNF
FK866
Fo
ld
 c
h
an
ge
 in
 e
xp
re
ss
io
n
Fo
ld
 c
h
an
ge
 in
 e
xp
re
ss
io
n
Fo
ld
 c
h
an
ge
 in
 e
xp
re
ss
io
n
A B
C
 181 
 
 
FIGURE 6.12: The effects of NAMPT inhibition on the TNFα induced activation of apoptotic pathways. The apoptotic signalling pathway from IPA was overlaid 
with the fold changes (<1.5 fold) induced by A. TNFα (fold change from control) or B. FK866 pre-treatment plus TNFα (fold change from TNFα alone). Green – down-
regulated, red – upregulated, grey – no change, white – no expression. 
TNFα - Fold change from control FK866 + TNFα - Fold change from TNFαA B
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b558, and the cytosolic components p40
 PHOX
 (NCF4), p47
 PHOX 
(NCF1), p67
 
PHOX (NCF2). Stimulation with TNFα appeared to slightly increase 
transcripts for many components of the oxidase, but this was less than 1.5-
fold in all cases. TNFα also decreased expression of p67 PHOX 1.6-fold (Fig. 
6.13A). Pre-treatment with FK866 down-regulated the TNFα induced 
transcripts in many of the oxidase components, although again these 
changes were no greater than 1.5-fold in any component. This is 
summarised in Figure 6.13B. FK866 pre-treatment had no effect on the 
expression of the transcripts for the oxidase-associated proteins 
cytoplasmic Rac2 and membrane bound Rap1A that bind to the core 
complex. However, FK866 did slightly decrease the TNFα induced 
expression of RhoGPIα and RhoGPIβ (1.5 and 1.3-fold respectively), that 
both serve to sequester Rac2 in the cytoplasm and prevent binding to the 
core oxidase complex (Fig. 6.13A).  
6.4 Discussion 
The role of NAMPT as a cytokine in the absence of its enzyme activity 
remains controversial, and many studies do not address the role of 
NAMPT in NAD synthesis when investigating its cytokine-like function. 
I have shown here that exogenous NAMPT has some stimulatory effect 
on the phosphorylation of signalling molecules NF-κB and STAT3, but 
these changes were much lower than those stimulated by the 
inflammatory cytokines, TNFα and GM-CSF. These low-level 
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FIGURE 6.13: The effects of TNF and FK866 and TNF in combination on the 
expression of genes coding for compnents of the NADPH oxidase. A. Shown is the 
fold change in expression of  neutrophil oxidase components from control (untreated) 
cells, to those either treated with TNFα alone (TNF – grey bars) or pre-treated with 
FK866 prior to TNFα stimulation (FK866 – black bars). Numbers >1 indicate a change 
in expression (red line) B. Interacting components of the oxidase from IPA was overlaid 
with the fold changes (<1.5 fold) induced by FK866 pre-treatment plus TNFα (fold 
change from TNFα alone). Green – down-regulated, red – upregulated, grey – no 
change, white – no expression. 
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stimulatory effects were not paralleled by changes in the transcription of 
cytokines regulated by these signalling pathways. In support of these low 
level effects, addition of NAMPT also had little effect on neutrophil 
function, as detailed in Chapter 4, although exogenous NAMPT did delay 
neutrophil apoptosis and the turnover of Mcl-1, as described in section 
4.3.4. These experiments appear to indicate that the function of NAMPT 
as a cytokine-like signalling molecule with neutrophils is rather limited to 
its affect on apoptosis, although this could be further validated by 
simultaneously blocking NAMPT enzyme activity. There has been more 
convincing evidence of NAMPT functioning as a cytokine reported for 
other cell types. For example, NAMPT in the absence of its enzyme 
activity, has been shown to stimulate cytokine expression and delay 
apoptosis in endothelial cells and macrophages respectively 
21,22
. 
It is clear that NAMPT exerts a number of effects on neutrophils when 
acting as an enzyme. Experiments inhibiting the function of the NAMPT 
enzyme in neutrophils show that this inhibition abrogated activation of 
signalling molecules NF-κB, STAT3 and ERK1/2 that regulate key 
neutrophil signalling pathways controlling a wide variety of neutrophil 
processes including development, function, cytokine expression and 
apoptosis 
267–269
. This is seen also in the wide-ranging effects of NAMPT 
inhibition on the neutrophil transcriptional profile; neutrophils pre-treated 
with FK866 showed many differentially regulated genes when stimulated 
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with TNFα, compared to those not pre-treated with the inhibitor. 
However, these effects were not global, as the expression of less than 
15% of the genes mapped was altered by NAMPT inhibition, when 
compared to untreated or TNFα treated cells, suggesting specific targeted 
effects. Some of the greatest effects on expression were seen on those 
genes and pathways downstream of NF-κB activation, as TNFα 
stimulation alone induces significant activation of this pathway, which is 
abrogated when NAMPT is inhibited. As might be expected from 
inhibition of this pathway, NAMPT inhibition also decreases the TNFα-
induced expression of a number a key inflammatory cytokines and 
chemokines. In vivo a decrease in the inflammatory cytokines released by 
neutrophils would be expected to dampen the inflammatory response and 
could be beneficial in inflammatory conditions where the level of 
inflammation is inappropriate. A number of experiments using FK866 in 
animal models of inflammatory joint disease have shown a decrease in 
inflammatory cytokines such as TNFα in the circulation, and a 
corresponding improvement in joint swelling and destruction 
33,34
. 
NAMPT inhibition also affected the expression of a number genes 
involved in control of neutrophil apoptosis. It is important that neutrophil 
apoptosis is regulated to enable an appropriate response to immune 
challenge, but to also to prevent inappropriate release of potentially 
tissue-damaging products from neutrophils. Dysregulated neutrophil 
apoptosis is a feature of many inflammatory diseases such as RA 
11
.  
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FK866 was developed as a pro-apoptotic agent that induced apoptosis via 
the intrinsic (mitochondrial) pathway following depletion of NAD over a 
number of days 
206
. However, NAMPT inhibition had no effect on 
neutrophil apoptosis measured in this thesis by annexin V binding and 
uptake of PI (section 3.3.6). As neutrophils have a relatively short 
lifespan (estimated at 6-18 h 
38
), the pro-apoptotic effects of FK866 may 
be masked by the high rates of constitutive neutrophil apoptosis. 
However, when neutrophils are pre-treated with FK866 prior to 
stimulation with an anti-apoptotic concentration of TNFα, the 
transcriptional profile changes dramatically from cells stimulated with 
TNFα alone. NAMPT inhibition altered expression of both pro- and anti-
apoptotic regulators, but FK866 pre-treated cells exhibited a generally 
pro-apoptotic transcriptional profile with regard to members of the Bcl-2 
family. Most notably, FK866 pre-treatment prior to TNFα stimulation 
caused down-regulation of expression of anti-apoptotic Mcl-1 and 
upregulation of the pro-apoptotic BIM and BAX. Turnover of Mcl-1 is 
the major way in which neutrophils regulate apoptosis, as this pro-
survival protein has a short half-life of around 2 h, and caspase-mediated 
turnover facilitates constitutive neutrophil apoptosis in the absence of 
stimulus. Pro-inflammatory stimuli alter the phosphorylation state of 
Mcl-1 to delay its cleavage and promote neutrophil survival, but they do 
not generally induce more than a small increase in Mcl-1 mRNA 
expression 
38,133, as is shown here with TNFα stimulation. NAMPT 
187 
 
inhibition prior to TNFα addition, however, decreases transcript levels for 
Mcl-1, and this alongside the upregulation of pro-apoptotic Bcl-2 family 
members BIM and BAX, demonstrates that FK866 inhibits the anti-
apoptotic action of low dose TNFα on neutrophils. 
It was not within the scope of this experiment to explain the mechanism 
for these effects on the neutrophil transcription, although it has been 
shown previously that FK866 can affect transcription by decreasing the 
availability of NAD for NAD-consuming enzymes involved in 
transcriptional control, such as sirtuins 
33,35,169
. However, I have also 
shown previously that inhibition of NAMPT causes a significant decrease 
in the amount of ROS produced by neutrophils (Chapter 3). In addition to 
their role in bacterial killing, ROS can also act as signalling molecules 
270
. It may be that the inhibition of ROS production by FK866 has 
downstream effects on ROS-mediated signalling pathways, as indicated 
by the large-scale down-regulation of the NRF2-mediated oxidative stress 
response pathway predicted by IPA, which is activated by ROS. 
This effect of NAMPT inhibition on the activity of the ROS-generating 
NADPH oxidase complex was also investigated here. It was hypothesised 
that FK866 inhibited production of ROS by depleting the NAD pool and 
decreasing the availability of NADP that provides the reducing power for 
the oxidase. The results shown here provide no evidence that the decrease 
in ROS is due to decreased expression of the oxidant components or its 
188 
 
associated regulatory proteins, so the inhibition is likely to be linked to 
the NAD bioavailability. 
The whole transcriptome analysis of NAMPT-inhibited neutrophils is a 
powerful tool that provides a large amount of information about the role 
of NAMPT and NAD in the neutrophil. The function of this enzyme is 
clearly important for a number of signalling pathways, production of 
inflammatory mediators and control of apoptosis, and it can be 
appreciated how changes in these processes could affect the neutrophil 
functions studied in Chapter 3. Most of these observed effects can be 
attributed to depletion of NAD in the cell, but these preliminary studies 
suggest that a more detailed investigation into the mechanisms 
responsible for this down-regulation of gene expression is warranted. 
However, as the effects of NAMPT inhibition resulted in a selective 
decrease in gene expression, it may be predicted that more-specific 
mechanisms, other than NAD depletion, are responsible. Although this 
transcriptomic sequencing has only been carried out once to date, and 
will require further validation, the correspondence with previous findings 
in this thesis and in the wider literature, endorses the validity of the data. 
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CHAPTER 7: General Discussion and Conclusions 
Neutrophils have a pathologically important role in the progression of 
chronic inflammatory diseases such as rheumatoid arthritis, and have a 
great capacity to cause tissue damage by virtue of their cytotoxic contents. 
This research aimed to examine the role of the pleiotropic protein NAMPT 
in the regulation of neutrophil functions that are important in inflammation, 
including the rate of neutrophil apoptosis and expression of mRNA from 
these cells. The role of NAMPT, as both an NAD-biosynthesis enzyme and 
as a cytokine-like molecule has been evaluated; the most striking effects on 
neutrophil function and mRNA expression have been mediated by 
inhibiting NAMPT enzyme. 
The main findings in this thesis were as follows: 
 Inhibition of NAMPT depleted intracellular NAD(P)H, and 
decreased the ability of neutrophils to produce reactive oxidants in 
response to both receptor-mediated and receptor-independent 
stimulation. Despite this, NAMPT inhibition did not affect 
phagocytosis or bacterial killing (Chapter 3). 
 Exogenous NAMPT delayed constitutive neutrophil apoptosis by 
stabilising the key neutrophil anti-apoptotic protein Mcl-1. 
NAMPT inhibition had no effect on this process (Chapters 3 and 
4). 
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 NAMPT was constitutively expressed by neutrophils but did not 
appear to be dynamically regulated by cytokines; however, 
NAMPT expression was elevated in synovial fluid neutrophils of 
RA patients compared to paired blood neutrophils. NAMPT 
mRNA expression also appeared to correlate with expression of 
TNFα in RA patients considered for biologic therapy, prior to 
starting treatment (Chapter 5). 
 NAMPT inhibition decreased the activation of a number of 
signalling molecules (NF-κB, ERK, STAT3) in response to 
stimulation of neutrophils, and decreased the expression of TNFα 
in response to stimuli (Chapter 6). 
 NAMPT inhibition also had wide-ranging effects on neutrophil 
gene expression. RNA sequencing identified that FK866 pre-
treatment decreased the TNF-induced expression of a number of 
genes, including those encoding cytokines and chemokines. 
NAMPT inhibition prior to TNFα stimulation led to a distinct 
change in the overall transcriptional profile compared to 
neutrophils stimulated with TNFα alone. However, NAMPT 
inhibition resulted in selective, rather than global, changes in 
mRNA levels (Chapter 6). 
In Chapter 3, the effects of NAMPT inhibition on neutrophil functions 
central to roles in both innate immunity and chronic inflammation were 
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investigated. In vivo a number of mechanisms act in concert to facilitate 
neutrophil activation and response to inflammatory stimuli.  In this 
Chapter, these processes were investigated in isolation to determine the 
effects of NAMPT inhibition and NAD depletion on each of these stages. 
Initial experiments identified that FK866 depleted intracellular NAD/H and 
NADP/H, and that pre-incubation of freshly isolated neutrophils with 
FK866 prevented the increases in NAD(P)/H observed during priming and 
activation. Neutrophils were pre-incubated with FK866 for at least 30 min 
in subsequent experiments, as preliminary experiments identified that 
NAMPT inhibition had the greatest effect when time was allowed for 
NAD(P)H depletion to occur prior to stimulation of function. Where 
possible neutrophils were pre-treated for 1 h, however for many functional 
tests (especially those that relied on membrane receptor expression), 
control neutrophils became less responsive after a >30 min pre-incubation 
time. The prominent results from this Chapter were that NAMPT inhibition 
decreased the ability of neutrophils to mount a respiratory burst in response 
to both receptor-independent (PMA) and receptor-dependent stimuli, 
which included both bacterial (fMLP and S. aureus) and inflammatory 
stimuli (immune complexes); however this decrease in the amount of ROS 
produced by NAMPT-inhibited neutrophils did not decrease the capacity 
for bacterial killing. Precedent for this has been shown in some patients 
with autosomal recessive CGD who are able to maintain sufficient 
bacterial killing despite defects in the NADPH oxidase 
100
. It was 
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hypothesised that FK866 decreased the amount of ROS produced by 
neutrophils because it decreased the availability of NADPH required to 
fuel reduction of molecular oxygen in the first step of the respiratory burst. 
It was confirmed that FK866 inhibited production of the initial oxygen free 
radical, O2
-
, and inhibited the increase of NADP/H stimulated by PMA. It 
has been shown previously that the neutrophil intracellular concentration of 
NADP/H is increased greater than 3-fold upon activation, to provide a 
sufficient store of reducing power to the oxidase 
83
. The NADPH oxidase is 
a multi-component enzyme made up of pre-formed subunits that are 
assembled at the plasma membrane upon neutrophil priming. The fact that 
the amount of ROS produced by neutrophils was decreased in a time- and 
dose-dependent manner by NAMPT inhibition, rather than completely 
ablated, lends credence to the hypothesis that inhibition occurs due to the 
gradual depletion of NADPH. Also, in Chapter 6 it was shown that 
NAMPT inhibition did not have any effect on the de novo transcription of 
the oxidase subunits. It would be of interest to further investigate the 
contribution of NAD metabolism to neutrophil ROS production by 
inhibiting other enzymes of the NAD biosynthetic pathway, such as 
NMNAT and NAD kinase. The decrease in production of ROS by 
neutrophils achieved after NAMPT inhibition, without a concomitant 
decrease in the capacity for bacterial killing, suggest that FK866 could be a 
viable therapeutic agent to modulate the destructive capacity of neutrophils 
in inflammatory disease, without adversely compromising host defence. In 
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support of this, animal models of inflammatory arthritis have shown 
improvement following administration of FK866, which included a 
decrease in radiological joint damage, and decrease in circulating cytokines 
33,34
. One study suggested that inhibition of NAMPT is as effective as 
targeting of TNFα by etanercept in these models 33.  
This same approach to investigating the effects of NAMPT inhibition on 
neutrophil function was also employed to assess the functional effects of 
stimulation with exogenous NAMPT, with the aim of addressing whether 
NAMPT could activate neutrophils like a cytokine, in the absence of an 
identifiable NAMPT surface receptor. NAMPT is elevated in 
inflammation, and NAMPT serum concentration correlates with disease 
activity in RA 
18,32,165,218
. It is proposed that exogenous NAMPT can 
stimulate the activity of immune cells, such as macrophages 
22
 and it has 
been reported to exert pro-inflammatory effects on neutrophils; NAMPT 
delays neutrophil apoptosis and contributes to assembly of the NADPH 
oxidase 
19,224
. For the majority of neutrophil functions tested in this thesis, 
exogenous recombinant NAMPT at pathophysiological concentrations did 
not induce a primed phenotype, as compared to treatment with known 
priming agents such as GM-CSF and TNFα. This was with the exception 
of the effect of NAMPT on neutrophil apoptosis; in line with other 
published data 
19
, NAMPT significantly delayed neutrophil apoptosis, and 
this was achieved by stabilisation of the anti-apoptotic protein, Mcl-1. 
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NAMPT inhibition had no effect on neutrophil apoptosis and turnover of 
Mcl-1. This was initially surprising as FK866 was developed as a pro-
apoptotic anti-cancer agent, but its effect on cell line apoptosis manifests 
over a number of days, as NAD is gradually depleted leading to eventual 
cell death via the intrinsic apoptotic pathway 
205,206
. However, due to the 
short half-life of neutrophils, this effect was likely masked by constitutive 
apoptosis. It has been proposed that NAMPT decreases the activity of 
caspases-8 and -3 in neutrophils, but not caspase-9, suggesting that 
NAMPT inhibits the extrinsic or death-receptor mediated apoptotic 
pathway 
19
.  Whether exogenous NAMPT directly delays apoptosis, or 
whether it occurs in an autocrine/paracrine manner via activation of 
expression of other cytokines, is not clear from this research. However, in 
Chapter 7 of this thesis, it was shown that although NAMPT may stimulate 
low levels of activation of NF-κB and STAT3, it does not appear to 
robustly induce downstream expression of the inflammatory mediators that 
were examined. It would be necessary to investigate the effects of NAMPT 
on neutrophils, in combination with other inflammatory cytokines, and 
with other immune cell types, as this would be more indicative of the 
inflammatory environment in vivo. It may be that NAMPT has a 
synergistic effect with other cytokines, as it does with IL-17 on pre-B-cell 
maturation 
167
, or that the NAMPT-stimulated expression of inflammatory 
mediators from other cell types indirectly leads to enhanced neutrophil 
activation. 
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NAMPT is present at relatively high concentrations at sites of chronic 
inflammation, such as in the rheumatoid joint 
18,32,165
, and it has been 
reported that serum NAMPT correlates with leukocyte counts in children 
184
. This suggests that these cells contribute to circulating NAMPT, 
although no method for NAMPT secretion has been robustly identified 
212
. 
Chapter 5 examined the expression and release of NAMPT by neutrophils. 
qPCR and immunoblotting were used to measure NAMPT mRNA and 
protein in healthy neutrophils, both resting and stimulated with 
inflammatory cytokines, and also from the peripheral blood and synovial 
fluid neutrophils of RA patients. The aims were to establish whether 
neutrophils regulate NAMPT expression and release in response to 
cytokines, and also to examine the dynamics of NAMPT expression in the 
neutrophils of RA patients at different stages of disease. Expression of 
NAMPT transcripts was increased slightly by cytokine stimulation of 
neutrophils, but immunoblotting for NAMPT protein was problematic due 
to degradation of the protein, and no significant effects of cytokine 
treatment were observed. NAMPT is also constitutively expressed at high 
levels in resting neutrophils, by a mechanism that can be blocked by the 
NF-κB inhibitor, BAY-11. Transcriptome sequencing of resting, healthy 
neutrophils showed that only a small number of genes exhibited higher 
expression than NAMPT, indicating that it is one of the most abundant 
transcripts in neutrophils. NAMPT was, however, not readily detected in 
neutrophil cell culture medium, suggesting that neutrophils do not actively 
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secrete this protein. However, because neutrophils appear to express high 
basal levels of NAMPT, that may be further augmented by cytokine 
treatment, NAMPT could be released during cell death. Neutrophil 
apoptosis is not appropriately regulated during chronic inflammation, and 
secondary necrosis of immune cells may well contribute to the high 
concentration of NAMPT reported at inflammatory loci, such as in the 
rheumatoid joint. It was shown here, that activated synovial fluid 
neutrophils contain significantly more NAMPT protein than peripheral 
blood neutrophils from the same patient. Thus, the combination of 
inflammatory stimuli in the multicellular environment of the rheumatoid 
joint, plus the effects of transmigration, appear to increase NAMPT 
expression in a manner that was not observed with single cytokine 
stimulation in vitro. 
NAMPT expression by peripheral blood neutrophils of RA patients did 
appear to correlate with expression of TNFα in patients whose disease was 
not well controlled by DMARD therapy. This correlation did not hold 
following commencement of biologic therapy (with either Rituximab or 
Adalimumab) and expression of neither molecule correlated with the 
patients disease activity score before or after treatment, in this small cohort. 
RA is a heterogeneous disease driven by a variety of inflammatory 
mediators, but as NAMPT protein appears to be elevated in RA synovial 
fluid neutrophils and NAMPT RNA correlates with TNFα in some RA 
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patient neutrophils preliminarily identified here, it could be suggested that 
elevated NAMPT expression indicates an activated neutrophil phenotype. 
As neutrophils contribute to tissue-damage in RA, this supports the 
hypothesis that targeting NAMPT may be beneficial to down-regulate 
neutrophil-mediated joint damage. This preliminary study of RA patients, 
however, only contains small numbers of patients and a larger patient 
cohort would be required to validate these conclusions. 
In view of the effects of NAMPT inhibition on neutrophil function, 
experiments in Chapter 6 examined the global impact of NAMPT on 
neutrophil gene expression. NAMPT appeared to stimulate low-level 
increases in activation of signalling molecules NF-κB and STAT3, 
although this did not affect expression of the key neutrophil cytokines 
analysed.  In contrast, inhibition of NAMPT significantly decreased 
activation of NF-κB, ERK1/2 and STAT3, and initial experiments showed 
that it also decreased expression of TNFα in response to stimuli. These 
observations were expanded by mRNA sequencing of healthy neutrophils 
to compare the gene expression profile of resting cells to those stimulated 
with TNFα or pre-treated with FK866 prior to TNFα stimulation. Although 
this experiment was only conducted once, many of the observed changes 
correlated with the effects on neutrophil function determined in this thesis 
and in the wider-literature. For example, NAMPT inhibition significantly 
affected the NRF2 pathway which is mediated by ROS, which was shown 
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to be decreased by NAMPT inhibition in Chapter 3 of this thesis. FK866 
pre-treated cells exhibited a more pro-apoptotic expression profile than 
those treated with TNFα, and this correlates with the anti-apoptotic action 
of this molecule reported in the literature. NAMPT-inhibition prior to 
TNFα treatment down-regulated many of the TNF-induced neutrophil 
responses, including production of cytokines and chemokines. However, 
the decrease in expression was not global, suggesting a more targeted 
effect of this inhibitor, rather than just NAD depletion affecting the basal 
transcriptional machinery of the cell. This could be investigated further by 
targeting a different enzyme involved in NAD biosynthesis. It would also 
be of interest to examine the effects of NAMPT inhibition on transcription 
stimulated by different cytokines. These FK866-mediated effects on the 
neutrophil transcriptional profile further support the hypothesis that 
NAMPT inhibition may be beneficial in chronic inflammatory disease. The 
changes in gene expression with FK866 suggest a neutrophil phenotype 
that would produce less inflammatory mediators and be more inclined to 
undergo apoptosis, both of which would be expected to dampen the 
chronic immune response in vivo. 
The NAMPT inhibitor FK866 was initially developed as an anti-cancer 
agent, and has recently completed phase II clinical trials for the treatment 
of solid and haematological malignancies, with a good safety profile 
231,232
. 
There is precedent for drugs initially developed for the treatment of cancer 
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to be used successfully for the treatment of inflammatory diseases such as 
RA. The most notable example of this is methotrexate, which at low-doses 
can be very effective at managing RA 
271,272
. 
In conclusion, this research has identified that NAMPT expression by 
neutrophils is increased in the rheumatoid joint, and correlates with TNFα 
in RA patient blood neutrophils, suggesting NAMPT may be a marker of 
inflammation in these cells. Secondly, this work has shown that NAMPT 
regulates neutrophil function via its role as an NAD biosynthetic enzyme. 
Inhibition of NAMPT decreases the amount of potentially tissue-damaging 
ROS produced by neutrophils, without adversely affecting the ability of 
these cells to kill bacteria, and it also down-regulates neutrophil expression 
of cytokines and chemokines. Further research is required to establish the 
mechanisms by which NAMPT inhibition and NAD depletion affect 
neutrophil functions and gene expression, but taken together these data 
suggest that NAMPT may be a viable target for the treatment of chronic 
inflammatory diseases such as RA, and that FK866 may represent a 
promising new therapy. 
A number of other inhibitors of the NAMPT enzyme have emerged over 
recent years, including GMX1778 (a pyridyl cyanoguanidine compound) 
and CB-30865 (a quinazoline-based pyridine-containing compound) 
273
, 
and a high-throughput screening mechanism has been developed to 
discover novel NAMPT inhibitors 
274
 . So going forward from the work 
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carried out in this thesis it would be of interest to verify the findings of this 
work using alternative inhibitors of NAMPT enzyme function. However, 
before NAMPT inhibitors can be considered as a viable option for treating 
inflammatory diseases, such as RA, the global implications of blocking this 
pleiotropic enzyme need to be further explored, both in vitro and ultimately 
in vivo. 
7.1 Future directions 
One way in which knowledge could be expanded on the global effects of 
NAMPT on neutrophils would be to silence the expression of this enzyme 
using RNA interference.  Utilising small interfering RNA (siRNA) would 
also remove potential confounding, off-target effects of the NAMPT 
inhibitor. NAMPT gene knock-out in mice is embryonic lethal 
26,31,174
, 
however targeted knock-down of the NAMPT gene in neutrophils or 
neutrophil-like cell lines, would allow a comprehensive study into the role 
of NAMPT in these cells. Previous work has demonstrated that 
transfection of ex-vivo neutrophils can be unreliable and problematic due to 
the tendency of these cells to engulf particles by phagocytosis, so the use of 
a neutrophil-like cell line may be more practical for RNA interference 
studies. The human promyelocytic HL-60 cell line can be induced to 
differentiate into neutrophil-like cells in response to a variety of chemical 
stimuli such as retinoic acid and dimethylsulphoxide 
275
. 
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To expand this work further, it would also be of interest to study the 
effects of either NAMPT inhibited or NAMPT depleted neutrophils in a 
multicellular model, more representative of the rheumatoid joint in vivo. 
This would provide some insight into the role of NAMPT produced by 
neutrophils in paracrine signalling. To produce a more representative 
model of the rheumatoid joint in vitro incubations of NAMPT inhibited 
or depleted neutrophils could be carried out in rheumatoid synovial fluid 
and under hypoxic conditions. Previous work has identified that in vitro 
neutrophil transmigration towards IL-8 prior to incubation in 
inflammatory synovial fluid is preferable to incubation with freshly 
isolated cells (C. Lam and H. Wright, unpublished data). 
NAMPT inhibition has also been reported to exert effects on a number of 
immune cell types critical to the establishment and progression of RA 
1819,22
, and some cells such as T-lymphocytes have been described as 
exquisitely sensitive to NAMPT inhibition 
223
. So, to truly understand the 
role of NAMPT in chronic inflammation and the potential of NAMPT 
inhibition to alleviate the chronic inflammatory state, it would be of 
interest to explore similar studies to those conducted in this thesis, using 
other inflammatory cell types in isolation or as part of a multicellular 
model. 
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Gene 
Symbol 
Entrez Gene Name 
RPKM expression values Fold Change TNF to 
T+FK 
Type(s) 
Control TNF T+FK 
IL1A interleukin 1, alpha 0.54 47.40 1.74 -27.32 cytokine 
GPR84 G protein-coupled receptor 84 1.19 120.65 6.85 -17.62 
G-protein coupled 
receptor 
IL1B interleukin 1, beta 333.14 
3462.0
4 
203.5
0 
-17.01 cytokine 
IL1RN interleukin 1 receptor antagonist 90.59 
1162.9
8 
77.52 -15.00 cytokine 
FOSL1 FOS-like antigen 1 7.47 14.38 0.89 -14.38 transcription regulator 
ARL5B ADP-ribosylation factor-like 5B 45.19 114.33 9.08 -12.59 enzyme 
PTGS2 prostaglandin-endoperoxide synthase 2 252.81 669.66 53.87 -12.43 enzyme 
KCNJ2 
potassium inwardly-rectifying channel, 
J2 
11.33 152.93 17.39 -8.80 ion channel 
EREG epiregulin 4.04 19.92 2.39 -8.35 growth factor 
XBP1 X-box binding protein 1 6.91 47.27 5.67 -8.34 transcription regulator 
TABLE 6.1: Protein coding transcripts showing greatest decrease in expression (from control) when neutrophils are pre-
treated with FK866 prior to TNFα stimulation 
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Gene 
Symbol 
Entrez Gene Name 
RPKM expression values Fold Change TNF 
to T+FK 
Type(s) 
Control TNF T+FK 
GADD45G 
growth arrest and DNA-damage-inducible, 
gamma 
6.57 1.98 19.05 9.61 other 
HHEX hematopoietically expressed homeobox 10.93 3.42 30.49 8.91 transcription regulator 
STX6 syntaxin 6 14.43 9.20 81.75 8.89 transporter 
BMP6 bone morphogenetic protein 6 3.40 2.99 24.91 8.32 growth factor 
HMOX1 heme oxygenase (decycling) 1 12.40 6.96 49.42 7.10 enzyme 
ENC1 
ectodermal-neural cortex 1 (with BTB-like 
domain) 
34.81 10.54 65.31 6.20 peptidase 
RPL21 ribosomal protein L21 5.72 0.00 6.16 6.16 other 
PROC 
protein C (inactivator of coagulation factors Va 
and VIIIa) 
1.03 0.40 6.15 6.15 peptidase 
ZHX2 zinc fingers and homeoboxes 2 6.00 5.65 33.82 5.98 transcription regulator 
FHL3 four and a half LIM domains 3 22.12 15.82 93.55 5.91 other 
TABLE 6.2: Protein coding transcripts showing greatest increase in expression (from control) when neutrophils are pre-
treated with FK866 prior to TNFα stimulation 
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Gene 
Symbol 
Entrez Gene Name 
RPKM expression values 
Fold change 
from control 
Fold change 
from TNF 
Control TNF T+FK TNF T+FK T+FK 
ACTB Actin, beta 2721.26 2556.07 2152.97 -1.06 -1.26 -1.19 
B2M Microglobulin, beta 2 
12414.4
0 
11816.7 11744.9 -1.05 -1.06 -1.01 
GAPD
H 
Glyceraldehyde-3-phosphate 
dehydrogenase 
265.22 215.59 379.20 -1.23 1.43 1.76 
HPRT1 Hypoxanthine phosphoribosyltransferase 1 2.61 2.50 1.59 -1.04 -1.64 -1.57 
RPLP0 Ribosomal protein, large, P0 35.18 33.71 26.55 -1.04 -1.32 -1.27 
        TABLE 6.5: Expression of a selection of housekeeping genes across all treatments 
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Upstream 
TF 
Fold 
Change 
p-value Target molecules in dataset 
NFkB 
complex 
  1.56E-32 BBC3,BCL2A1,BCL3,BID,BIRC3,CCL20,CCL3,CCL3L1/CCL3L3,CCL4,CD274 
RELA 1.635 2.40E-26 BBC3,BCL2A1,BCL3,BIRC3,BTG2,CCL20,CCL3,CDKN1A,CDKN1B,CXCL1 
NFKB1 1.376 2.95E-22 BCL2A1,BCL3,BIRC3,BTG2,CCL20,CCL3L1/CCL3L3,CCL4,CDKN1A,CXCL2,CXCL3 
REL 1.933 4.38E-17 BBC3,BCL2A1,BCL3,CCL4,CDKN1A,F3,GADD45B,ICAM1,IER3,IL18 
JUN -1.055 6.95E-16 ACAT2,ACP5,BBC3,BCL2A1,BCL3,BIRC3,BTG1,C3AR1,CD14,CD274 
EGR1 -1.224 4.39E-13 CCL3L1/CCL3L3,CCL4,CDK5R1,CDKN1A,CXCL2,CXCL3,ELK1,F3,FOSL1,GADD45B 
HMGB1 -1.189 1.37E-11 CCL20,CCL3,CCL4,CD83,CDKN1A,CXCL3,ICAM1,IL1A,IL1B,IL8 
FOXL2   4.33E-11 BCL2A1,CCL20,CCL3,CCL3L1/CCL3L3,CXCL2,CXCL3,ICAM1,IER3,MAFF,PPP1R15A 
STAT3 -1.071 1.58E-10 BCL3,CCL20,CCL3L1/CCL3L3,CCL4,CD274,CD83,CDKN1A,CDKN1B,CXCL2,FFAR2 
CEBPB 1.186 2.59E-09 BCL2A1,CCL3,CCL3L1/CCL3L3,CCL4,CD14,CDC42EP3,CDKN1A,CDKN1B,CLEC4E,CXCL2 
CEBPA -1.480 1.52E-08 BCL2A1,BTG1,BTG2,C3AR1,CCL20,CD14,CDKN1A,CKAP4,G0S2,GBP1 
CREB1 -1.006 2.19E-08 BTG2,CD79A,CSRNP1,CXCL2,DUSP1,GADD45B,HMOX1,IL1B,JUNB,LDLR 
Ap1   2.57E-08 BCL2A1,C3AR1,CCL3,CCL3L1/CCL3L3,CCL4,F3,FOSL1,HMOX1,IL1A,IL1B 
NfkB-RelA   3.54E-08 CCL3,CXCL3,ICAM1,IL1B,IL8,NFKBIA,PTGS2,TNF 
NFKB2 3.095 4.68E-06 BIRC3,CCL20,CDKN1A,IL8,PTGS2,SOD2,TNF,TRAF1 
TABLE 6.6: Transcription factors identified by IPA as activated with TNFα treatment 
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Upstream 
TF 
Fold 
Change 
p-value Target molecules in dataset 
NFkB 
complex   5.92E-13 ABCG1,ATF3,B3GNT5,BAX,BBC3,BCL11A,BCL2A1,BCL2L11,BCL3,BIRC3 
RELA -1.412 5.19E-09 ACTN4,BBC3,BCL2A1,BCL3,BIRC3,BTG2,CARD8,CASP8,CCL20,CCL3 
HMGB1 -1.368 4.73E-08 BAX,BRCA1,CCL20,CCL3,CCL4,CCNG1,CD58,CD83,CXCL3,ICAM1 
CREB1 -1.107 4.91E-08 ABCA1,ATF3,ATP1A1,BHLHE40,BTG2,CCND3,CD68,CEBPB,CEBPD,CIITA 
REL -2.721 7.41E-08 AHR,BBC3,BCL2A1,BCL2L11,BCL3,CCL4,CIITA,E2F3,EGR2,F3 
NFKB1 1.978 3.05E-06 BCL2A1,BCL3,BIRC3,BTG2,CCL20,CCL3L1/CCL3L3,CCL4,CCL5,CIITA,CREB3 
FOXL2   7.96E-05 ATF3,BCL2A1,CCL20,CCL3,CCL3L1/CCL3L3,CXCL2,CXCL3,FOS,HRH2,ICAM1 
NfkB-RelA   4.48E-04 CCL3,CCL5,CXCL3,ICAM1,IL1B,IL8,NFKBIA,PTGS2,TNF 
SREBF1 1.653 3.66E-03 ABCA1,ACLY,BAX,CEBPA,CEBPB,CEBPD,DARS,DHCR7,FAS,FDFT1 
BCL10 -1.476 5.25E-03 CCL4,CCL5,CXCL2,IL8,TNF 
JUND -2.053 2.81E-02 BCL3,CCL5,CYBB,F3,FOSL1,HMOX1,JUND,NCF2,NR4A1,PLAUR 
Ap1   4.05E-02 ATF3,BCL2A1,BCL2L11,CCL3,CCL3L1/CCL3L3,CCL4,F3,FOS,FOSL1,GSTP1 
NfkB1-RelA   4.27E-02 CCL5,CXCL1,ICAM1,IL8,PTGS2,TNF 
FOSL2 1.201 4.33E-02 ABCA1,CEBPB,F3,FAS,FOSL1,GCM1,IL8,RELB 
TRIM24 -1.691 9.18E-02 CMPK2,DHX58,EIF5A,HERC6,IFIH1,IFIT2,IFIT3,IRF7,IRF9,JAK2 
TABLE 6.7: Transcription factors identified by IPA as inhibited with FK866  prior to TNFα treatment 
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Upstream TF 
Fold 
Change 
p-value Target molecules in dataset 
GFI1 1.000 3.20E-11 BCL3,CDKN1A,CDKN1B,CEBPE,ETS2,ICAM1,IL1A,IL1B,IL8,IRAK2 
MEOX2 
 
4.03E-11 CCL20,CD69,CDKN1A,CXCL1,CXCL2,CXCL3,F3,ICAM1,IL8,PTX3 
ZFP36 4.626 1.01E-06 BIRC3,CCL3L1/CCL3L3,CDKN1A,IL1B,PTGS2,TNF 
KLF2 -1.048 5.10E-06 BCL3,CCL3,CCL4,CDKN1A,F3,HYAL2,IL1B,IL8,JUNB,NFKBIA 
NRF1 -1.004 4.32E-03 CCL20,HMOX1,IL1A,IL1RN,IL8 
Nr1h 
 
8.95E-03 CCL3,CXCL1,IL8,PTGS2,TNF 
    TABLE 6.8: Transcription factors identified by IPA as inhibited with TNFα treatment 
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Upstream TF 
Fold 
Change 
p-value Target molecules in dataset 
IRF3 -1.516 4.88E-05 AHNAK,B4GALT5,BIRC3,CCL3,CCL3L1/CCL3L3,CCL4,CCL5,CD58,CLIC4,CXCL1 
MEOX2   1.14E-04 CCL20,CD69,CDKN2D,CXCL1,CXCL2,CXCL3,CXCL6,F3,ICAM1,IL8 
FOSL1 -14.375 2.22E-04 CCL3L1/CCL3L3,CCL4,CXCL6,EGR1,EGR2,FOS,FOSB,FOSL1,GCLC,GCM1 
TFEB 2.167 3.26E-03 ATP6V1H,CLCN7,CTSD,GBA,HEXA,MCOLN1,SGSH,TPP1,VEGFA 
ZFP36 -2.819 4.75E-03 BIRC3,CCL3L1/CCL3L3,FOS,IL1B,PTGS2,TNF 
HDAC5 1.058 5.10E-03 CASP8,CDK7,HES1,HK2,MAP3K3,MAPK7,MEF2C,PTEN,TNF,TNFRSF1A 
Nr1h   6.51E-02 ABCA1,ABCG1,ACSL3,CCL3,CCL5,CXCL1,IL8,PTGS2,SREBF1,TNF 
BCL3 -2.405 1.97E-01 CCL5,IL1B,IL8,PLAUR,TNF 
LHX1 1.000 1.00E00 ANPEP,JAG1,KCNJ15,ZKSCAN1 
TABLE 6.9: Transcription factors identified by IPA as activated with NAMPT inhibition prior to TNFα treatment
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